# ON TWO PROBLEMS IN COMPARATIVE GENOMICS OF EUKARYOTES 

## APPROVED BY SUPERVISORY COMMITTEE

[^0]Joseph Albanesi, Ph.D. (Chair)

Lindsay Cowell, Ph.D.

Zbyszek Otwinowski, Ph.D.

Woodring Wright, M.D., Ph.D.

## DEDICATION

To my parents and to Jessica.

# ON TWO PROBLEMS IN COMPARATIVE GENOMICS OF EUKARYOTES 

by<br>\section*{JEREMY RAYMOND SEMEIKS}

## DISSERTATION / THESIS

Presented to the Faculty of the Graduate School of Biomedical Sciences The University of Texas Southwestern Medical Center at Dallas In Partial Fulfillment of the Requirements

For the Degree of

## DOCTOR OF PHILOSOPHY

The University of Texas Southwestern Medical Center at Dallas

Dallas, Texas

May, 2013

# ON TWO PROBLEMS IN COMPARATIVE GENOMICS OF EUKARYOTES 

Publication No.<br>Jeremy Raymond Semeiks, Ph.D.<br>The University of Texas Southwestern Medical Center at Dallas, 2013<br>Supervising Professor: Nick Grishin, Ph.D.

The recent advent of whole-genome sequencing allows us to use novel comparative methods to explore the genetic bases for traits of interest. Here, I present two case studies of such methods applied to eukaryote genomes.

The first study regards the evolution of longevity in the mammalian proteome. Evolutionary theory suggests that the force of natural selection decreases with age. To explore the extent to which this prediction directly affects protein structure and function, I used computational methods to identify positions of proteins conserved in long-lived but not in shortlived mammal species. I analyzed 7,590 orthologous protein families in 33 mammalian species, accounting for body mass, phylogeny, and species-specific mutation rate. Overall, I found that
the number of longevity-selected positions in the mammalian proteome is much greater than would be expected by chance. Further, these positions are enriched in domains of several proteins that interact with one another in inflammation and other aging-related processes, as well as in organismal development. I present as an example the kinase domain of anti-Müllerian hormone type-2 receptor (AMHR2). AMHR2 inhibits ovarian follicle recruitment and growth, and my results show that its longevity-selected positions cluster near a SNP associated with delayed human menopause. Distinct from its canonical role in development, this region of AMHR2 may function to regulate the protein's activity in a lifespan-specific manner.

The second study concerns the genetic basis for toxin production in the black mold genus Stachybotrys, which produces several diverse toxins that can damage human health. Its strains comprise two mutually-exclusive toxin chemotypes, one producing satratoxins (a subclass of trichothecenes) and the other producing the less-toxic atranones. To determine the genetic bases for chemotype-specific differences in toxin production, I sequenced and assembled de novo four Stachybotrys genomes, including two from atranone strains and two from satratoxin strains. Comparative analysis of these four $35-\mathrm{Mbp}$ genomes revealed several chemotype-specific gene clusters that are predicted to make atranones and satratoxins, based on several lines of evidence. I show that chemotype-specific gene clusters are likely the genetic basis for the mutuallyexclusive toxin chemotypes of Stachybotrys. I then present a unified biochemical model for Stachybotrys toxin production.

## TABLE OF CONTENTS

## CHAPTER ONE

A method to find longevity-selected positions in the mammalian proteome ..... 1
1.1. Introduction. ..... 1
1.1.1. The problem of aging: an evolutionary perspective ..... 1
1.1.2. Innovations of the present work. ..... 4
1.2. Materials and methods ..... 6
1.2.1. Selection of positions to analyze. ..... 6
1.2.2. Column correction, fitting, and analysis ..... 6
1.2.3. Homology modeling and structural analysis of AMHR2. ..... 8
1.3. Results and discussion. ..... 10
1.3.1. Due to overall conservation, most positions in the mammalian proteome are not longevity-selected. ..... 10
1.3.2. Among nonconserved positions, longevity-selected positions occur more often than expected by chance. ..... 11
1.3.3. Longevity-selected positions are enriched in protein domains with known roles in inflammation, development, and other diverse functions. ..... 14
1.3.4. Longevity-selected positions cluster in the kinase domain and C-terminal tail of AMHR2. ..... 16
1.3.5. Comparison with previous methods. ..... 23
1.4. Conclusions and recommendations ..... 26
1.4.1. AMHR2 ..... 26
1.4.2. Improvement of mammalian genomic data ..... 28
CHAPTER TWO
Comparative genome sequencing of the toxigenic black mold Stachybotrys ..... 42
2.1. Introduction ..... 42
2.1.1. Personal motivation. ..... 42
2.1.2. The problem of mutually exclusive toxin chemotypes in Stachybotrys. ..... 43
2.2. Materials and methods ..... 46
2.2.1. Stachybotrys culture, DNA extraction, and library construction. ..... 46
2.2.2. Genome assembly and resequencing of specific loci ..... 47
2.2.3. Proteome assembly ..... 49
2.2.4. Genetic nomenclature of Stachybotrys. ..... 49
2.2.5. Protein and rRNA phylogenies ..... 50
2.2.6. Proteome comparisons and PKS inventory ..... 50
2.2.7. Identification of chemotype-specific gene clusters. ..... 51
2.3. Results and discussion ..... 52
2.3.1. Sequencing and assembly of Stachybotrys genomes. ..... 52
2.3.2. Comparative proteome content of Stachybotrys ..... 53
2.3.3. The core trichothecene gene cluster of Stachybotrys diverges from those of other trichothecene producers ..... 56
2.3.4. The products of the core atranone cluster likely suffice to make all known atranone species ..... 58
2.3.5. Gene clusters specific to satratoxin strains of Stachybotrys ..... 62

### 2.3.6. Phylogenies for four trichothecene biosynthesis protein families in

Stachybotrys, and functional implications................................................................. 65
2.3.7. The hard problem: why are the chemotype-specific gene clusters mutually exclusive?.................................................................................................................... 67
2.4. Conclusions and recommendations......................................................................... 69

Bibliography................................................................................................................... 154

## PRIOR PUBLICATIONS

Semeiks J, Borek D, Otwinowski Z, Grishin NV (2013) Comparative genome sequencing of the toxigenic black mold Stachybotrys. Manuscript submitted for publication.

Semeiks J, Grishin NV (2012) A method to find longevity-selected positions in the mammalian proteome. PLoS ONE 7(6): e38595. doi:10.1371/journal.pone. 0038595.

Coppe J-P, Amend C, Semeiks J, Baehner FL, Bayani N, Campisi J, Benz CC, Gray JW, Neve RM (2010) ERBB receptor regulation of ESX/ELF3 promotes invasion in breast epithelial cells. Open Cancer J 3:89-100.

Rizki A, Weaver VM, Lee S-Y, Rozenberg GI, Chin K, Myers CA, Bascom JL, Mott JD, Semeiks JR, Grate LR, Mian IS, Borowsky AD, Jensen RA, Idowu MO, Chen F, Chen DJ, Petersen OW, Gray JW, Bissell MJ (2008) A human breast cell model of preinvasive to invasive transition. Cancer Res 68:1378-87.

Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Molecular Oncology 1:84—96.

Semeiks JR, Rizki A, Bissell MJ, Mian IS (2006) Ensemble attribute profile clustering: discovering and characterizing groups of genes with similar patterns of biological features. BMC Bioinformatics 7:147.

Semeiks JR, Grate LR, Mian IS (2005) Text-based analysis of genes, proteins, aging, and cancer. Mech Ageing Dev 126:193-208.

Semeiks JR, Grate LR, Mian IS (2004) Biological information networks of genetic loci and the scientific literature. Proceedings of the 2004 International Conference on Complex Systems.
LIST OF FIGURES
Figure 1-1. Conceptual example of multiple regression method. ..... 32
Figure 1-2. Phylogeny of species used in this study ..... 33
Figure 1-3. Density histograms of $p_{M L S}$ values. ..... 34
Figure 1-4. Density histograms of $p_{M L S}$ values yielded by fitting alternate input sets ..... 35
Figure 1-5. OrthoMaM alignment of the C-terminal region of the AMHR2 kinase domain. ..... 36
Figure 1-6. AMHR2 kinase domain mapped onto experimental structure of BMPR2 kinase
domain ..... 37
Figure 2-1. The two toxin chemotypes of Stachybotrys. ..... 73
Figure 2-2. Stachybotrys strains and other trichothecene producers. ..... 74
Figure 2-3. Ortholog-based maximum likelihood phylogeny of Stachybotrys and other fungi. ..... 75
Figure 2-4. Distribution of orthologs of Fusarium and Stachybotrys. ..... 76
Figure 2-5. The core trichothecene clusters and satratoxin cluster SC3 of each Stachybotrys strain77
Figure 2-6. The core atranone clusters of the Stachybotrys atranone strains ..... 78
Figure 2-7. Model of atranone biosynthesis ..... 79
Figure 2-8. Biosynthetic model of satratoxins and other macrocyclic trichothecenes. ..... 80
Figure 2-9. Satratoxin-specific clusters SC1 and SC2 of Stachybotrys ..... 81
Figure 2-10. Maximum likelihood phylogenies of selected Tri homologs ..... 83
Figure 2-11. Unified genetic model for atranone and satratoxin biosynthesis ..... 84

## LIST OF TABLES

Table 1-1. Number of positions and alignments selected, fit, and conserved............................... 38
Table 1-2. Predicted secondary structure in all positions of the human proteome and in two subsets of longevity-selected positions.......................................................................................... 39

Table 1-3. Selected clusters, not mutually exclusive, of ontology terms enriched in top protein domains

Table 1-4. Eutherian species of gerontological interest recommended to include in search for
$\qquad$
Table 2-1. Features of Stachybotrys genome and proteome assemblies .86

Table 2-2. Ortholog-based pairwise proteome identities of Stachybotrys and other fungi........... 87
Table 2-3. Summary of functions putatively encoded by genes in satratoxin clusters SC1, SC2, and SC3 .88

## LIST OF APPENDICES

APPENDIX A (Chapter 1)
The 107 protein domains that contain at least two longevity-selected positions. ..... 88
APPENDIX B (Chapter 1)
Longevity-selected positions of the protein domains shown in Appendix A ..... 93
APPENDIX C (Chapter 2)
Domains enriched in the Stachybotrys proteome. ..... 103
APPENDIX D (Chapter 2)
Putative polyketide synthases of Stachybotrys. ..... 106
APPENDIX E (Chapter 2)
Summary of selected putative Stachybotrys proteins. ..... 107
APPENDIX F (Chapter 2)
Selected draft sequences of putative Stachybotrys proteins ..... 110
APPENDIX G (Chapter 2)
Parameters used in Stachybotrys genome annotation. ..... 148

## LIST OF ABBREVIATIONS

ATR (eg, ATR1, ATR2) - set of genes specific to atranone-producing Stachybotrys strains AC - Stachybotrys atranone strain-specific gene cluster
ACVR1, 2A, or 2 B - activin receptor type-1, type-2A, or type-2B
AMH - anti-Müllerian hormone
AMHR2 - anti-Müllerian hormone type-2 receptor
BMPR1A or BMPR2 - bone morphogenetic protein receptor type-1A or type-2
BVMO - Baeyer-Villiger monooxygenase
B80 or BLOSUM80 - Blocks Substitution Matrix with minimum $80 \%$ identity
CAC - core atranone gene cluster
CDD - NCBI Conserved Domain Database
CTAB - cetyltrimethylammonium bromide
CTC - core trichothecene gene cluster
EPT - 12,13-epoxytrichothec-9-ene
FPP - farnesyl pyrophosphate
GGPP - geranylgeranyl pyrophosphate
kbp - DNA kilobase pair
MSA - multiple sequence alignment
MLS - maximum lifespan
PKS - polyketide synthase
PMDS - persistent Müllerian duct syndrome
PGLS - phylogenetic generalized least squares
SAT (eg, SAT1, SAT2) - set of genes specific to satratoxin-producing Stachybotrys strains
SC - Stachybotrys satratoxin strain-specific gene cluster
SMB - secondary metabolite biosynthesis
SNP - single nucleotide polymorphism
TGFbeta - transforming growth factor beta
TGFBR2 - TGF-beta Receptor Type II
TRI (eg, TRI3, TRI4, TRI5) - set of genes required for synthesis of trichothecenes

# CHAPTER ONE <br> A method to find longevity-selected positions in the mammalian proteome <br> <br> 1.1. INTRODUCTION 

 <br> <br> 1.1. INTRODUCTION}

### 1.1.1. The problem of aging: an evolutionary perspective

This chapter is adapted from an article conceived and published in the course of my graduate work (Semeiks and Grishin, 2012). It concerns the biomedical problem that most interests me: why do we humans age? More precisely, what are the molecular bases of the human aging phenotype?

For an organism, I define aging as experiencing a set of time-related changes that adversely affect function and increase mortality risk as a function of time ${ }^{1}$. Advanced age in humans is clearly the greatest risk factor for a large number of diseases, eg stroke, Alzheimer's disease, and many types of cancer (Gorelick, 2004; Yancik and Ries, 1994). Toward preventing such diseases as well as preserving healthy function late in life, I find it worthwhile to ask whether there are common and intelligible mechanisms of aging in humans that might be modified with medical intervention. Contrarily, it is also possible that what we term aging is a completely unintelligible phenomenon that is secondary only to time.

Why do we age? is a question that must be addressed at several levels. Teleologically, the classical evolutionary theory of antagonistic pleiotropy (Williams, 1957) posits that aging arises due to the decrease in selection pressure that occurs after successful reproduction. More specifically, in any population whose lifespans are initially limited by external factors such as predation, maximization of reproductive fitness earlier in life will occur at the expense of

[^1]personal fitness later in life, leading to aging as a teleological epiphenomenon.
Conversely, and consistently with this theory, lifespan extension has been shown to occur in Drosophila when selection pressure is experimentally increased in later age (Rose, 1984).

Mechanistically, the causes of human aging remain elusive. At the level of physiology, many theories have been advanced that propose some single mechanism as the main driver of aging. Most of these theories have not been well-tested, because the experiments would require great time, expense, and in many cases the development of interventions that do not presently exist. One counterexample that has been relatively well-tested and found lacking, at least in mice, flies, and other model organisms, is the mitochondrial free radical theory, which in strong form states that the primary cause of aging is free radical species generated by the mitochondria (critically reviewed by Lapointe and Hekimi, 2010). Although single-cause physiological theories are attractive due to their simplicity, the accepted evolutionary theory provides no reason to favor any single-cause physiological theory over more complex theories.

In the context of my current field of computational biology, it makes more sense to explore aging mechanisms at the level of the genome, broadly defined to include the proteome. Questions of genomics are computationally more tractable than those of physiology, and certainly if common physiological mechanisms of aging exist, they will ultimately have at least partial genomic bases. At the level of the genome as at the level of physiology, if aging is an intelligible process, it may be caused by several
nonexclusive mechanisms. These mechanisms may entail features or changes in the sequence, structure, function, and abundance of DNA, RNA, and proteins. Here, I focus on the relatively well-understood genomic phenomenon of changes in protein coding sequence and structure caused by fixed amino acid substitutions within mammal species.

If I am first interested in the genomics of human aging, then why here do I study the proteomes of many mammal species? In short, because of the way that mammals have evolved, this broader perspective may identify novel proteins and other genomic features that are implicated in human aging. Despite a $10-100$-fold difference in maximum lifespan (MLS), most known mammal species show similar phenotypes of aging, in contrast to the more diverse phenotypes exhibited by many other clades (Finch, 1990). Some such phenotypes include vascular lesions, menopause, and wearing of teeth. This commonality suggests that the genetic determinants of mammalian aging and lifespan may have been relatively plastic starting from at least the time of the eutherian radiation 80 million years ago.

Regarding my chosen problem to identify fixed amino acid substitutions related to aging, two recent studies (Jobson, Nabholz, and Galtier, 2010; Li and de Magalhães, 2011) predicted a simple consequence of the evolutionary theory: one might expect that proteins necessary for slower mammalian aging (ie, greater MLS) would be conserved to a greater extent in long-lived versus short-lived species. Thus, the principle underlying these two studies is that it is possible to identify aging-related proteins (more specifically, families of orthologous proteins) by inferring and comparing some measure of
preferential DNA or amino acid substitutions, here called longevity-selected positions, among the several dozen mammal species whose proteomes are available. Jobson et al (2010) accomplished this comparison from the perspective of classical genetics, applying to a codon model a measure similar to the well-known dN/dS ratio (reviewed by Yang and Bielawski, 2000). Two pertinent features of Jobson et al's method were that (1) species were binned as "long-lived" or "short-lived" based on MLS and (2) in keeping with the conventional framework, the total estimate of synonymous substitutions in a gene determined the threshold for whether any particular codon position in that gene was called longevity-selected.

### 1.1.2. Innovations of the present work

In contrast to the genetics-based approach described above, here I have started from the perspective of protein structure to identify longevity-selected positions in the mammalian proteome. More so than classical genetics, structural biology emphasizes two concepts that may be useful to find interesting longevity-selected positions. First, positions within a protein are not interchangeable; whatever the estimated synonymous substitution rate, a single nonsynonymous substitution in a certain structural context can change a protein's function. Second, not all nonsynonymous substitutions are equal; rather, a priori one should expect those amino acid substitutions that commonly change biochemical function to matter most for the function of a specific protein. Based on these observations, I present a simple regression-based method to find longevity-selected
positions in orthologous protein families of mammals. My method employs the phylogenetic generalized least squares framework (PGLS, equivalent to phylogenetic independent contrasts; Freckleton, Harvey, and Pagel 2002) to relate, for each position (column) of a protein alignment, the MLS of the species represented in the column to the biochemical divergence of their residues from the residue of a long-lived reference species. Two benefits of PGLS are that (1) it is straightforward to control for common gerontological confounders, including species-specific mutation rate, body mass, and shared phylogeny (Speakman, 2005), and (2) one can naturally fit a continuous variable such as MLS, removing the need to arbitrarily bin species.

I use my method as a starting point to analyze longevity-selected positions, placing emphasis on their structural contexts. My results concern both the proteome as a whole and a specific protein domain identified by our analysis, the kinase domain of antiMüllerian hormone type-2 receptor (AMHR2; kinase nomenclature per Knighton et al, 1990). AMHR2 is a receptor protein serine/threonine kinase in the TGF-beta Receptor Type II (TGFBR2) subfamily. The canonical role of AMHR2 is to inhibit the Müllerian ducts during development of the male fetus, and mutations cause the rare disease persistent Müllerian duct syndrome (PMDS; Imbeaud et al, 1995). More recently, a role for AMHR2 in ovarian follicle development of the adult female has also been identified (Durlinger, Visser, and Themmen, 2002), and this noncanonical function may relate to my findings.

### 1.2. MATERIALS AND METHODS

### 1.2.1. Selection of positions to analyze

I analyzed a selected subset of the OrthoMaM database version 6, which comprises multiple sequence alignments (MSAs) of 11,746 protein ortholog families from 36 mammalian species (Ranwez et al, 2007). Most of the sequences in the database were extracted from lowcoverage genomes, so completeness and quality of alignments varied considerably. I first masked nonstandard isoforms and other divergent subsequences using a sliding window-based approach. Specifically, I excluded from further analysis any subsequence of at least 10 residues in which every 10 -residue window had at least four residues each with less than $30 \%$ sequence identity to the rest of its column. I also excluded the three non-eutherian species due to high sequence divergence. Of the remaining data, I selected for fitting only columns that (1) included at least ten characters overall and (2) specifically included characters for both human and shrew. I refer to this subset as selected columns.

### 1.2.2. Column correction, fitting, and analysis

I define fit columns as the subset of selected columns that have at least three characters different from the human reference character, and conserved columns as all other selected columns. I independently fit each column in the fit subset to a phylogenetic generalized linear model (Freckleton, Harvey, and Pagel, 2002), as implemented in the R package caper, version 0.4 (Orme et al, 2011). Briefly, this framework assumes a Brownian model of trait evolution and uses the method of generalized least squares to perform multiple regression with correction for
global phylogenetic dependence, as indicated by the mammalian supertree. Specifically, for each column I fit the regression model
$\mathrm{B} 80_{\text {mut }} \sim \log _{10}$ MLS $+\log _{10}$ mass

Here, $M L S$ are the maximum lifespans and mass the body masses of each species as reported in AnAge version 11 (de Magalhães and Costa, 2009). $B 80_{\text {mut }}$ are the BLOSUM80 scores for each nonhuman ortholog character in the column versus the human ortholog character (Henikoff and Henikoff, 1992), corrected for mutation rate as described below. I used caper's default parameter values, including fixed nonterminal branch length multiplier $(\lambda)$ of 1 for phylogenetic correction. As the input phylogeny, I used the mammalian supertree (Bininda-Emonds et al, 2007), which is ultrametric. Fitting completed after running for one day on a standard single processor $(2.2 \mathrm{GHz}, 16 \mathrm{~GB}$ RAM).

To control for each species' overall mutation rate, I used an approach similar to that of Li and de Magalhães (2011). Specifically, to estimate these mutation rates I constructed by maximum likelihood (protml; Adachi and Hasegawa, 1996) a tree whose total branch length, $m_{s}$, for each species $s$ was the expected number of amino acid substitutions for $s$, as estimated from the set of all MSAs. I used this tree to correct each BLOSUM80 score for the mutation rate of $s$ relative to human by adding $\log _{10}\left(m_{s} / m_{r e f}\right)$
to the score, where $m_{r e f}$ was the total branch length of human. I restricted the range of each $\mathrm{B} 80_{\text {mut }}$ score to the standard range of B 80 scores attainable by its human character.

Each fit yielded both a longevity-selected slope, $b_{M L S}$, and p-value, $p_{\text {MLS }}$. I defined as a longevity-selected position any column with both $b_{M L S}>0$ and $p_{M L S}<0.01$. Conserved columns were assigned $b_{M L S}=0$ and $p_{M L S}=1$.

For the large-scale analyses, in the human orthologs I predicted secondary structure with PSIPRED (Jones, 1999); differences in composition were tested with Pearson's $\chi^{2}$ test. Protein domain definitions and other features were taken from SwissProt (Boeckmann et al, 2003) and mapped to OrthoMaM alignments by aligning each Swiss-Prot sequence to its human counterpart in OrthoMaM. Ontology enrichment analysis was performed using the Functional Annotation Clustering module of DAVID (Huang, Sherman, and Lempicki, 2009) with default parameters, including the human genome as background. I report only Benjamini-corrected p-values. For the rollingwindow analysis of positions, I included only contiguous blocks of 10 selected positions.

To construct the randomized control dataset, for each species $A$ except human, I swapped MLS, body mass, and phylogenetic label with those of one species $B$, which was randomly selected without replacement. All alignments remained unchanged, meaning that the same set of columns were fit in both the randomized control and real sets.

### 1.2.3. Homology modeling and structural analysis of AMHR2

I created a homology model of AMHR2 with Modeler (Eswar et al, 2007), using as template the kinase domain of BMPR2 (PDB ID: 3G2F). Homology models made with SWISS-MODEL (Arnold et al, 2005), or using as template the kinase domain of ACVR2B (PDB ID: 2QLU), yielded similar results. Positional conservation was calculated with AL2CO (Pei and Grishin, 2001), using 3G2F as the structural model.

### 1.3. RESULTS AND DISCUSSION

### 1.3.1. Due to overall conservation, most positions in the mammalian proteome are not longevity-selected

To identify specific positions (i.e., alignment columns) in the mammalian proteome that are conserved in long-lived but not in short-lived species, I fit a generalized multiple regression model to each position independently. My overall approach followed from the observation that many of the positions I sought were distinguished by high correlation between (1) each species' MLS and (2) functional similarity of each species' residue to that of a long-lived reference species. I used human as the reference species, both because it was the longest-lived mammal whose sequence was available and because I had the best confidence in the accuracy of its sequence. Figure 1-1 shows a simplified conceptual example of my approach. My method also accounted for each species' body mass and overall mutation rate relative to human. I emphasize that I chose multiple regression not for rigorous statistical reasons, but only as a computational tool to help form new biological hypotheses.

In this manner, I fit selected columns among the proteomes of 33 species (Figure 1-2), with MLS ranging from 3 y (shrew) to 90 y (human). Initially, I attempted to fit the entire unfiltered OrthoMaM database. However, this effort yielded many obvious false-positives driven by low sample size and data of questionable quality, including highly divergent sequence at exon-intron boundaries and alternate isoforms. For this reason, I implemented several heuristic filters for selection. In particular, because rodents are over-represented among the short-lived species of OrthoMaM, I selected only columns containing a character for shrew (Sorex araneus), the shortest-lived non-rodent. (Sections 1.2.1 and 1.2.2 give precise definitions of the sets
selected, fit, and conserved.) Using these criteria, I verified that most selected positions in the mammalian proteome ( $80 \%$ ) are conserved across all species (Table 1-1; also found previously by Jobson, Nabholz, and Galtier [2010] and Li and de Magalhães [2011]). In particular, at least 10 of 261 genes in the GenAge database of aging-related genes (de Magalhães et al, 2009) have protein products that show near-complete conservation in mammals ( $\geq 90 \%$ ratio of conserved positions to total human ortholog length), for example beta-catenin (CTNNB1), valosin-containing protein (VCP), fibroblast growth factor receptor 1 (FGFR1), and lamin A (LMNA). Thus, if these genes contribute to differences in mammalian longevity, it is likely via some mechanism other than structural differences in their protein products.

### 1.3.2. Among nonconserved positions, longevity-selected positions occur more often than expected by chance

For each selected position, my fitting procedure yielded both a longevityassociated slope $\left(b_{M L S}\right)$ and associated p -value ( $p_{M L S}$ ), as well as corresponding measures for body mass ( $b_{\text {mass }}$ and $p_{\text {mass }}$ ). Only those positions with significantly positive slope were called longevity-selected ( $b_{\text {MLS }}>0$ and $p_{\text {MLS }}<0.01$ ) or mass-selected ( $b_{\text {mass }}>0$ and $p_{\text {mass }}<$ 0.01). There were no positions that were both longevity-selected and mass-selected, suggesting that $p_{M L S}<0.01$ was a reasonable cutoff in general for my analyses.

Among positions with positive MLS slope, I analyzed the distribution of $p$-values in order to determine whether proteome-wide trends existed with regard to longevity-
selected positions (Figure 1-3). As a negative control, I also analyzed a matched set of positions whose MLS, body mass, and phylogenetic position had been randomly swapped ("randomized control"). If there were no overall relationship between MLS and amino acid conservation, then one would expect significant p -values to be no more common than nonsignificant p -values after accounting for shared phylogeny and body mass. This is indeed the case for the randomized control (Figure 1-3B). However, for the real data (Figure 1-3A), positions with more significant p-values are clearly overrepresented relative to those with less significant p -values. These results indicate that overall, longevity-selected positions in the mammalian proteome are much more likely than would be expected by chance.

This finding is robust to several perturbations of the data (Figure 1-4), including use of chimp as the reference instead of human (Figure 1-4A) and use of BLOSUM62 scores instead of BLOSUM80 scores (Figures 1-4D and 1-4E). I note that although BLOSUM62 is more commonly used than BLOSUM80, in this case BLOSUM80 is more appropriate because mammalian proteomes typically have $80-90 \%$ sequence identity. The result also holds for input in which all nonhuman primates except one (here, rhesus) are omitted (Figure 1-4B), indicating that it is not an artifact of primate overrepresentation in OrthoMaM. Almost all $(7,689 / 7,723)$ of the positions called significant in Figure 1-3A have $p_{M L S}<0.05$ in this control set, suggesting that its relative lack of very significant $p_{M L S}$ values is simply due to fewer data available for each position ( $\mathrm{n}=26$ versus 32 species available to fit). Finally, as one would expect the result does not hold
when dog, a shorter-lived species, is used as the reference instead of human (Figure 14C).

A plausible biological hypothesis to explain this overall plethora of longevityselected positions is that the evolution of longer mammalian lifespan requires particular concerted patterns of substitutions throughout the proteome that subtly affect protein properties such as binding affinity, folding, and stability. Consistent with this hypothesis is that relative to mouse (MLS 4 y ), the proteome of naked mole rat (a rodent with MLS $\sim 30 \mathrm{y}$ ) is more resistant to urea-induced unfolding (Pérez et al, 2009), suggesting increased protein stability in the longer-lived rodent. An analogous process requiring concerted patterns of substitution may be the convergent evolution of hyperthermostability in archaea and bacteria (Suhre and Claverie, 2003).

To determine overall trends in longevity-selected positions with regard to structural features of the proteome, I created and searched databases of both predicted secondary structure and predicted disordered regions for the human proteome. Table 1-2 shows the secondary structure composition of the human genome as a whole, as well as in the longevity-selected positions of both the real fit data and the randomized control data. This table shows two trends. The first trend is that, in both real and randomized longevity-selected positions, random coils are overrepresented, at the expense of $\alpha$ helices and $\beta$-strands, relative to the human proteome as a whole $\left(\chi^{2}(2, \mathrm{n}=7,702)=\right.$ 265.23, $p<2.2 \mathrm{e}-16$ ). This is easily explained by the observation that sequence in random
coils tends to be less conserved than other sequence; thus, fit positions will tend to be overrepresented in these regions.

The second trend is that, relative to randomized longevity-selected positions, real longevity-selected positions are slightly enriched in $\alpha$-helices at the expense of $\beta$-strands $\left(\chi^{2}(2, \mathrm{n}=7,702)=18.36, p=1.0 \mathrm{e}-4\right)$. The significance of this finding is unknown, but it is possible that an abundance of $\alpha$-helices imparts extra stability to proteins and protein complexes, eg via coiled-coil interactions (Mason and Arndt, 2004).

### 1.3.3. Longevity-selected positions are enriched in protein domains with known roles in inflammation, development, and other diverse functions

The majority of longevity-selected positions are located in regions of proteins that are unannotated and presumably unstructured. Since these regions are generally of unknown function at present, it is difficult to interpret the biochemical significance of substitutions within them. Thus, to find longevity-selected positions with the best likelihood of causing well-characterized changes to protein structure and function, I next narrowed my focus to known protein domains. Specifically, I compiled a list of all 129 domains that contain at least two longevity-selected positions. The 129 domains are contained in 114 proteins. Appendix A summarizes the proteins and domains, and Appendix B shows data for each longevity-selected position in the domains, including number of characters (ie, species) fit and all slopes and p-values. Five genes for the 114 proteins shown in these tables are present in the GenAge database (de Magalhães et al,
2009): serine-protein kinase ATM, ATM; serine/threonine protein kinase ATR, ATR; breast cancer type 1 susceptibility protein, BRCA1; ATP-dependent DNA helicase Q4, RECQL4; and DNA-dependent protein kinase catalytic subunit, PRKDC. Functional annotation clustering revealed that several of the 114 proteins belong to functional classes that have been associated with aging (Table 1-3). I give three examples. First, leukemia inhibitory factor receptor (LIFR) and interleukin-6 receptor subunit beta (IL6ST) dimerize to form the receptor for leukemia inhibitory factor (LIF; not present in our results), whose signaling is upregulated with age in association with thymic atrophy (Sempowski et al, 2000). Second, arachidonate 15-lipoxygenase (ALOX15) is an enzyme that is upregulated in aging rat brain $(\mathrm{Qu}, \mathrm{Uz}$, and Manev, 2000); it functions in production of inflammatory leukotrienes, and may also function nonenzymatically to upregulate NFкB (Manev et al, 2000). Third, several of these proteins function in blood coagulation, markers of which increase with age and may interact with markers of inflammation (Kanapuru and Ershler, 2009). Detailed structural analysis of these domains remains to be performed.

Table 1-3 also indicates that several of our hits are involved in development, and this highlights a limitation of my data set. It is well-known that developmental schedule and longevity have co-evolved in mammals (Finch, 1990; de Magalhães, Costa, and Church, 2007); thus, these positions may specifically be conserved due to their effect on development, or they may pleiotropically affect both development and adult longevity. I did not attempt to correct for developmental schedule when fitting the data. In my
framework, such correction is possible in concept by adding to the regression model a third predictor variable, species age at maturity. However, the present set of species exhibits the problem of multicollinearity: age at maturity is too well-correlated with MLS for correction to be a realistic goal $\left(\mathrm{R}^{2}=0.48\right.$ on $\mathrm{n}=30$ species for age at female maturity after phylogenetic correction). Additionally, no maturity data are available for three important species in our set: Pteropus, Tarsius, and Tupaia. Thus, it is not possible to distinguish in general whether the positions found by my method are conserved due to their roles in development, adult longevity, or both. But most of these proteins, including the next discussed example AMHR2, do have verified roles in the adult organism and may plausibly affect longevity.

### 1.3.4. Longevity-selected positions cluster in the kinase domain and C-terminal tail of AMHR2

The domain containing the greatest number of longevity-selected positions ( $\mathrm{n}=7$ ) was the protein kinase domain of AMHR2, a protein introduced in Section 1.1. In human, this domain comprises residues 203 - 517 . Downstream of this domain is the C-terminal tail of the protein, residues 518-573. This cysteine-rich tail is unique to the AMHR2 ortholog family and is predicted to lack secondary structure. On average, the residues in the region $463-573$ that do not form secondary structure have $p_{M L S}$ values that are consistently in the top $2 \%$ of the 3.6 million selected positions (median $p_{M L S}<0.568$ by sliding window analysis). But this trend does not hold for AMHR2 overall (median $p_{M L S}$ is 0.800 excluding secondary structure positions), suggesting that specifically the kinase

C-lobe and downstream C-terminal tail of AMHR2 are under lifespan-related selective pressure.

In sequence, five of the seven longevity-selected positions in the kinase domain of AMHR2 concentrate in two regions near the C-terminus of the domain (Figure 1-5). To determine the likely locations of our longevity-selected positions on the structure of AMHR2, I mapped them to the recently-solved structure of the kinase domain of bone morphogenetic protein type 2 receptor (BMPR2). This domain is the closest homolog to the kinase domain of AMHR2, with $40 \%$ sequence identity. My mapping (Figure 1-6) shows that these five longevity-selected positions cluster at or near a common surface of the AMHR2 kinase C-lobe. Specifically, they are all located on two loops near the bottom-front face of the domain: the $\alpha \mathrm{G}-\alpha \mathrm{H}$ loop (Y465, T469, and F473) and the Cterminal loop following $\alpha \mathrm{I}$ (E513 and H515). All five side-chains at least partially face solvent.

The side-chain of Y465 forms an intra-loop hydrogen bond with R462, a conserved residue. Thus, in conjunction with P464, the length of the Y465 side-chain constrains the angle of a second conserved arginine, R463, which forms hydrogen bonds to residues on $\alpha \mathrm{F}$ and the $\alpha \mathrm{F}-\alpha \mathrm{G}$ loop. Y465 is conserved in $8 / 9$ species with MLS of at least 30 y , but in $9 / 19$ shorter-lived species it is instead $H, F, C, N$, or $D$, none of which (except possibly H) can hydrogen-bond with R463 at the same angle as can Y. I predict that these substitutions would abolish at least the hydrogen bond with R462, destabilizing the $\alpha \mathrm{G}-\alpha \mathrm{H}$ loop. Although the $\alpha \mathrm{G}-\alpha \mathrm{H}$ and C -terminal loops are both quite divergent
overall and contain several positions that did not meet the significance criterion for longevity conservation, Y465 is the only nonconserved residue within them whose sidechain is predicted to interact with another residue of AMHR2.

T469 represents a position that may be differentially phosphorylated, but it also highlights some current limitations of my method and data set. T469 is the only predicted phosphorylation site on the $\alpha \mathrm{G}-\alpha \mathrm{H}$ loop (NetPhos score 0.692; Blom, Gammeltoft, and Brunak, 1999). However, Figure 1-5 shows that this residue is consistently serine or threonine in all species except shrew, where it is alanine. Substitution to a nonphosphorylatable residue would be of biological interest, but it is also possible that this position simply represents a genome assembly error in shrew. This position has $p_{M L S}=$ 0.006 , making it the least significant position of the five. My method could exclude it and many similar cases by adding more criteria to the position selection process, but at the cost of decreased sensitivity and increased complexity. I expect that the coming availability of high-coverage de novo mammalian genome assemblies will resolve many such cases (eg, Gnerre et al, 2011; Kim et al, 2011).

F473 faces forward in our model. It is conserved hydrophobic (F or L) in all species except guinea pig, rat, mouse, and shrew, where it is S or C . Thus, F473 may be involved in a hydrophobic interaction with a binding partner.

I have low confidence in the exact placement of the short C-terminal loop, because it is not conserved in BMPR2 and lacks contacts with the other elements of our model. However, both E513 and H515 on this loop are preferentially charged in long-
lived species, consistent with differential binding affinity. E513 is conserved in all species except rat, mouse, and shrew, where it is V , G , and A . H515 is conserved positive (H or R) in $16 / 17$ species with MLS at least 16 y , but it is charged ( $H, R$, or D ) in only 3/9 shorter-lived species. The preference for hydrophilic residues in long-lived species at these two positions specifically may suggest that flexibility of the C-terminal loop is a longevity-conserved property.

Most of the residues on the $\alpha \mathrm{G}-\alpha \mathrm{H}$ loop face the solvent, suggesting that they may interact with another domain or protein. If this is the case, then assuming that the gross function of AMHR2 is conserved within mammals, one would expect other residues on a common surface with the $\alpha \mathrm{G}-\alpha \mathrm{H}$ loop to be conserved. I used positional conservation analysis to determine conservation of the surface residues of two alignments, (1) mammalian AMHR2 orthologs exclusively and (2) a representative set of mammalian orthologs in the TGFBR2 subfamily, including orthologs of TGFBR2, activin receptor type-2A and B (ACVR2A and ACVR2B), BMPR2, and AMHR2 (not shown). This analysis revealed two conserved solvent-facing patches flanking the region of our longevity-selected positions. One patch, mainly comprising the $\alpha \mathrm{H}-\alpha \mathrm{I}$ loop, is conserved in all TGFBR2 subfamily members, confirming a previous observation (Belville et al, 2009). The other patch, mainly comprising the $\alpha \mathrm{F}-\alpha \mathrm{G}$ loop, is conserved only in AMHR2 orthologs.

Overall, these findings are consistent with the existence of a large interaction surface conserved in all AMHR2 orthologs whose area, and thus binding affinity, varies
at the $\alpha \mathrm{G}-\alpha H$ loop in a species-specific manner. It is likely that this is a novel docking surface involved in the regulation of AMHR2; one possible regulatory binding partner is the C-terminal tail of AMHR2 itself, whose positions also have consistently low $p_{M L S}$ values relative to the proteome overall, as noted above. Since loop $\alpha \mathrm{G}-\alpha H$ flanks this conserved patch, and four of the five residues face solvent in my model, it is possible that overall these positions contribute to lifespan-specific binding affinity.

I am unaware of reported mutations specifically in the two loops of AMHR2 that contain the longevity-selected positions described above. However, two prior lines of inquiry are consistent with my docking-surface hypothesis. First, Belville et al (2009) also mapped the AMHR2 kinase domain to a solved structure in order to investigate natural mutations found in PMDS. Although based on a structure of the more distantlyrelated ACVR2B instead of BMPR2, its details are similar to those of my model, including both overall tertiary structure and specific residue orientation. Of the seven mutated positions they analyzed, four were located in the C-lobe of the kinase domain. One, D491, lies in the conserved $\alpha \mathrm{H}-\alpha \mathrm{I}$ loop and faces solvent; its mutation to H causes PMDS. This mutation further supports the idea that the solvent-facing bottom of the Clobe is critical for proper AMHR2 function.

Second, closer to the two loops on the bottom face of the domain is the residue E485, which is in $\alpha \mathrm{H}$ and also faces solvent. In two independent population studies of Dutch women, the mutation E485Q was associated with menopause delayed by up to one year (Kevenaar et al, 2007; Voorhuis et al, 2011). In addition to its canonical role in male
fetal development, AMHR2 also plays a second role in adult reproductive function. It is expressed in granulosa cells of adult females, where it seems to act as a feedback inhibitor of follicle recruitment and growth by binding its ligand, AMH, which is secreted in a paracrine manner specifically by more mature follicles (Durlinger, Visser, and Themmen, 2002). Follicle depletion is the cause of menopause (Finch, 1990), and follicular decline or menopause has been observed in most or all mammals studied, including whales (Ward et al, 2009; Foote, 2008), nonhuman primates (Walker and Herndon, 2008), rodents, and others (Finch, 1990; Finch and Gosden, 1986), although admittedly data are lacking for most species in the wild. A reasonable deduction is that a species' rate of follicle depletion scales inversely with its longevity. I speculate that differential regulation of AMHR2 in a lifespan-dependent manner could act as a mechanism that effects this scaling, increasing the probability that a female has used all her reproductive potential before her death. This hypothesis could be viewed as a case of the disposable soma theory of aging (Kirkwood, 1977). It might be tested by relating AMHR2 ortholog sequence to rate of follicular decline across several species.

I also note the unusual cysteine conservation in the C-terminal tail, which is unique to AMHR2 orthologs. There are eight cysteine residues in this region of human AMHR2, all of which are relatively conserved. Multiple regression revealed a specific fit of the number of cysteines conserved to $\log _{10} \operatorname{MLS}\left(p_{M L S}=0.002\right.$ and $p_{\text {mass }}=0.082$ after phylogenetic correction). It is possible that these residues bind zinc or another metal ion,
thus imparting structure to this region, but the region does not match known zinc finger motifs.

### 1.3.5. Comparison with previous methods

Generally, I did not observe overlap between the longevity-selected proteins I identified and those identified in previous work (Jobson, Nabholz, and Galtier, 2010; Li and de Magalhães, 2011). But this is not surprising, because I differed in my assumptions, goals, and data sets used, as detailed in Sections 1.1 and 1.2.1. Most notably, I fit a smaller subset of high-quality protein alignments, focused on structured protein regions, and chose to ignore synonymous codon substitutions. Thus, I view my results as complementary, not conflicting, to prior work. Notably, both my method and that of Li and de Magalhães (2011) identified "myosin complex" as an ontology term enriched in longevity-selected proteins (Table 1-3). The two methods also agreed that two proteins were longevity selected, rho guanine nucleotide exchange factor 16 (ARHGEF16) and lymphokine-activated killer T-cell-originated protein kinase (PBK). As both myosin and ARHGEF16 are involved in cell migration (Hiramoto-Yamaki et al, 2010), there may be lifespan-specific differences in this activity, or our concordant findings may simply reflect its standard role in organismal development.

One apparent novelty of my method is that it allows analysis of individual positions in the proteome, not just entire proteins. In fact, this is not novel, as the method of Jobson et al (2010) also entails identification of specific longevity-selected positions, and the genes they called "longevity-selected" and "longevity-relaxed" were simply
genes with statistical over- or under-abundances of such positions. Here, I have emphasized individual positions rather than entire proteins for three reasons. First, I think it plausible, as did Jobson et al (2010), that a mark of a longevity-selected protein is an abundance of longevity-selected positions. Second, a focus on individual positions allows to more precisely determine arbitrary regions of a protein that may be longevity-selected, as exemplified by the C-terminus of AMHR2. In theory, such specific focus can suggest novel biochemical mechanisms. Third, since aging is a complex trait that is under weak selection, it is plausible that some major determinants are subtle general properties of the proteome itself (discussed in Section 1.3.2), rather than the explicit activity of a single protein or even a few functional collections of proteins. Longevity-selected positions are the most obvious markers of such properties, and so may provide clues to identify them, in the same way as they may identify individual longevity-selected proteins. In short, I do not suggest that the positions that I call longevity-selected, in isolation, are major determinants of mammalian longevity. I only suggest that they may mark proteins or proteomic features that are such determinants, but are less obvious.

For detecting longevity-selected protein positions, benefits of my method versus standard codon-level methods such as the codeml program of PAML (Yang, 2007) include emphasis on detection of significant biochemical changes that are likely to affect protein structure; straightforward single-position resolution, allowing to easily test hypotheses regarding arbitrary regions of proteins, as described above; simple control for species-specific mutation rate and shared phylogeny and fitting of body mass as an
alternate hypothesis to MLS; avoidance of the need to arbitrarily bin species by MLS; and faster run time. I reiterate that my method in theory is compatible with any quantitative trait, as illustrated by my inclusion of both MLS and body mass, although in practice correlations between predictor variables in the data limit the application of this for the predictors of greatest interest, such as developmental schedule (Section 1.3.3). However, this is a limitation that my approach shares with the others, given the set of species available. Some unique drawbacks of my method, in addition to those described in Section 1.3.4, include its reliance on a single reference proteome and lack of a specific model of protein evolution, implying unsuitability for rigorous statistical hypothesistesting. It is a task for future work to combine the benefits of this method with those of standard codon model-based methods.

### 1.4. CONCLUSIONS AND RECOMMENDATIONS

Based on principles of protein structure, I have developed a simple, extensible, and gerontologically-oriented method to find longevity-selected positions in the mammalian proteome. Using this method I found that, surprisingly, longevity-selected positions are much more common in the mammalian proteome than would be expected based on a randomized control. I also used this method to identify specific protein regions that deserve further study in the context of the comparative biology of aging and development, as well as specific agingrelated proteins that are likely not lifespan-conserved due to their overall conservation. The protein region I found that is most likely to be lifespan-conserved is the kinase domain and Cterminal tail of AMHR2, in which the longevity-selected residues lie on a common surface of unknown functional significance. Given caveats with my methodology (Section 1.3.5) and also with the dataset I used (Section 1.4.2), I have found my method to be a reasonable starting point for comparative analysis of protein function.

Given my conclusions, the following two topics are best suited for follow-up study.

### 1.4.1. AMHR2

To determine the functional significance of the longevity-selected surface of AMHR2 identified here, this protein should be further characterized in vitro. Currently, the key question regards the identity of AMHR2's binding partners. Of course, the extracellular domain of AMHR2 binds its canonical ligand, AMH (di Clemente et al, 1994). It has also been shown in rodent cells (Belville et al, 2005) that AMHR2 signals through a BMPR-like pathway, indirectly
activating mothers against decapentaplegic homolog 1 (SMAD1) by heterodimerization with the TGF $\beta$ Type I receptors activin receptor type-1 (ACVR1) and bone morphogenetic protein receptor type-1A (BMPR1A). To identify other protein binding partners in culture, it may be possible to perform a pulldown experiment with a glutathione S-transferase-tagged AMHR2 fusion construct, or to perform chemical crosslinking followed by fragmentation and mass spectroscopy. As discussed in Section 1.3.4, it is also possible that the cysteine-rich C-terminal tail of AMHR2 binds zinc or another metal ion. This might be tested in vitro by mobility assays of a C-terminal tail construct in the presence of various metals. Ultimately, crystallization of the AMHR2 kinase domain and C-terminal tail may be feasible. If C-terminal ligands can be identified, then a crystal structure that includes them would likely reveal a novel mode of kinase regulation, as the longevity-selected surface is distinct from known kinase regulatory regions (Goldsmith et al, 2007). Ideally, all these experiments would be performed using AMHR2 ortholog sequence from both long-lived (eg, human) and shortlived species (eg, shrew or mouse) to contrast their binding partners and structures.

More difficult would be to test my physiological hypothesis that AMHR2 can regulate timing of menopause in a lifespan-specific manner in mammals (Section 1.3.4). Conceptually, a straightforward approach would be to create a transgenic mouse line that replaces the wildtype $A m h r 2$ with the $A M H R 2$ ortholog of a long-lived species. Then follicle count and quality of aged transgenic animals could be compared to that of aged wildtypes, in a design similar to that of Perez et al (1999). However, due to this
experiment's substantial time and cost, it should not be attempted until AMHR2 has been characterized further in vitro, as above.

An alternate, but purely phenomenological, approach to explore the relationship between AMHR and menopause would be to count follicles throughout the lifespans of a sample of the species listed in Figure 1-5, and then correlate their patterns of decline with features of their AMHR2 sequences. This study would necessarily be poorly controlled, and even with a cross-sectional design the expense would currently be prohibitive due to two factors: the difficulty of obtaining the longest-lived nonhuman species, and lack of a noninvasive method to count total follicle population or otherwise measure ovarian reserve in diverse species. Although ultrasound has been used to count antral follicles noninvasively in species including mouse and cow (Jaiswal, Singh, and Adams, 2009; Burns et al, 2005), antral follicle population is cyclic, and thus cannot represent the total follicle population. The current spatial resolution of ultrasound is too low to resolve primordial follicles ( $<100 \mu \mathrm{~m}$ diameter; Palma et al, 2012), which comprise the majority of follicles.

### 1.4.2. Improvement of mammalian genomic data

To more accurately identify longevity-selected positions in the mammalian proteome, data issues must be addressed at four levels: the initial selection of genomes to sequence, sequencing and assembly per se, gene annotation, and finding orthologs in finished proteomes. All four of these levels are interrelated, but the only one specific to
the present project is the conceptual question of which genomes should be sequenced for gerontological analysis, so I focus on that question in this section. My major personal reason for performing the Stachybotrys work described in Chapter 2 was to become familiar with the state of the art at the other three levels. Thus, I demonstrate what I have learned about those more technical levels in Chapter 2. However, not all the techniques I describe for fungi will apply to mammalian genomes, which tend to be more complex.

Although OrthoMaM is mainly intended for use by phylogenists (Ranwez et al, 2007), I chose it for this gerontological study because it is curated and contains the highest-quality sequences currently available. However, for any comparative study of mammalian aging, OrthoMaM's selection of species is ultimately inadequate, because it contains relatively few species and also does not represent the full diversity of eutherian lifespans. Relatedly, as detailed in Section 1.3.1, two major problems are that all but one of the shortest-lived species (shrew) is a rodent, and most of the longest-lived species are primates, thus conflating longevity and phylogeny given a naive approach. Table 1-4 lists additional species whose genomes should ideally be included in any gerontological database. Three of these species' genomes have very recently been sequenced, to varying degrees of completeness, by short read-based methods. It should be possible, although labor-intensive, to determine whether the two conclusions of this chapter are robust to addition of these newly-sequenced proteomes to the original OrthoMaM dataset.

In compiling a gerontological genome database for any set of organisms, the primary constraint is the availability of accurate longevity records for each species. This
is because to determine MLS often takes many years and, for the case of a population in captivity, requires that we know how to maintain good health (Finch, 1990). The AnAge database (de Magalhães and Costa, 2009) reports acceptable- or high-quality estimates of MLS for 883 eutherian species in 19 orders (of 21 total) and 97 families (of 108 total), so this should be considered the upper limit on the size of such a gerontological database in the near future. Because the base cost of genome sequencing has dropped dramatically since the introduction of short-read sequencing, given sufficient funding it is possible that a genome database near this size could be assembled within a decade, which would increase the power of the method described here and would certainly prove useful in many other comparative efforts. Given the short read-based sequencing that is most prevalent today, I anticipate that the two biggest areas of challenge in assembling such a genome database would be (1) collection and coordination of DNA samples from zoos and other sources around the world and (2) ensuring high de novo assembly completeness and contiguity of these complex and repeat-rich genomes, eg through development of cheaper and less biased methods for construction of jumping libraries.

A final gerontological consideration in deciding which genomes to sequence is that for species of greatest interest, sequencing multiple individuals within the same species may be warranted. Due to the current lack of available data, for non-model organisms it has been implicitly assumed, in this study and many others (eg, Jobson, Nabholz, and Galtier, 2010; Li and de Magalhães, 2011), that the proteome of a single sequenced individual represents all fixed substitutions present in the species. However, at
least a quarter of human genes are known to contain a coding-region SNP (Stetson et al, 2003), and there is no reason a priori to assume that other species' genomes are any less diverse. So, given that the mammalian proteome is a large search space (several million positions), this one individual, one species assumption could cause false positives for methods with position-level resolution such as mine. A remedy would be to sequence the genomes of several unrelated individuals within each species to get a sense of which divergent positions are truly fixed substitutions and which are only (non-fixed) singlenucleotide polymorphisms (SNPs). When automatic and manual approaches are combined to identify longevity-selected positions, this would be of particular interest for unique species such as those listed in Table 1-4. I expect that this consideration will increase in importance when comparative analysis is extended to noncoding regions, where SNPs occur even more frequently than in coding regions.


Figure 1-1. Conceptual example of multiple regression method
This example shows my regression method applied to a single aligned amino acid position, Y465 of AMHR2. For full result of this fit, see Appendix B. Left. Characters shown ordered by species MLS. For each non-human species, calculate the similarity score (BLOSUM80) for the species' amino acid character versus the human character (here Y); eg, this score for Tursiops would be the similarity score for H versus Y , which is 2. Right. Now, fit the MLS of all non-human species to their similarity scores; eg, Tursiops' contribution to this fit is the point $(52,2)$. Not shown are the steps to correct for mutation rate and shared phylogeny, and the simultaneous fit of body mass. For this column, the data provide relatively strong support for a nonzero slope in the fit of similarity to MLS, even given trends in mutation rate, phylogeny, and body mass, and so this position is assigned a relatively significant p -value ( $p_{M L S}<0.01$ ).


Figure 1-2. Phylogeny of species used in this study

Shown next to each species' node are its binomial, common name, and MLS.


Figure 1-3. Density histograms of $p_{M L S}$ values
A. Real data. B. Randomized control. Each histogram shows the $\mathrm{n}=407,568$ fit positions with $b_{M L S}>0$ in the real dataset. See Section 1.3.2 for details.


Figure 1-4. Density histograms of $p_{M L S}$ values yielded by fitting alternate input sets
Complete methods for these fits are described in Section 1.2.2. As in Figure 1-3, only fit positions with $b_{M L S}>0$ are included. A. Chimp (Pan troglodytes) is the reference, and human is absent. B. Rhesus (Macaca mulatta) is the only primate fit. Human is the reference. C. Dog (Canis lupus) is the reference. D. Scores taken from BLOSUM62 instead of BLOSUM80. Real data. E. Randomized control data for (D).

[^2]Figure 1-5. OrthoMaM alignment of the C-terminal region of the AMHR2 kinase domain

Orthologs are ordered by species MLS. The five longevity-selected positions in this region (Y465, T469, F473, E513, and H515) are highlighted in gray. $X$ indicates regions that were masked due to excessive divergence (Section 1.2.1). Long regions of gaps are not necessarily real genome deletions, but are more likely to have been missed during genome assembly or annotation.


Figure 1-6. AMHR2 kinase domain mapped onto experimental structure of BMPR2 kinase domain

Structure is rainbow-colored by position in sequence, with N-terminus in blue and Cterminus in red. All seven longevity-selected positions found in this domain are shown as black sticks and are further described in Appendix B. The five longevity-selected positions discussed in the text are labeled; they are found on the $\alpha \mathrm{G}-\alpha \mathrm{H}$ loop (Y465, T469, and F473) and the C-terminal loop following $\alpha \mathrm{I}$ (E513 and H515).

| subset | columns <br> $\left(\times \mathbf{1 0}^{6}\right)$ | alignments |
| :--- | :--- | :--- |
| include human | 7.01 | $12,746^{\mathrm{a}}$ |
| ... selected | 3.64 | $7,708^{\mathrm{a}}$ |
| $\ldots . .$. fit | 0.73 | $7,590^{\mathrm{a}}$ |
| $\ldots . .$. conserved | 2.91 | $118^{\mathrm{b}}$ |

${ }^{\mathrm{a}}$ Number of alignments that include at least one position in the indicated subset.
${ }^{\mathrm{b}}$ Number of alignments that include only conserved positions.
Table 1-1. Number of positions and alignments selected, fit, and conserved
These three terms are defined in Sections 1.2.1 and 1.2.2.

|  | $\boldsymbol{\alpha}$-helix | $\boldsymbol{\beta}$-strand | random coil | total |
| :--- | :--- | :--- | :--- | :--- |
| human proteome | $2,108,348$ <br> $(29.95 \%)$ | 956,422 <br> $(13.59 \%)$ | $3,974,432$ <br> $(56.46 \%)$ | $7,039,202$ <br> $(100 \%)$ |
| real data | $1,922(24.95 \%)$ | $736(9.56 \%)$ | $5,044(65.49 \%)$ | $7,702(100 \%)$ |
| randomized <br> control | $160(23.26 \%)$ | $62(9.01 \%)$ | $466(67.73 \%)$ | $688(100 \%)$ |

Table 1-2. Predicted secondary structure in all positions of the human proteome and in two subsets of longevity-selected positions

| functional class | $\boldsymbol{p}$ | examples |
| :--- | :--- | :--- |
| extracellular region | $5.1 \mathrm{e}-5$ | BTD, CP, LAMA2, LAMA3, PRSS12 |
| cytokine-mediated signaling <br> pathway | 0.033 | JAK1, IL31RA, IL6ST, LIFR, RIKP1, KIT |
| protein tyrosine kinase activity | 0.018 | JAK1, ROS1, MST1R, NIN, OBSCN, KIT, TYK2 |
| multicopper oxidase; copper <br> ion binding | $9.4 \mathrm{e}-3$ | AFP, CP, F8, HEPHL1 |
| developmental process | 0.041 | AFP, AMHR2, ALOX15, CFTR, ATR, ATM, <br> BRCA1, RECQL4 |
| motor activity; myosin <br> complex | 0.015 | KIF18B, KIF20B, KIF22, MYO5C, MYO7B, <br> MYO18A |
| complement and coagulation <br> cascades; humoral immune <br> response | 0.061 | F8, F11, CR2, C1R, CFD, LTF, CD83 |
| serine-type endopeptidase <br> activity | 0.063 | F11, C1R, CFD, KLK6, LTF, PRSS12 |

Table 1-3. Selected clusters, not mutually exclusive, of ontology terms enriched in top protein domains

| binomial | common name | $\begin{aligned} & \text { MLS } \\ & (\mathrm{y}) \end{aligned}$ | reference (if sequenced) | interest |
| :---: | :---: | :---: | :---: | :---: |
| Balaena mysticetus | bowhead whale | 211 | Keane, de Magalhães, et al, unpublished | longest-lived mammal |
| Eubalaena spp | right whale | 70 |  | shorter-lived confamilial of bowhead |
| Blarina brevicauda | short-tailed shrew | 4 |  | a second shortlived shrew species |
| Heterocephalus glaber | naked mole rat | 28 | Kim et al, 2011 | small long-lived rodent |
| Hystrix brachyura | Old World porcupine | 27 |  | large long-lived rodent |
| Microgale dobsoni | Dobson's longtailed tenrec | 6 |  | shorter-lived confamilial of $E$ telfairi |
| Setifer setosus | greater hedgehog tenrec | 14 |  | shorter-lived and larger confamilial of Etelfairi |
| Trichechus manatus | Caribbean manatee | 56 | Broad Institute, unpublished | sirenian that continually replaces teeth |
| Dugong dugon | dugong | 73 | Broad Institute, in progress | long-lived sirenian that cannot replace teeth |
| Cebus capucinus | white-faced capuchin | 54 |  | long-lived small primate |

Table 1-4. Eutherian species of gerontological interest recommended to include in search for longevity-selected positions

MLS estimates from AnAnge (de Magalhães and Costa, 2009). For sirenian discussion and references, see Finch (1990), p 201.

# CHAPTER TWO <br> Comparative genome sequencing of the toxigenic black mold Stachybotrys 

### 2.1. INTRODUCTION

### 2.1.1. Personal motivation

This chapter is adapted from a manuscript conceived and prepared in the course of my graduate work (Semeiks et al, 2013). The genome, gene, and protein sequences described have been submitted to NCBI, and will be available under Bioproject PRJNA186748.

If my primary interest is the problem of human aging (Section 1.1.1), then why for nearly a year did I choose to study the genome of a mold that is all but certainly irrelevant to the biology of aging? I have two answers, both related to the difficulty of studying the genomics of aging.

The first answer is technical. As an initial step toward correcting the weaknesses I observed in my mammalian gerontological dataset (Section 1.4.2), my goal was to learn how to produce new genome and proteome assemblies de novo from start to finish. It is still quite difficult to solve a mammalian genome de novo, because the methods required are arcane, costly, and still evolving (eg, Gnerre et al, 2011; Williams et al, 2012). In contrast, fungal genomes are more easily soluble due to their smaller size and reduced complexity; yet building a fungal genome entails many of the same basic techniques in use for mammals. In learning these techniques, I have accomplished my goal, and in Section 2.2 I describe in detail what I have learned.

The second answer is biological. Originally, Stachybotrys was suggested (by my collaborator Dominka Borek) as a good fungus to sequence because it was thought to have a small genome and was one of the few known medically-relevant organisms that had remained unsequenced. However, in reading the Stachybotrys literature I realized something more: here was an opportunity to design a clean study in comparative genomics that answered a well-defined question of genetics and toxicology. In short, the problem I describe here has many of the desirable scientific qualities that the problem of human aging is currently lacking. It remains an open question whether it is possible to think about the problem of aging in ways that promote these qualities.

### 2.1.2. The problem of mutually exclusive toxin chemotypes in Stachybotrys

Stachybotrys is a genus of filamentous fungi found in soil worldwide (Jarvis, 2003). It can also inhabit damp buildings. It is mainly a saprophyte that feeds by degrading cellulose and other dead plant matter. However, it is related to cellulolytic plant pathogens including Fusarium and Myrothecium, and there is a report of soybean invasion (Li et al, 2002). Stachybotrys does not infect animals, but it does produce a variety of toxins that have killed livestock and sickened humans after contact with contaminated feed, most famously in Ukraine in the 1930s. More recently, several studies have suggested various links between Stachybotrys-infested buildings and poor health, but confounders are many (Kuhn and Ghannoum, 2003).

At the basic level, there is a puzzle of genetics in the toxins produced by Stachybotrys. Harmful Stachybotrys products include both proteins (Shi, Smith, and Miller 2011) and secondary metabolites (Pestka et al, 2008). Of these, the two most wellknown classes of secondary metabolite toxins are the trichothecenes and the atranones (Figure 2-1). Both are terpenoids, but they are not otherwise related in structure. The more toxic class, trichothecenes, are strong inhibitors of protein synthesis, and structurally they are further divided into two subclasses, simple and macrocyclic trichothecenes, with the latter subclass including the highly-toxic compounds called satratoxins (intranasal median lethal dose $\left[\mathrm{LD}_{50}\right] \sim 1 \mathrm{mg} / \mathrm{kg}$ in rodents [Jarvis, 2003]). Of the $\sim 200$ strains of Stachybotrys that have been tested, all can make simple trichothecenes (Andersen, Nielsen, and Jarvis, 2002). However, only a third of these strains can make macrocyclic trichothecenes (eg, satratoxins). Of the other two-thirds, most can make the less-toxic atranones; in fact, they are the only known atranone-producing organisms. Significantly, a strain of Stachybotrys that makes both satratoxins and atranones has never been observed, meaning that these chemotypes are likely mutually exclusive. I am not aware of another eukaryote with such a drastic difference in chemotype, and a priori there is no apparent biochemical rationale.

To determine the genetic bases for the two chemotypes of Stachybotrys and to compare Stachybotrys to other trichothecene toxin producers including Fusarium and Trichoderma, I have sequenced and assembled de novo the genomes of four cultured Stachybotrys strains. Two of these strains make atranones, and the other two make
satratoxins. I report some global properties of these genomes, most notably an unexpected richness of polyketide synthase (PKS) genes. I then present the core trichothecene cluster (CTC) of Stachybotrys, which diverges significantly from the CTCs of other trichothecene producers, with a genomic context that appears to be chemotypespecific. Finally, I use comparative methods to show that toxin chemotype in Stachybotrys likely arises from the presence of strain-specific secondary metabolite biosynthesis gene clusters, including three satratoxin-specific clusters and a novel $35-\mathrm{kbp}$ locus that I have named the core atranone cluster (CAC).

### 2.2. MATERIALS AND METHODS

### 2.2.1. Stachybotrys culture, DNA extraction, and library construction

Stachybotrys strains were kindly provided by Kristian F. Nielsen (Center for Microbial Biotechnology, DTU, Denmark). Initially, fungus was grown on potato dextrose agarose to establish monoclonal populations by single-spore selection; these monoclonal populations were used for all subsequent procedures. Strain identities were verified by PCR-based sequencing of TRI5 (Andersen et al, 2003). For sequencing libraries, hyphae were grown in 3-ml tubes of potato dextrose broth at $25^{\circ} \mathrm{C}$ in the dark for $1-2$ weeks until confluent. Genomic DNA for sequencing libraries was obtained by a method based on cetyltrimethylammonium bromide (CTAB) disruption and phenol-chloroform extraction that is similar to a previously-described method (Cruse et al, 2002). Fresh hyphae were drained of media and pulverized in liquid $\mathrm{N}_{2}$. The sample was added to a tube containing hot 2 x CTAB buffer and $\mathrm{n}=35-\mathrm{mm}$ glass beads, and then bead-beaten on a vortexer for 1 mn . DNA was extracted with 25:24:1 phenol:chloroform:isoamyl alcohol, treated with Riboshredder (Epicentre) for 30 mn at $37^{\circ} \mathrm{C}$, and precipitated with isopropanol.

Multiplexed Illumina DNA fragment libraries were constructed as follows. For each strain, $500-1000 \mathrm{ng}$ genomic DNA was sheared by sonication (Bioruptor, Diagenode) to $\sim 500$ bp. Fragments were end-repaired (NEBNext End Repair Module, NEB), dA-tailed (NEBNext dA-Tailing Module, NEB), and ligated (NEBNext Quick Ligation Module, NEB) to custom Yadapters that included strain-specific 4- or 5-bp barcodes. Each respective reaction product was purified with Agencourt AMPure XP beads (Beckman). Ligated product was size-selected to 350 bp (nominal) by electrophoresis on $2 \%$ agarose, excision, and gel extraction (MinElute Gel

Extraction kit, Qiagen) overnight at room temperature. Following size selection, each library was amplified by PCR (Phusion High Fidelity PCR Master Mix with GC Buffer, NEB) using the standard Illumina primers, with 3 ng template, $0.5 \mu \mathrm{M}$ primers, 12 PCR cycles per reaction, and other reagents and reaction parameters per NEB's instructions. All PCRs in this study were performed on a PCR Express thermal cycler (Thermo Hybaid). PCR product was size-selected as above to remove unreacted primer and adapter dimers. The four libraries were then pooled to 2.5 nM each and submitted to the UT Southwestern Genomics Core for sequencing on a single lane of an Illumina HiSeq 2000.

### 2.2.2. Genome assembly and resequencing of specific loci

Base-calling of reads from intensity data was accomplished with AYB 2.11 (Massingham and Goldman, 2012). This yielded 394 million paired reads, $72 \%$ of which passed purity filtering. Pure reads were demultiplexed and sequencing artifacts (including reads containing adapter and primer sequence) were removed using custom scripts. The remaining reads were end-trimmed to quality 20 or higher. Reads were spectrally corrected with Quake 0.3.0 (Kelley, Schatz, and Salzberg, 2010) and then assembled de novo into contigs and scaffolds with SOAPdenovo 1.05 (Li et al, 2010) and AbySS 1.3.4 (Simpson et al, 2009). For each strain and assembler, we produced $\mathrm{n}=27$ (SOAPdenovo) or 10 (AbySS) separate assemblies, in each case iterating K from 31 to 81 . I then selected as representative an assembly with a subjectively good combination of total size and $\mathrm{N}_{50}$ length; these parameters were generally robust over a wide range of K values. The final

SOAPdenovo assemblies had the following K values: strain 40285, $\mathrm{K}=43$; strain 40288, $K=53$; strain 40293, $K=45$; and strain $7711, K=51$.

Two loci discussed in Results are each split over two different sequences in our assemblies: the CTC of strain 40293 and the CAC of strain 40288. I verified by Sanger sequencing of PCR amplicons that each of these regions is in fact a single contiguous locus, although in each case the two flanking regions are separated by an estimated 50100 bp repeat that has not proven possible to sequence by either the parallel or the Sanger method. The PCR primers I used were as follows; they include two independent pairs for each locus. For CTC, primer pair 1: forward TTGGTCGTCTCTTGAGATTCACTGGC, reverse CCAAAGTGGAAGGTTCATGGTTGAGC; primer pair 2: forward TTCCCTTGCTTCCGTACCTTATTCCC, reverse

TTATTCCCATCCTTTGTCCGGAGTGG. For CAC, primer pair 1: forward AAGTCTCATCTTGCCTCGGAATCAGG, reverse AGTTCAACCTTCTCTCAGGAACAGGG; primer pair 2: forward CCTGATCTTGGACATTGCTATTCCGC, reverse TTTGCATGAGCTAAACACACCGGG. The CTC was amplified in a $50 \mu \mathrm{l}$ reaction including $5 \mu \mathrm{l}$ Accuprime Pfx reaction mix, $0.4 \mu \mathrm{l}$ Accuprime Pfx DNA polymerase, 0.3 $\mu \mathrm{M}$ each primer, and 3 ng genomic DNA from strain 40293. The CAC was amplified in a $100 \mu \mathrm{l}$ reaction including $10 \mu \mathrm{l}$ Accuprime Pfx reaction mix, $0.8 \mu \mathrm{l}$ Accuprime Pfx DNA polymerase, $0.3 \mu \mathrm{M}$ each primer, and 3 ng genomic DNA from strain 40288. PCR parameters included $30(\mathrm{CTC})$ or $35(\mathrm{CAC})$ cycles of denaturation at $95^{\circ} \mathrm{C}$ for 15 s ,
annealing at $55^{\circ} \mathrm{C}(\mathrm{CTC})$ or $58^{\circ} \mathrm{C}(\mathrm{CAC})$ for 30 s , and extension at $68^{\circ} \mathrm{C}$ for 60 s . Before sequencing, both products were gel purified (Minelute Gel Extraction Kit, Qiagen), reamplified with the same PCR parameters as were used for the first reaction, and repurified (Wizard SV kit, Promega).

### 2.2.3. Proteome assembly

For proteome assembly (ie structural annotation) I used MAKER 2.26 (Holt and Yandell, 2011), which incorporated both homology-based (BLAST 2.2.26 and Exonerate 2.2.0) and de novo methods (GeneMark 2.3e and Augustus 2.6.1) and output only transcript models that were supported by both types of evidence. For each strain, MAKER was run twice. The second pass was run in reannotation mode, and included as homology targets all four proteomes output by the first pass. On both passes, other homology targets included the Swissprot database (current build as of 20 Aug 2012) and the three Fusarium proteomes (Ma et al, 2010). Full input parameters for MAKER are listed in Appendix G.

To compare the genomes of Stachybotrys and Fusarium, features of the $F$. graminearum genome were obtained from the Fusarium graminearum Genome Database (Wong et al, 2011).

### 2.2.4. Genetic nomenclature of Stachybotrys

In naming Stachybotrys genes and proteins, I chose to follow the conventions in use for E. coli and Fusarium. All gene and protein names are three letters followed by a
number. Gene names are all-uppercase and italicized, eg "TRI5". Corresponding protein names are capitalized and in standard face, eg "Tri5".

### 2.2.5. Protein and rRNA phylogenies

To construct phylogenies, proteins were downloaded from NCBI using the accessions listed in the cited references. Following protein alignment with the L-INS-i method of mafft 6.903 b (Katoh and Toh, 2008), any position containing a gap was discarded. Protein phylogenies were inferred with PhyML 20120412 (Guindon et al, 2010), using 100 bootstrap replicates and otherwise default parameters.

### 2.2.6. Proteome comparisons and PKS inventory

To obtain groups of homologous proteins as described in Results, OrthoMCL 2.0 (Li, Stoeckert, and Roos, 2003) was run on nine proteomes using default parameters, including BLAST E-value cutoff of 1e-5. Protein domains were identified by searching the nine proteomes with RPS-BLAST 2.2.26 against the NCBI Conserved Domain Database (CDD; current as of 2 Aug 2012), and then filtering results using the NCBI Specific Hits algorithm (Marchler-Bauer et al, 2011). Domain enrichment analysis was done using Fisher's exact test with correction for multiple testing, as described in Appendix C. All domain identifiers mentioned in Results are the unique "domain short names" assigned by CDD.

I define a putative Stachybotrys PKS as any predicted protein that includes all three of the CDD domains PKS, PKS_AT, and either PKS_PP or PP-binding.

### 2.2.7. Identification of chemotype-specific gene clusters

I define a chemotype-specific gene cluster as a locus containing at least three genes, all of which are both chemotype-specific and contiguous. Chemotype-specific gene cluster candidates were identified by collating OrthoMCL gene clusters with chemotype-specific loci found by whole-genome alignment with Mugsy 1r2.2 (Angiuoli and Salzberg, 2011); I used custom scripts to process Mugsy's output in this manner. After identification of candidate clusters, OrthoMCL results were analyzed to exclude those clusters that did not meet the above definition of "chemotype-specific gene cluster". Of the 10-20 total candidate clusters, most were easily excluded because Mugsy had missed strain-specific alignments, as verified by BLASTN, and simultaneously there were obvious chemotype-independent orthologs found by OrthoMCL.

### 2.3. RESULTS AND DISCUSSION

### 2.3.1. Sequencing and assembly of Stachybotrys genomes

The four Stachybotrys strains that I sequenced are shown in phylogenetic context in Figure 2-2. The strains include two species, S. chlorohalonata (IBT strain 40285) and $S$. chartarum (IBT strains 40288, 40293, and 7711), that are distinguishable by both morphology and molecular markers. Strains 40285 and 40288 make atranones, while strains 40293 and 7711 make satratoxins (Andersen et al, 2003).

The genomes of these four strains were obtained by massive parallel sequencing on an Illumina Hiseq 2000. For each strain, I constructed a separate $300-\mathrm{bp}$ nominal genomic fragment library. I multiplexed these libraries in order to combine them all on a single sequencer lane, which yielded $\sim 70$ million 101-bp reads per strain after demultiplexing and error correction. I then assembled each genome independently with SOAPdenovo (Li et al, 2010), followed by structural annotation of each assembly with MAKER (Holt and Yandell, 2011) using a crossstrain iterative strategy.

Table 2-1 summarizes the genome and proteome assemblies, and for comparison also includes a finished assembly of the trichothecene producer Fusarium graminearum obtained by Sanger sequencing (Ma et al, 2010). As shown in the table, these five genome and proteome assemblies are similar in size, although those of the $S$. chlorohalonata strain 40285 are slightly smaller than the three $S$. chartarum strains. Except for $\mathrm{N}_{50}$ length, the features of all four Stachybotrys assemblies, eg their short introns and sparse repeat content, are comparable to the finished F. graminearum assembly. This is consistent with the fact that Fusarium is one of the closest relations to Stachybotrys whose genome has been sequenced.

I independently assembled each strain with ABySS (Simpson et al, 2009) to validate the SOAPdenovo results. While scaffold $\mathrm{N}_{50}$ length obtained from ABySS was reduced by $20-80 \mathrm{kbp}$ versus scaffold $\mathrm{N}_{50}$ length from SOAPdenovo, total genome sizes were nearly identical. Also, the seven gene clusters I describe below for the SOAPdenovo build were appropriately present in the ABySS assemblies. Specifically, in both the ABySS and SOAPdenovo assemblies, the core trichothecene cluster had identical architecture in all four strains, and the six other novel clusters I describe were consistently atranone- or satratoxin-specific.

### 2.3.2. Comparative proteome content of Stachybotrys

To estimate the completeness of my proteome assemblies and compare them to those of other sequenced fungi, I used two methods. First, I used CEGMA (Parra, Bradnam, and Korf, 2007) to search the Stachybotrys genome assemblies for 458 proteins known to be highly conserved in eukaryotes. By this criterion, all four Stachybotrys assemblies are $98 \%$ complete, with identical completeness found for $F$. graminearum and the two other sequenced Fusarium genomes, $F$. oxysporum and $F$. verticillioides, neither of which make trichothecenes. All proteins found by CEGMA were independently found by MAKER in the full Stachybotrys proteomes, suggesting that my four genome assemblies are relatively complete.

Second, I identified groups of homologs in the proteome assemblies with OrthoMCL (Li, Stockert, and Roos, 2003). For diversity, I used nine proteomes in total: the four Stachybotrys assemblies; the three Fusarium proteomes named above (Ma et al,
2010); and two more divergent model fungi, Aspergillus nidulans (Arnaud et al, 2012) and Saccharomyces cerevisiae (Cherry et al, 1998). OrthoMCL clustered these proteomes into 16,311 groups, each containing at least two proteins. Of these groups, 2,177 contained exactly one orthologous sequence from each of the nine proteomes. Using this subset of proper orthologs, I constructed a robust phylogeny (Figure 2-3) and quantified proteome divergence by calculating pairwise sequence identities (or proteome identities; Table 2-2). This phylogeny matches both accepted taxonomy and a previous molecular phylogeny (Wu et al, 2003), grossly validating both my Stachybotrys proteomes and my OrthoMCL-based method. As expected given prior analysis of Stachybotrys genetic markers (Andersen et al, 2003), the proteome identities indicate that the $S$. chlorohalonata strain 40285 is the most divergent of the four Stachybotrys strains, but this divergence is relative: there is $98 \%$ proteome identity between 40285 and any $S$. chartarum strain, versus $74 \%$ identity between Stachybotrys and Fusarium and $>99 \%$ identity within strains of S. chartarum.

Figure 2-4 summarizes the distribution of homolog groups in the four genera. Of the 16,311 homolog groups, most included orthologs from Stachybotrys ( $68 \%$ of all groups) and Fusarium (80\%). Many groups were exclusive to Stachybotrys (16\% of all groups) or Fusarium ( $24 \%$ ), perhaps reflecting genus-specific secondary metabolites or other phenotypes. As might be expected, most of the proteins in the 2,615 groups exclusive to Stachybotrys lack known domains (only $37 \%$ contain at least one domain from the Conserved Domain Database [CDD; Marchler-Bauer et al, 2011], vs $\sim 65 \%$ of
all Stachybotrys proteins). Domain enrichment analysis (full results in Appendix C-1) revealed that of the Stachybotrys-exclusive protein domains, those enriched relative to the domains of non-exclusive Stachybotrys proteins likely have specialized functions such as mating enforcement (the CDD HET domain), degradation of plant materials (glycosyl hydrolases Glyco_hydro_61 and Glyco_hydro_6; several peptidase domains including M28; the pectate lyase domain Amb_all; and the cellulose-binding domain fCBD), and synthesis of novel secondary metabolites or other products (methyltransferases, acetyltransferases, and cytochrome P450 monooxygenases).

I also compared the whole domain compositions of the Stachybotrys and Fusarium proteomes, independently of homology considerations. Domain enrichment analysis (Appendix C-2) revealed remarkably few significant differences in gross domain composition between the two genera (only nine domains differentially present of 5,752 tested). Four CDD domains are enriched in the Stachybotrys proteome relative to Fusarium. Two of them, fCBD and Glyco_hydro_61, are also enriched in the Stachybotrys-exclusive proteins described above, and may reflect genus-specific differences in nutrient intake. The other two domains, PKS and PKS_AT, are respectively the ketosynthase and acyltransferase domains that are found constitutively in type I iterative polyketide synthases (PKSs). In fungi, PKSs are large proteins of variable domain architecture that are responsible for producing a diverse array of polyketide secondary metabolites (reviewed by Cox, 2007). It is noteworthy that each strain of $S$. chartarum conservatively encodes 35-37 PKSs, over twice as many as Fusarium and
more than any other fungus known, suggesting that a multitude of secondary metabolites from Stachybotrys remain uncharacterized (Appendix D). PKSs also appear to play roles in Stachybotrys's biosynthesis of trichothecenes and atranones, as discussed next.

### 2.3.3. The core trichothecene gene cluster of Stachybotrys diverges from those of other trichothecene producers

Many fungal secondary metabolites are made by products of genes that are found adjacent to one another in a single contiguous locus (Keller, Turner, and Bennett, 2005). I refer to such genetic loci as secondary metabolite biosynthesis (SMB) clusters. In the simple trichothecene producers Fusarium graminearum and $F$. sporotrichioides, a wellstudied SMB cluster is the core trichothecene gene cluster (CTC). The Fusarium CTC encodes $11-12$ genes, most of which are required to catalyze specific steps in trichothecene production (Brown et al, 2004). CTC sequences are also available for Trichoderma arundinaceum and T. brevicompactum (Cardoza et al, 2011); each contains only seven genes. This divergence of the Fusarium and Trichoderma CTCs reflects the divergence of trichothecene pathways between the genera. Most prominently, Fusarium makes only products modified at backbone position C-3, such as deoxynivalenol and T-2 toxin. In contrast, Trichoderma (like Stachybotrys) does not modify C-3, but makes exclusively trichothecenes modified at backbone position C-4, including trichodermol (Figure 2-1; McCormick et al, 2011).

Each of the four Stachybotrys assemblies includes a complete and identical ~30kbp locus that I name the Stachybotrys CTC. The CTC structure is shown in Figure 2-5,
with more detail in Appendix E-1 (hypothesized protein functions) and Appendix F (full protein sequences). The CTC comprises nine genes, including putative orthologs of seven Fusarium and Trichoderma genes: the terpene cyclase TRI5, the acetyltransferase TRI3, the hydroxylases TRI4 and TRI11, the transcription factors TRI6 and TRI10, and a gene of unknown function TRI14. The remaining two genes in the Stachybotrys CTC are novel, so I name them by convention: the putative PKS TRII7, and adjacent to it the TRI3 paralog TRI18.

The products of the Fusarium, Trichoderma, and Stachybotrys CTCs are consistent with both the divergence of the Stachybotrys CTC from that of Fusarium and the similar gene content of the Stachybotrys and Trichoderma CTCs (six genes are shared). However, I was surprised by the divergence in Stachybotrys gene order from the Trichoderma CTC, since the initial trichothecenes made by Stachbotrys and Trichoderma are identical. For example, versus Trichoderma TRI5, Stachybotrys TRI5 is located within the CTC, and I cannot identify any simple rearrangements that would convert one CTC to the other. At least two additional data support the novel CTC architecture of Stachybotrys. First is the fact that two independent assemblers yielded the same sequence (Section 2.3.1). Second is the fact that the recently-sequenced CTC of the macrocyclic trichothecene producer Myrothecium roridum has a similar architecture, including mostly-conserved gene order and the presence of putative TRII7 and TRII8 orthologs (Robert H. Proctor, personal communication). The diversity of the CTC is consistent with
the hypothesis that it is a hotspot for insertion and deletion of enzyme-coding genes, in turn allowing for substantial structural diversity of trichothecenes.

I have identified two Stachybotrys loci outside of the CTC that contain paralogs of CTC genes. First, there is the satratoxin-specific cluster SC2, which contains paralogs of TRI3 and TRI4; it is discussed in the satratoxin section below. Second, the assembly of strain 40293 includes a small scaffold that contains only two genes, which I name TRI19 and TRI20, that are respective paralogs of TRI5 and TRI6. With the arguable exception of TRI8 (Section 2.3.5), I have not observed Stachybotrys orthologs of any other known Fusarium trichothecene biosynthesis (TRI) gene. The most surprising absence is that of the trichothecene exporter TRI12, which is present in the CTCs of both Fusarium and Trichoderma (Cardoza et al, 2011).

### 2.3.4. The products of the core atranone cluster likely suffice to make all known atranone species

I hypothesized that the two mutually-exclusive chemotypes of Stachybotrys were due to the presence of strain-specific SMB clusters. To test this hypothesis computationally, I searched the four Stachybotrys genome assemblies for loci that were present in both satratoxin strains but in neither atranone strain, or vice versa. The search strategy combined two methods. At the genomic level, I employed four-way wholegenome alignment, using Mugsy (Angiuoli and Salzberg, 2011). At the level of the proteome, I considered the sets of homologs compiled with OrthoMCL as described in Section 2.3.2. Whole-genome alignment was needed to show genomic context, but in
practice Mugsy did not correctly align some locus boundaries, so I manually adjusted its results as described in Methods. The search yielded a formal total of two atranonespecific and four satratoxin-specific gene clusters; I describe the satratoxin-specific clusters in Section 2.3.5.

The larger of the two atranone-specific gene clusters I name the core atranone cluster (CAC, or AC1; Figure 2-6, with details in Appendices E-2 and F). This is a $\sim 35-$ kbp PKS-based cluster, and it has a nearly-identical architecture of 13-14 genes in both atranone strains. I name these genes ATR1—ATR14. The CAC is complete in the sense that both its flanking loci, or their orthologs, are present in all four strains.

I predict that the products of the CAC suffice to catalyze most or all steps of atranone synthesis, starting from geranylgeranyl pyrophosphate (GGPP; Figure 2-1). This prediction is based on two observations. First, the CAC is one of only two clusters exclusive to two relatively divergent strains of Stachybotrys (Figure 2-3 and Table 2-2). Second, the predicted CAC products satisfy some key constraints of the chemical model for atranone biosynthesis (Figure 2-7) proposed by Hinkley et al (2000). Specifically, the Hinkley model entails two particular reactions: the initial cyclization of GGPP to dolabellane, and a Baeyer-Villiger oxidation near the end of the scheme to convert atranones D and E to atranones F and G. Putatively, CAC products can catalyze both of these reactions: ATR13 encodes a terpene cyclase (characteristic terpene cyclase motif DDXXE [Keller, Turner, and Bennett, 2005] and best BLAST hits [E $<1 \mathrm{e}-40$ ] to related fungal terpene cyclases), while ATR8 encodes a Baeyer-Villiger monooxygenase
(BVMO; characteristic BVMO motif FXGXXXHXXXWD [Fraaije et al, 2002]; best BLAST hits $[\mathrm{E}<1 \mathrm{e}-65]$ to the BVMO phenylacetone monooxygenase from fungi, including Paracoccidioides, and bacteria). Although terpene cyclases are relatively common in the four Stachybotrys proteomes, the BVMO motif is very rare. There is only one other set of homologs that contain the BVMO motif. This second BVMO set has representatives in all four strains; OrthoMCL groups it separately from the atranonespecific pair found in the CAC; and each of its members are located in a chemotypeindependent gene cluster that also contains glycosyl hydrolases, consistent with a possible role in feeding rather than secondary metabolism per se. Taken together, all these data suggest that the function of the CAC's products is to synthesize atranones.

Of the CAC's other predicted products, the largest is the reducing PKS Atr6. A BLAST search suggests that this protein is related to both fungal and bacterial PKSs, with the best hit to an uncharacterized PKS from Aspergillus fumigatus. Some other predicted CAC products include four oxygenases, three short-chain reductases, an esterase, and a methyltransferase. These are all plausibly involved in the various steps of atranone biosynthesis, although their specific roles must await experimental determination, because the types of reactions that they catalyze appear frequently in the Hinkley model (Figure 2-7).

If my predicted function for the CAC is correct, then it remains an open problem how atranone biosynthesis is regulated. Unlike the CTC and satratoxin-specific SMB clusters found in Stachybotrys, I have not been able to identify any transcription factors
or other putative regulatory genes within the CAC or nearby; the closest is a chemotypeindependent GAL4-family gene that is 21 kbp upstream. Another example of a fungal SMB cluster lacking internal regulatory genes is the penicillin cluster of Aspergillus nidulans and other species (Spröte et al, 2008). A scan of the 14 putative CAC promoter regions revealed that two-thirds contain both the motif TGTCT and its reverse complement AGACA. (Specifically, 25 of the 28 promoter regions contain AGACA, 24 contain TGTCT, and 20 contain both motifs.) These inverted repeats may be bound by a single transcription factor, as yet unidentified. Alternatively, some CAC products may be widely expressed, with post-transcriptional regulation additionally possible; consistent with this hypothesis is the report that most atranone-producing Stachybotrys strains easily produce simple dolabellane derivatives in culture, but do not always produce atranones per se (Andersen, Nielsen, and Jarvis, 2002).

From a genetic perspective, it would be ideal to confirm the CAC's predicted function by exogenous expression in either a model organism such as yeast or, better yet, a satratoxin strain of Stachybotrys. However, at present this would be difficult. In addition to the uncertain regulation noted above, practical challenges include the large size of the cluster and the fact that, to my knowledge, Stachybotrys has not yet been used as a recombinant organism.

The second atranone-specific gene cluster is named AC 2 ; its products are not shown. It is smaller than the CAC, spanning 12 kbp and containing six genes. Unlike the $\mathrm{CAC}, \mathrm{AC} 2$ is missing one flank in our assemblies, meaning it may be incomplete. Also,
three of its genes are homologous to those of a second distinct locus conserved in all $S$. chartarum strains (on scaffold645 of 40288, scaffold1203 of 40293, and scaffold1305 of 7711). The largest gene in AC 2 putatively encodes the phosphate transporter domain PHO4, and another encodes a helix-loop-helix (HLH) transcription factor. Two other genes yielded relatively weak BLAST hits ( $\mathrm{E} \approx 1 \mathrm{e}-4$ in both cases) to cyclins and arrestins, respectively, suggesting overall that AC 2 could be related to environmental phosphate sensing. Because phosphate-substituted compounds are used in synthesis of terpenes, specifically-regulated phosphate transport may be necessary for appropriate production of farnesyl pyrophosphate (FPP) or other atranone precursors.

### 2.3.5. Gene clusters specific to satratoxin strains of Stachybotrys

A general biosynthesis model for the satratoxins has been proposed, based on the known structures of similar molecules that are taken to be intermediates (Figure 2-8, adapted from Degenkolb et al, 2008). In this model, satratoxins and all other macrocyclic trichothecenes derive from trichodermol, first by sequential esterification of two sidechain species to C-4 and C-15 hydroxyl groups on the trichothecene skeleton, and second by condensation of the two sidechains to form the macrocycle. Based on their structures, the sidechains are plausibly polyketide products, although they would need to be modified by external hydroxylases to yield the primary hydroxyl groups that are observed. Optionally, PKS-independent reductases and methyltransferases may also be involved.

The whole-genome comparative method described above revealed four satratoxinspecific gene clusters, three of which encode the types of enzymes just described (Table 2-3; Appendices E-3, E-4, and E-5; and Appendix F). I refer to them as satratoxin clusters (SCs) 1-4, in order of size. The two largest, SC1 and SC2 (Figure 2-9), are classical PKS-based SMB clusters. SC3 (Figure 2-5) is smaller and is not a complete SMB cluster on its own, but it is found adjacent to the CTC. As shown in the figures, all three of these SCs are missing at least one flank in the assembly (ie, they are at the borders of their respective scaffolds), raising the possibility that in fact they are all located close to the CTC and can thus be easily coregulated.

SC1 (Figure 2-9 and Appendix E-3) is a 30-kbp cluster that contains ten genes, SAT1-SAT10. The largest genes are SAT8, which encodes a putative PKS with a conventional nonreducing architecture (Cox, 2007), and SAT10, whose putative product contains four ankyrin repeats (RPS-BLAST prediction) and thus may be involved in protein scaffolding. The putative short-chain reductase Sat3 may assist the PKS in some capacity. Sat6 contains a secretory lipase domain and is similar to the Fusarium trichothecene C-15 esterase Tri8 (BLASTP E-value 3e-93, 40\% identity, $85 \%$ coverage), although it is even more similar to other unstudied proteins from Fusarium and Aspergillus. The adjacent gene SAT5 encodes a putative acetyltransferase, and so the two together may effect endogenous protection from toxicity in the same manner as Tri8 and Tri101 of Fusarium (McCormick and Alexander, 2002).

SC2 (Figure 2-9 and Appendix E-4) is 20 kbp and contains six genes, SAT11SAT16, the largest of which encodes the putative reducing PKS Sat13. SC2 is unique in that three of its putative products are paralogs of Stachybotrys products otherwise encoded exclusively by the CTC. Sat11 is a cytochrome P450 monooxygenase and a Tri4 paralog, while Sat14 and Sat16 are respectively complete and truncated paralogs of the acetyltransferase Tri3. Finally, the cluster may be regulated by the zinc finger protein Sat15, which is most similar to the putative LolU transcription factor reported in an SMB cluster of the grass-endophytic fungus Neotyphodium (Spiering et al, 2005). I can find only six putative LolU homologs in Stachybotrys 7711, and one also flanks the CTC of M. roridum (Robert H. Proctor, personal communication). Taken together with the novel architecture of the Stachybotrys CTC, these data indicate that SC2 may have originated as a duplication of the CTC and has subsequently undergone rearrangements and divergence in function.

In contrast to SC1 and SC2, SC3 (Figure 2-5 and Appendix E-5) is a small 10-kbp cluster that contains five genes, SAT17—SAT21. Although none of these genes encodes a PKS, the cluster itself is found adjacent to the CTC in satratoxin strains (Figure 2-5), suggesting that the two loci may be coregulated. One SC3 gene, SAT21, encodes a putative major facilitator superfamily-type transporter that may function to specifically export macrocyclic trichothecenes, analogously to Tri12 of Fusarium (Alexander, McCormick, and Hohn, 1999). The four other putative products of SC3 include the TauD
hydroxylase Sat17, the methyltransferase Sat18, the acetyltransferase Sat19, and the Cys6-type zinc finger Sat20; the latter likely assists in regulation of the cluster.

The smallest satratoxin-specific locus, SC4 (not shown), is in the middle of a chemotype-independent gene cluster that does not appear to encode any of the types of enzymes described above. I have not been able to predict the function of SC4, and so I mention it mainly for completeness. In general, versus the atranone case, I am not aware of any unusual chemistry proposed for the biosynthesis of satratoxins that would more specifically inform as to the relevance of any of these four chemotype-specific loci. Indeed, given the recent divergence of the satratoxin strains relative to the atranone strains (Table 2-2), it is possible that SC4 or other clusters are unrelated to satratoxin biosynthesis. A powerful way to further explore the function of these clusters genomically would be to search for them in the genome of Myrothecium roridum, a more divergent macrocyclic trichothecene producer that to our knowledge has not yet been fully sequenced.

### 2.3.6. Phylogenies for four trichothecene biosynthesis protein families in

## Stachybotrys, and functional implications

Four well-studied CTC proteins are Tri5, Tri4, Tri11, and Tri3. In particular, Tri5 and Tri4 are the earliest known enzymes in the trichothecene pathway: Tri5 cyclizes FPP to trichodiene, and Tri4 multiply hydroxylates trichodiene and its derivatives (McCormick et al, 2011). Both Tri4 and Tri11 are known to catalyze differing reactions
in Fusarium versus Trichoderma (Cardoza et al, 2011), resulting in two genus-specific series of trichothecenes (C-3 vs non-C-3 substituted, as discussed above). To infer the functions of these genes in Stachybotrys and more generally to explore the evolution of the CTC and SC2, I constructed maximum likelihood-based phylogenies of these four proteins and their novel paralogs (Figure 2-10). I used homologs from Stachybotrys, Myrothecium (only Tri5 and Tri4 are available), Trichoderma, and Fusarium. Partial 18S rRNA sequences are available for all four genera, and I used these to construct a reference phylogeny (Figure 2-10a). Excluding the Stachybotrys SC2 products and other paralogs, the topology of the 18 S tree matches that of Tri4 (Figure 2-10c) and Tri3 (Figure 2-10e). However, the 18S tree differs from that of Tri5 (Figure 2-10b), in which Trichoderma Tri5 is divergent, and Tri11 (Figure 2-10d), in which Fusarium Tri11 is divergent. The Tri5 topology may relate to the fact that, uniquely, Trichoderma TRI5 is external to the CTC (Cardoza et al, 2011). The Tri11 topology is consistent with Stachybotrys Tri11 conserving the function of Trichoderma Tri11, which is to hydroxylate the trichothecene skeleton at C-4 to yield trichodermol (Cardoza et al, 2011). While no functional prediction for Stachybotrys Tri4 can be made based only on this tree, I assume that (like Trichoderma Tri4 and versus Fusarium Tri4) it lacks the ability to hydroxylate C-3, since C-3 substituted trichothecenes have not been observed in Stachybotrys (McCormick et al, 2011).

That three of these four tree topologies (Tri5, Tri4, and Tri3) mostly match that of 18S supports a single origin for the CTC, at least in part, in the common ancestor of all
four genera. However, the Stachybotrys paralogs differ in this regard: while the 18 S topology may be conserved for the Tri5 paralog Tri19, 18S topology is not conserved for the Tri4 paralog Sat 11 (diverges before Myrothecium Tri4), nor for the Tri3 paralogs Tri18 and Sat12 (they form the outgroup to all Tri3 and Sat16). These results are consistent with either gene duplication or independent horizontal transfer events occurring prior to Stachybotrys speciation. Further, the clustering of Tri3 with Sat 16 on the one hand, and Tri18 with Sat12 on the other, is consistent with my hypothesis that the satratoxin-specific cluster SC2 originated as a duplication of the CTC (Section 2.3.5).

### 2.3.7. The hard problem: why are the chemotype-specific gene clusters mutually exclusive?

Although I have shown that the presence of certain gene clusters may suffice to produce the strain-specific products observed in Stachybotrys, I have not addressed the mechanism or selection pressures by which these clusters have come to be mutually exclusive, and I am not aware of a way to address these issues with computational methods. I do not think that chemotype mutual exclusivity in Stachybotrys is wellexplained either by chance or by geographic isolation, because the chemotypes of $\sim 200$ Stachybotrys strains are known (Jarvis 2003), and there is no relationship between chemotype and geographic location. (For example, three of the strains reported here were isolated from the San Francisco Bay Area; two of these, 40285 and 40293, were taken from the same apartment unit [Cruse et al, 2002].) Another hypothesis contradicted by
my results is that both chemotypes in fact have all the machinery needed to produce both atranones and satratoxins, but there is a strain-specific metabolic shunt at work that minimizes production of one type of toxin or the other. It is possible that by unknown mechanisms, presence of the atranone cluster increases a strain's susceptibility to satratoxin toxicity, and vice versa; one way to test this would be to transfect the CAC into a satratoxin strain and observe colony growth, but as noted in the atranone section above, this experiment is not currently feasible. A more interesting, though even more speculative, hypothesis is that there is some novel regulatory mechanism at work that prevents inclusion of both sets of clusters in a single strain.

### 2.4. CONCLUSIONS AND RECOMMENDATIONS

I summarize my findings with a unified genetic model for atranone and satratoxin biosynthesis in Stachybotrys (Figure 2-11) that also incorporates much previous work by biochemists (Cardoza et al, 2011; McCormick et al, 2011; Hinkley et al, 2000; Degenkolb et al, 2008). The main novel feature of this model is that atranones are made by enzyme products of a single gene cluster (viz, the core atranone cluster) found only in atranone strains, while satratoxins are made by enzyme products of up to three gene clusters (viz, satratoxin-specific clusters 1, 2, and 3) found only in satratoxin strains.

Some aspects of this model are speculative, most notably the precise location of the boundary between trichothecenes produced by atranone strains and those produced by satratoxin strains. Although atranone strains are known to make trichodermol, it is unknown whether they can make early macrocyclic trichothecene intermediates such as trichoverrols and trichoverrins. Due to the presence of the chemotype-independent PKS gene TRII7 within the CTC, I speculate that atranone strains can produce trichoverrols, though perhaps not trichoverrins. Assay of this chemotype in atranone-producing strains is possible by NMR spectroscopy (Jarvis et al, 1986), and this will be critical to more precisely determine the functions of the putative satratoxinspecific enzymes that I have identified in this study.

One toxicological application of this work would be development of a sensitive PCRbased assay to easily distinguish the presence of the two different Stachybotrys chemotypes in an infested building. Although satratoxins are extremely toxic in certain experimental settings (Jarvis, 2003), still unknown is their real potential for harm in typical human environments, especially relative to the chronic inflammatory effects of atranones or of other products made by
both strains (Pestka et al, 2008; Shi, Smith, and Miller, 2011). A simple assay to distinguish between chemotypes present in an infested building, in conjunction with rigorous and consistent medical examination of the affected occupants, might help to distinguish the practical medical importance of these types of toxins. However, to find a few informative cases would almost certainly require to test a great number of infested buildings, since both chemotypes are often found together (Cruse et al, 2002), and Stachybotrys is usually found alongside other toxigenic fungi due to their shared predilection for dark, damp growth conditions (Kuhn and Ghannoum, 2003).

Other recommendations that follow from this project are found throughout Section 2.3, and so I only summarize them here. To verify the present model of Stachybotrys toxin production (Figure 2-11), the products of the core atranone cluster should be exogenously expressed in either a satratoxin-producing strain of Stachybotrys or in a model organism such as yeast; this will involve several technical challenges (Section 2.3.4). More easily, the functions of some enzymes discovered here, such as the PKS Tri17 encoded in the core trichothecene cluster (Section 2.3.3), can likely be verified by standard yeast feeding experiments (eg, Cardoza et al, 2011). Another straightforward project would be to sequence de novo the genome of the macrocyclic trichothecene producer Myrothecium roridum (Section 2.3.5); this result may inform the evolutionary origin of these two mutually-exclusive sets of gene clusters. Finally, the huge potential repertoire of PKSs found in all strains of Stachybotrys (Section 2.3.2) should be examined further, as it could be of pharmacological importance. A preliminary
comparison of these PKS sequences with the accepted fungal PKS phylogeny (Kroken et al, 2003) suggested that novel clades of PKSs may be expanded in the Stachybotrys lineage.

farnesyl pyrophosphate


Figure 2-1. The two toxin chemotypes of Stachybotrys
Both atranones and satratoxins are terpenoid secondary metabolites thought to derive from the primary metabolite farnesyl pyrophosphate (FPP). Box colors indicate each class of molecule and its specific secondary metabolite precursors: blue-gray for atranones, orange for simple trichothecenes, and pale green for macrocyclic trichothecenes, which include satratoxins. Atranones are diterpenoids thought to originate from cyclization of geranylgeranyl pyrophosphate to form dolabellane, which has an unusual eleven-membered ring (Hinkley et al, 2000). Atranones A (R H H) and B (R = O$\mathrm{Me})$ are shown as representative. Trichothecenes are sesquiterpenoids that are products of FPP cyclization. Trichodermol is shown as a representative simple trichothecene, and satratoxins $\mathrm{F}(\mathrm{R}=\mathrm{O})$ and $\mathrm{G}(\mathrm{R}=\mathrm{OH})$ as representative satratoxins. The pathway of trichodermol biosynthesis from FPP is known experimentally (Cardoza et al, 2011; Kimura et al, 2007), but there are no experimental data regarding biosynthesis pathways of satratoxins or other trichodermol derivatives, nor of atranones.


Figure 2-2. Stachybotrys strains and other trichothecene producers
This conceptual phylogeny shows the toxin chemotypes of the Stachybotrys strains we sequenced in relation to other trichotheceneproducing fungi of order Hypocreales. S. cerevisiae is only distantly related to Hypocreales and is shown for context. Topology adapted from Wu et al (2003).


Figure 2-3. Ortholog-based maximum likelihood phylogeny of Stachybotrys and other fungi
Phylogeny was constructed from alignment of 2,177 proper protein orthologs identified by OrthoMCL. Scale bar shows number of substitutions per 100 sites. All branches have $100 \%$ support.


Figure 2-4. Distribution of orthologs of Fusarium and Stachybotrys
This Venn diagram shows the number of protein homolog groups, of 16,311 total, in each combination of three sets: (1) groups with a homolog in any Stachybotrys genome; (2) groups with a homolog in any Fusarium genome; and (3) groups with a homolog in $A$. nidulans or S. cerevisiae, which are pooled as a single outgroup for simplicity.


Figure 2-5. The core trichothecene clusters and satratoxin cluster SC3 of each Stachybotrys strain
Each rectangle indicates a gene, and each gray arrowhead within indicates an exon and its transcriptional sense. The core trichothecene clusters are shown in the orange box, and the adjacent satratoxin cluster SC3 is shown in the pale green box. The other genes shown lack similarity to known trichothecene synthesis genes, so they are assumed to be in flanking regions outside these two clusters. A black arrow indicates that a scaffold extends to include other genes beyond the region shown, whereas lack of such an arrow indicates a scaffold border. Ruler at top indicates length in kbp.


Figure 2-6. The core atranone clusters of the Stachybotrys atranone strains
The core atranone clusters are shown in the blue-gray box. The other genes shown are chemotype-independent. Other figure conventions follow those of Figure 2-5. ATR12 of strain 40288 is shaded to indicate that it is a possible pseudogene; despite its translation having $\sim 90 \%$ identity to 40285 Atr12, in our assembly its exon 1 contains an internal stop codon.


Figure 2-7. Model of atranone biosynthesis
Shown are the structures of all atranones solved by Hinkley et al (2000), as well as types of enzymes capable of catalyzing two postulated reactions in the pathway.


Figure 2-8. Biosynthetic model of satratoxins and other macrocyclic trichothecenes
This is a conceptual pathway adapted from Degenkolb et al (2008) and references therein. It integrates results from several trichothecene producers. Molecule types are color-coded per Figure 2-1. Enzymes shown have been functionally characterized from Fusarium (Tri5) or Trichoderma (Tri4 and Tri11), but not yet from Stachybotrys. Trichodiol is shown to represent several intermediates that undergo both enzymatic hydroxylation and spontaneous rearrangement to form trichodermol, which is the first molecule shown that contains the trichothecene skeleton, ie the tricyclic ring 12,13-epoxytrichothec-9-ene (EPT). In Fusarium, trichodermol is not observed; instead, the pathway after trichodiol diverges to a series of products substituted at C-3 of EPT. There are two known trichoverrols (A and B) and two known trichoverrins (A and B), but the respective pairs differ only in the stereochemistry of the C-4 sidechain. The satratoxin F/G skeleton is shown as representative of satratoxins, and roridin E as representative of roridins. Omitted for brevity are the verrucarins (double arrow between roridins and satratoxins).


Figure 2-9. Satratoxin-specific clusters SC1 and SC2 of Stachybotrys
The satraxin-specific clusters are shown in the pale green boxes. The other genes shown are chemotype-independent. Other figure conventions follow those of Figure 2-5. (a) SC1. (b) SC2. Additionally, SC3 is shown in Figure 2-5.


Figure 2-10. Maximum likelihood phylogenies of selected Tri homologs
(a) Reference phylogeny made from partial 18 S rRNA sequences. (b) Tri5, including the paralog Tri19 from strain 40293. (c) Tri4, including Stachybotrys paralog from SC2. (d) Tri11. (e) Tri3, including all four Stachybotrys paralogs from CTC and SC2. Each phylogeny is rooted at midpoint. Taxon abbreviations are Scha, S. chartarum 7711; Schl, S. chlorohalonata 40285; Mr, Myrothecium roridum; Fs, Fusarium sporotrichioides; Fg, Fusarium graminearum; Ta, Trichoderma arundinaceum; and Tb, Trichoderma brevicompactum. Branches are labelled with support values of 100 total bootstrap replicates. Scale bars show number of substitutions per site.



Figure 2-11. Unified genetic model for atranone and satratoxin biosynthesis
Molecules are color-coded per Figure 2-1. Blue text indicates that a gene cluster or putative protein was discovered in the present study. Other protein names are in black. The dashed blue box indicates trichothecenes whose catalysis is uncertain; they may be synthesized by enzyme products of the core trichothecene cluster, by products of satratoxin-specific clusters, or by a mix of both types.

|  | S. chlorohalonata 40285 | $S$ <br> chartarum 40288 | S. chartarum 40293 | $S$ <br> chartarum 7711 | F. graminearum PH-1 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| paired reads (millions) | 66.4 | 58.6 | 68.8 | 71.4 | NA |
| assembled sequences | 1246 | 957 | 826 | 897 | 36 |
| assembly size (Mbp) | 34.2 | 36.5 | 36.1 | 36.2 | 36.2 |
| fold coverage | 196 | 162 | 192 | 199 | 10 |
| $\mathbf{N}_{50}$ length (kbp) | 116 | 130 | 214 | 177 | 5350 |
| assembly gaps (Mbp) | 0.25 | 0.08 | 0.16 | 0.13 | 0.22 |
| repeat content | 1.62\% | 0.93\% | 0.93\% | 1.01\% | 0.66\% |
| gene content | 51.75\% | 53.42\% | 53.19\% | 53.31\% | 57.18\% |
| predicted coding genes | 10866 | 11719 | 11532 | 11543 | 13332 |
| median gene <br> length (bp) | 1357 | 1377 | 1380 | 1379 | 1259 |
| median protein length (AA) | 403 | 411 | 412 | 413 | 375 |
| mean exons <br> per gene | 2.8 | 2.8 | 2.8 | 2.8 | 2.8 |
| median exon <br> length (bp) | 293 | 296 | 297 | 296 | 255 |
| median intron <br> length (bp) | 59 | 59 | 59 | 59 | 55 |
| predicted products with identified CDD domain | 65.87\% | 65.84\% | 66.29\% | 65.94\% | 61.43\% |

Table 2-1. Features of Stachybotrys genome and proteome assemblies
Stachybotrys assemblies include all contigs and scaffolds of at least 1 kbp . $\mathrm{N}_{50}$ is the sequence that includes the middle nucleotide of the assembly when the sequences are ordered by length.

|  | $\mathbf{7 7 1 1}$ | $\mathbf{4 0 2 9 3}$ | $\mathbf{4 0 2 8 8}$ | $\mathbf{4 0 2 8 5}$ | Fve | Fox | Fgr | Ani | Sce |
| :--- | ---: | ---: | ---: | ---: | :---: | :---: | :---: | :---: | :---: |
| $\mathbf{7 7 1 1}$ | 100 | 99.830 | 99.746 | 97.701 | 73.668 | 73.646 | 72.995 | 54.834 | 39.231 |
| $\mathbf{4 0 2 9 3}$ |  | 100 | 99.742 | 97.707 | 73.663 | 73.644 | 72.998 | 54.836 | 39.231 |
| $\mathbf{4 0 2 8 8}$ |  |  | 100 | 97.673 | 73.663 | 73.649 | 73.000 | 54.836 | 39.237 |
| $\mathbf{4 0 2 8 5}$ |  |  |  | 100 | 73.667 | 73.638 | 73.011 | 54.832 | 39.240 |
| Fve |  |  |  |  | 100 | 97.174 | 89.068 | 55.506 | 39.796 |
| Fox |  |  |  |  |  | 100 | 89.380 | 55.452 | 39.742 |
| Fgr |  |  |  |  |  |  | 100 | 54.934 | 39.373 |
| Ani |  |  |  |  |  |  |  | 100 | 39.740 |
| Sce |  |  |  |  |  |  |  |  | 100 |

Table 2-2. Ortholog-based pairwise proteome identities of Stachybotrys and other fungi
The genome abbreviations shown in the row and column headers are as follows. 7711, 40293, 40288, and 40285 are the respective strains of Stachybotrys sequenced in this study; Fve, Fusarium verticillioides; Fox, Fusarium oxysporum; Fgr, Fusarium graminearum; Ani, Aspergillus nidulans; Sce, Saccharomyces cerevisiae.

| putative function | SC genes |
| :--- | ---: |
| acetyltransferase | 5 |
| hydroxylase | 4 |
| regulatory | 3 |
| reductase | 2 |
| PKS | 2 |
| methyltransferase | 1 |
| transporter | 1 |
| other or unclassified | 3 |
| TOTAL | 21 |

Table 2-3. Summary of functions putatively encoded by genes in satratoxin clusters SC1, SC2, and SC3

## APPENDIX A (CHAPTER 1)

The 129 protein domains that contain at least two longevity-selected positions

| protein | domain | OrthoMaM start | OrthoMaM end | OrthoMaM length | longevityselected positions |
| :---: | :---: | :---: | :---: | :---: | :---: |
| AMHR2 | Protein kinase | 203 | 518 | 316 | 7 |
| C3orf48 | PP2C-like | 171 | 525 | 355 | 4 |
| KIF20B | Kinesin-motor | 55 | 405 | 351 | 4 |
| PRSS12 | Peptidase S1 | 631 | 874 | 244 | 4 |
| ALOX15 | Lipoxygenase | 115 | 662 | 548 | 3 |
| BHMT2 | Hcy-binding | 11 | 305 | 295 | 3 |
| BTD | CN hydrolase | 48 | 354 | 307 | 3 |
| EMID1 | Collagen-like | 181 | 370 | 190 | 3 |
| IL31RA | Fibronectin type-III 3 | 234 | 326 | 93 | 3 |
| LIPG | PLAT | 347 | 482 | 136 | 3 |
| MST1R | Sema | 31 | 522 | 492 | 3 |
| MTMR12 | Myotubularin phosphatase | 205 | 643 | 439 | 3 |
| NLRP14 | NACHT | 177 | 499 | 323 | 3 |
| NOV | VWFC | 108 | 174 | 67 | 3 |
| PARP14 | Macro 3 | 1040 | 1211 | 172 | 3 |
| PLXNA2 | Sema | 35 | 508 | 474 | 3 |
| SATL1 | N -acetyltransferase | 259 | 379 | 121 | 3 |
| SEMA4B | Sema | 42 | 518 | 477 | 3 |
| SHBG | Laminin G-like 2 | 224 | 390 | 167 | 3 |
| STRADB | Protein kinase | 58 | 369 | 312 | 3 |
| TMEM56 | TLC | 44 | 246 | 203 | 3 |
| TRIM26 | B30.2/SPRY | 295 | 539 | 245 | 3 |
| ABCA6 | ABC transporter 1 | 478 | 713 | 236 | 2 |
| AFP | Albumin 1 | 19 | 210 | 192 | 2 |
| AFP | Albumin 3 | 403 | 601 | 199 | 2 |
| ANGPTL3 | Fibrinogen C-terminal | 237 | 455 | 219 | 2 |


| protein | domain | OrthoMaM <br> start | OrthoMaM <br> end | OrthoMaM <br> length | longevity- <br> selected <br> positions |
| :--- | :--- | ---: | ---: | ---: | ---: |
| ARHGEF16 | PH | 501 | 620 | 120 | 2 |
| ARHGEF6 | PH | 443 | 548 | 106 | 2 |
| ATM | FAT | 1984 | 2566 | 583 | 2 |
| ATR | FAT | 1640 | 2185 | 546 | 2 |
| BRCA1 | BRCT 2 | 1756 | 1855 | 100 | 2 |
| C1R | Peptidase S1 | 463 | 701 | 239 | 2 |
| CD200 | Ig-like V-type | 28 | 138 | 111 | 2 |
| CD83 | Ig-like V-type | 20 | 114 | 95 | 2 |
| CD93 | C-type lectin | 32 | 174 | 143 | 2 |
| CDCP1 | CUB | 523 | 541 | 19 | 2 |
| CDON | Ig-like C2-type 5 | 405 | 516 | 112 | 2 |
| CFD | Peptidase S1 | 26 | 253 | 228 | 2 |
| CFTR | ABC transmembrane type-1 2 | 859 | 1155 | 297 | 2 |
| CLCA1 | VWFA | 306 | 475 | 170 | 2 |
| CP | F5/8 type A 1 | 20 | 357 | 338 | 2 |
| CP | F5/8 type A 3 | 730 | 1061 | 332 | 2 |
| CP | Plastocyanin-like 1 | 20 | 200 | 181 | 2 |
| CR2 | Sushi 11 | 719 | 775 | 57 | 2 |
| CTPS2 | Glutamine amidotransferase |  | 300 | 554 | 255 |


| protein | domain | OrthoMaM <br> start | OrthoMaM <br> end | OrthoMaM <br> length | longevity- <br> selected <br> positions |
| :--- | :--- | ---: | ---: | ---: | ---: |
| F8 | F5/8 type A 3 | 1713 | 2040 | 328 | 2 |
| FAT2 | Cadherin 14 | 1556 | 1660 | 105 | 2 |
| FAT2 | Cadherin 15 | 1661 | 1758 | 98 | 2 |
| FRAS1 | VWFC 2 | 67 | 127 | 61 | 2 |
| FREM1 | C-type lectin | 2061 | 2175 | 115 | 2 |
| GALNT5 | Ricin B-type lectin | 804 | 935 | 132 | 2 |
| GDPD1 | GDPD | 45 | 304 | 260 | 2 |
| HEPHL1 | Plastocyanin-like 3 | 376 | 558 | 183 | 2 |
| IFNAR1 | Fibronectin type-III 3 | 333 | 424 | 92 | 2 |
| IL12RB1 | Fibronectin type-III 2 | 143 | 236 | 94 | 2 |
| IL1RL1 | Ig-like C2-type 2 | 114 | 197 | 84 | 2 |
| IL6ST | Ig-like C2-type | 26 | 120 | 95 | 2 |
| IQGAP1 | Ras-GAP | 985 | 1218 | 234 | 2 |
| ISG20L2 | Exonuclease | 178 | 353 | 176 | 2 |
| JAK1 | FERM | 34 | 420 | 387 | 2 |
| KIF18B | Kinesin-motor | 4 | 279 | 276 | 2 |
| KIF22 | Kinesin-motor | 40 | 299 | 260 | 2 |
| KIRREL2 | Ig-like C2-type 2 | 123 | 222 | 100 | 2 |
| KIRREL2 | Ig-like C2-type 5 | 398 | 501 | 104 | 2 |
| KIT | Ig-like C2-type 2 | 121 | 205 | 85 | 2 |
| KLK6 | Peptidase S1 | 22 | 242 | 221 | 2 |
| LAMA2 | Laminin IV type A 2 | 1176 | 1379 | 204 | 2 |
| LAMA3 | Laminin EGF-like 5 | 514 | 566 | 53 | 2 |
| LETMD1 | LETM1 | 144 | 359 | 216 | 2 |
| LGTN | SUI1 | 391 | 564 | 74 | 2 |
| LIFR | Fibronectin type-III 2 | 428 | 97 | 2 |  |
| LRIT2 | Fibronectin type-III | 361 | 451 | 91 | 2 |
| LTF | Transferrin-like 2 | 364 | 695 | 332 | 2 |
| MAPK13 | Protein kinase | 308 | 284 | 2 |  |
| MCF2 | DH | 752 | 181 | 2 |  |
|  |  |  |  |  |  |


| protein | domain | OrthoMaM start | OrthoMaM end | OrthoMaM length | longevity- <br> selected <br> positions |
| :---: | :---: | :---: | :---: | :---: | :---: |
| MFI2 | Transferrin-like 2 | 432 | 706 | 275 | 2 |
| MTTP | Vitellogenin | 28 | 659 | 632 | 2 |
| MYO18A | Myosin head-like | 420 | 1186 | 767 | 2 |
| MYO5C | Myosin head-like | 2 | 755 | 754 | 2 |
| MYO7B | FERM 2 | 2037 | 2340 | 304 | 2 |
| MYO7B | MyTH4 1 | 983 | 1186 | 204 | 2 |
| NIN | EF-hand 4 | 219 | 252 | 34 | 2 |
| NLRP12 | NACHT | 211 | 528 | 318 | 2 |
| NTN5 | NTR | 345 | 475 | 131 | 2 |
| OBSCN | Ig-like 43 | 1805 | 1873 | 69 | 2 |
| ORC1L | BAH | 45 | 171 | 127 | 2 |
| PBK | Protein kinase | 32 | 322 | 291 | 2 |
| PDCD11 | S1 motif 9 | 1036 | 1109 | 74 | 2 |
| PDCD1LG2 | Ig-like V-type | 21 | 118 | 98 | 2 |
| PGBD1 | SCAN box | 44 | 126 | 83 | 2 |
| PKD1L1 | REJ | 377 | 1274 | 898 | 2 |
| PLA2G4A | PLA2c | 140 | 650 | 511 | 2 |
| PRKDC | FAT | 2882 | 3538 | 657 | 2 |
| PRLR | Fibronectin type-III 2 | 127 | 227 | 101 | 2 |
| PTPRC | Tyrosine-protein phosphatase 1 | 651 | 910 | 260 | 2 |
| RASSF6 | SARAH | 281 | 328 | 48 | 2 |
| RECQL4 | Helicase C-terminal | 683 | 850 | 168 | 2 |
| RIPK1 | Protein kinase | 17 | 289 | 273 | 2 |
| ROS1 | Fibronectin type-III 3 | 558 | 668 | 111 | 2 |
| ROS1 | Fibronectin type-III 7 | 1558 | 1653 | 96 | 2 |
| RPGRIP1 | C2 | 801 | 890 | 90 | 2 |
| RPS6KA6 | Protein kinase 2 | 426 | 683 | 258 | 2 |
| SHBG | Laminin G-like 1 | 45 | 217 | 173 | 2 |
| SHROOM1 | ASD2 | 543 | 825 | 283 | 2 |
| SNX25 | PXA | 1 | 164 | 164 | 2 |


| protein | domain | OrthoMaM <br> start | OrthoMaM <br> end | OrthoMaM <br> length | longevity- <br> selected <br> positions |
| :--- | :--- | ---: | ---: | ---: | ---: |
| SNX25 | RGS | 287 | 401 | 115 | 2 |
| SPINK5 | Kazal-like 6 | 361 | 423 | 63 | 2 |
| STK31 | Protein kinase | 534 | 842 | 309 | 2 |
| SVEP1 | Pentaxin | 1365 | 1482 | 118 | 2 |
| SVEP1 | Sushi 16 | 2259 | 2316 | 58 | 2 |
| SYPL1 | MARVEL | 10 | 219 | 210 | 2 |
| TECTA | VWFD 2 | 712 | 929 | 218 | 2 |
| TFPI2 | BPTI/Kunitz inhibitor 2 | 96 | 149 | 54 | 2 |
| TGFBRAP1 | CNH | 24 | 297 | 274 | 2 |
| TRIM25 | B30.2/SPRY | 439 | 630 | 192 | 2 |
| TYK2 | FERM | 26 | 431 | 406 | 2 |
| USH2A | Fibronectin type-III 6 | 1954 | 2051 | 98 | 2 |
| USH2A | Fibronectin type-III 7 | 2052 | 2138 | 87 | 2 |
| USP48 | DUSP 2 | 569 | 691 | 123 | 2 |
| ZNF541 | ELM2 | 1072 | 1164 | 93 | 2 |

## APPENDIX B (CHAPTER 1) <br> Longevity-selected positions of the protein domains shown in Appendix $A$

| protein | domain | reference <br> (human) <br> character | reference OrthoMaM position | nonreference characters | $\boldsymbol{b}_{\text {mls }}$ | $\boldsymbol{p}_{\text {mls }}$ | $\boldsymbol{b}_{\text {mass }}$ | $\boldsymbol{p}_{\text {mass }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AMHR2 | Protein kinase | M | 379 | 27 | 1.31 | 3.97e-3 | -0.07 | $4.58 \mathrm{e}-1$ |
| AMHR2 | Protein kinase | T | 447 | 27 | 3.62 | $2.63 \mathrm{e}-3$ | -0.49 | $4.47 \mathrm{e}-2$ |
| AMHR2 | Protein kinase | Y | 465 | 27 | 8.56 | 1.24e-3 | -1.14 | $3.22 \mathrm{e}-2$ |
| AMHR2 | Protein kinase | T | 469 | 27 | 2.09 | $6.02 \mathrm{e}-3$ | -0.20 | $1.97 \mathrm{e}-1$ |
| AMHR2 | Protein kinase | F | 473 | 27 | 6.00 | $2.30 \mathrm{e}-3$ | -0.61 | $1.18 \mathrm{e}-1$ |
| AMHR2 | Protein kinase | E | 513 | 26 | 3.85 | $4.61 \mathrm{e}-3$ | -0.17 | $5.28 \mathrm{e}-1$ |
| AMHR2 | Protein kinase | H | 515 | 25 | 7.84 | 5.98e-3 | -0.62 | $2.68 \mathrm{e}-1$ |
| C3orf48 | PP2C-like | P | 224 | 23 | 5.47 | 8.44e-3 | -0.20 | $6.36 \mathrm{e}-1$ |
| C3orf48 | PP2C-like | E | 405 | 22 | 4.54 | $4.08 \mathrm{e}-3$ | -1.08 | $2.62 \mathrm{e}-3$ |
| C3orf48 | PP2C-like | E | 411 | 20 | 3.02 | 5.74e-3 | -0.63 | 8.57e-3 |
| C3orf48 | PP2C-like | E | 459 | 21 | 5.34 | $7.61 \mathrm{e}-3$ | -1.35 | $3.74 \mathrm{e}-3$ |
| KIF20B | Kinesin-motor | S | 77 | 25 | 1.45 | 6.42e-3 | -0.06 | $5.31 \mathrm{e}-1$ |
| KIF20B | Kinesin-motor | Q | 144 | 25 | 1.58 | 5.50e-3 | -0.02 | $8.31 \mathrm{e}-1$ |
| KIF20B | Kinesin-motor | T | 235 | 28 | 2.68 | 8.60e-3 | -0.54 | 1.16e-2 |
| KIF20B | Kinesin-motor | A | 259 | 26 | 2.53 | 5.48e-3 | -0.27 | $1.42 \mathrm{e}-1$ |
| PRSS12 | Peptidase S1 | G | 641 | 26 | 3.39 | $7.58 \mathrm{e}-3$ | -0.63 | $2.29 \mathrm{e}-2$ |
| PRSS12 | Peptidase S1 | Q | 710 | 28 | 1.81 | $7.57 \mathrm{e}-3$ | -0.26 | $6.02 \mathrm{e}-2$ |
| PRSS12 | Peptidase S1 | G | 835 | 31 | 3.53 | 3.14e-3 | -0.14 | $5.70 \mathrm{e}-1$ |
| PRSS12 | Peptidase S1 | K | 874 | 30 | 2.00 | 6.46e-3 | -0.05 | $7.26 \mathrm{e}-1$ |
| ALOX15 | Lipoxygenase | P | 120 | 15 | 8.73 | $7.39 \mathrm{e}-4$ | -0.14 | $7.43 \mathrm{e}-1$ |
| ALOX15 | Lipoxygenase | R | 205 | 15 | 8.37 | 5.03e-4 | -0.28 | $5.00 \mathrm{e}-1$ |
| ALOX15 | Lipoxygenase | K | 643 | 14 | 4.97 | $1.98 \mathrm{e}-4$ | -0.54 | $1.59 \mathrm{e}-2$ |
| BHMT2 | Hcy-binding | M | 61 | 28 | 3.21 | 1.66e-3 | -0.15 | $4.50 \mathrm{e}-1$ |
| BHMT2 | Hcy-binding | N | 69 | 28 | 2.18 | $8.25 \mathrm{e}-3$ | -0.40 | $2.21 \mathrm{e}-2$ |
| BHMT2 | Hcy-binding | D | 89 | 28 | 6.71 | 1.97e-3 | -1.16 | $1.11 \mathrm{e}-2$ |
| BTD | CN hydrolase | V | 96 | 24 | 2.89 | 2.08e-3 | -0.45 | $2.60 \mathrm{e}-2$ |
| BTD | CN hydrolase | I | 221 | 24 | 5.82 | $6.26 \mathrm{e}-3$ | -0.92 | $5.46 \mathrm{e}-2$ |
| BTD | CN hydrolase | S | 350 | 25 | 5.30 | 2.77e-4 | -0.76 | $1.30 \mathrm{e}-2$ |


| protein | domain | reference <br> (human) <br> character | reference OrthoMaM position | non- <br> reference <br> characters | $\boldsymbol{b}_{\text {mls }}$ | $\boldsymbol{p}_{\text {mls }}$ | $\boldsymbol{b}_{\text {mass }}$ | $\boldsymbol{p}_{\text {mass }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| EMID1 | Collagen-like | S | 233 | 15 | 3.57 | 6.27e-3 | -0.06 | $8.16 \mathrm{e}-1$ |
| EMID1 | Collagen-like | H | 268 | 15 | 5.18 | 3.07e-3 | -0.78 | $2.77 \mathrm{e}-2$ |
| EMID1 | Collagen-like | R | 346 | 20 | 4.37 | 7.81e-3 | -0.03 | $9.33 \mathrm{e}-1$ |
| IL31RA | Fibronectin type-III 3 | E | 234 | 27 | 5.61 | 2.26e-3 | -0.76 | $3.89 \mathrm{e}-2$ |
| IL31RA | Fibronectin type-III 3 | N | 297 | 24 | 5.52 | $8.43 \mathrm{e}-3$ | -0.38 | $3.49 \mathrm{e}-1$ |
| IL31RA | Fibronectin type-III 3 | L | 300 | 24 | 6.66 | 6.96e-3 | -1.21 | $1.69 \mathrm{e}-2$ |
| LIPG | PLAT | Q | 421 | 26 | 2.77 | $1.38 \mathrm{e}-3$ | -0.23 | $1.73 \mathrm{e}-1$ |
| LIPG | PLAT | N | 445 | 26 | 5.92 | 2.66e-3 | -0.28 | $4.52 \mathrm{e}-1$ |
| LIPG | PLAT | N | 469 | 27 | 3.52 | $1.61 \mathrm{e}-3$ | -0.21 | $3.18 \mathrm{e}-1$ |
| MST1R | Sema | A | 257 | 20 | 4.29 | $9.01 \mathrm{e}-3$ | -0.24 | $4.60 \mathrm{e}-1$ |
| MST1R | Sema | S | 268 | 20 | 6.38 | $2.43 \mathrm{e}-3$ | -1.12 | $1.03 \mathrm{e}-2$ |
| MST1R | Sema | G | 393 | 19 | 7.25 | $9.80 \mathrm{e}-4$ | -0.64 | $1.29 \mathrm{e}-1$ |
| MTMR12 | Myotubularin phosphatase | R | 416 | 27 | 7.56 | 8.35e-4 | -1.37 | 4.26e-3 |
| MTMR12 | Myotubularin phosphatase | Q | 509 | 27 | 6.17 | 6.66e-4 | -0.05 | 8.95e-1 |
| MTMR12 | Myotubularin phosphatase | S | 615 | 28 | 3.64 | 1.93e-3 | -0.71 | 5.15e-3 |
| NLRP14 | NACHT | Y | 212 | 22 | 2.05 | 5.54e-3 | -0.08 | 5.97e-1 |
| NLRP14 | NACHT | L | 370 | 23 | 6.08 | 3.99e-4 | -0.79 | $1.55 \mathrm{e}-2$ |
| NLRP14 | NACHT | A | 432 | 24 | 2.02 | 3.28e-3 | -0.07 | 6.04e-1 |
| NOV | VWFC | S | 126 | 29 | 3.16 | 8.25e-4 | -0.11 | $5.42 \mathrm{e}-1$ |
| NOV | VWFC | K | 128 | 29 | 1.94 | $2.94 \mathrm{e}-3$ | -0.06 | $6.28 \mathrm{e}-1$ |
| NOV | VWFC | E | 162 | 30 | 4.69 | 3.84e-3 | -0.49 | $1.39 \mathrm{e}-1$ |
| PARP14 | Macro 3 | G | 1182 | 25 | 6.84 | 5.90e-4 | -0.86 | $2.90 \mathrm{e}-2$ |
| PARP14 | Macro 3 | D | 1201 | 24 | 3.77 | $7.15 \mathrm{e}-3$ | -0.17 | $5.22 \mathrm{e}-1$ |
| PARP14 | Macro 3 | V | 1202 | 24 | 1.74 | $4.83 \mathrm{e}-3$ | -0.10 | $3.91 \mathrm{e}-1$ |
| PLXNA2 | Sema | S | 93 | 27 | 1.40 | $8.23 \mathrm{e}-3$ | -0.04 | 6.96e-1 |
| PLXNA2 | Sema | S | 321 | 26 | 3.12 | $4.03 \mathrm{e}-4$ | -0.43 | $1.41 \mathrm{e}-2$ |
| PLXNA2 | Sema | D | 332 | 25 | 2.41 | $2.39 \mathrm{e}-3$ | -0.13 | $4.09 \mathrm{e}-1$ |


| protein | domain | reference (human) character | reference OrthoMaM position | non- <br> reference <br> characters | $\boldsymbol{b}_{\text {mls }}$ | $\boldsymbol{p}_{\text {mls }}$ | $\boldsymbol{b}_{\text {mass }}$ | $p_{\text {mass }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| SATL1 | N -acetyltransferase | E | 271 | 17 | 3.26 | 9.85e-4 | -0.29 | 1.70e-1 |
| SATL1 | N -acetyltransferase | Q | 317 | 20 | 5.79 | 7.16e-3 | -0.96 | $2.32 \mathrm{e}-2$ |
| SATL1 | N -acetyltransferase | A | 353 | 21 | 3.90 | 3.82e-3 | -0.25 | $3.65 \mathrm{e}-1$ |
| SEMA4B | Sema | R | 363 | 23 | 4.49 | $4.07 \mathrm{e}-3$ | -0.73 | $3.38 \mathrm{e}-2$ |
| SEMA4B | Sema | G | 475 | 25 | 3.88 | 5.54e-3 | -0.08 | $7.75 \mathrm{e}-1$ |
| SEMA4B | Sema | I | 486 | 25 | 1.39 | 3.54e-3 | -0.14 | $1.65 \mathrm{e}-1$ |
| SHBG | Laminin G-like 2 | G | 255 | 20 | 7.22 | 6.81e-3 | -1.01 | $9.90 \mathrm{e}-2$ |
| SHBG | Laminin G-like 2 | H | 264 | 20 | 8.37 | 4.91e-4 | -1.98 | $7.23 \mathrm{e}-4$ |
| SHBG | Laminin G-like 2 | G | 293 | 23 | 6.54 | 8.80e-4 | -0.40 | $2.85 \mathrm{e}-1$ |
| STRADB | Protein kinase | I | 291 | 27 | 4.66 | 1.01e-3 | -0.64 | $2.53 \mathrm{e}-2$ |
| STRADB | Protein kinase | S | 320 | 27 | 1.82 | 7.85e-3 | -0.05 | $7.28 \mathrm{e}-1$ |
| STRADB | Protein kinase | S | 335 | 27 | 1.24 | $4.59 \mathrm{e}-3$ | -0.05 | 5.54e-1 |
| TMEM56 | TLC | I | 107 | 24 | 1.30 | 3.31e-3 | -0.06 | 5.12e-1 |
| TMEM56 | TLC | Y | 109 | 23 | 5.57 | $1.87 \mathrm{e}-3$ | -0.26 | $4.46 \mathrm{e}-1$ |
| TMEM56 | TLC | A | 163 | 25 | 4.42 | 9.77e-3 | -0.57 | $1.48 \mathrm{e}-1$ |
| TRIM26 | B30.2/SPRY | H | 347 | 20 | 9.19 | $9.47 \mathrm{e}-3$ | -1.88 | 2.54e-2 |
| TRIM26 | B30.2/SPRY | D | 415 | 19 | 2.67 | 9.40e-3 | -0.25 | $3.10 \mathrm{e}-1$ |
| TRIM26 | B30.2/SPRY | L | 434 | 20 | 5.25 | 7.24e-4 | -0.55 | $1.08 \mathrm{e}-1$ |
| ABCA6 | ABC transporter 1 | E | 535 | 20 | 6.08 | 7.99e-3 | -1.16 | 1.91e-2 |
| ABCA6 | ABC transporter 1 | E | 590 | 21 | 5.53 | $1.68 \mathrm{e}-3$ | -0.77 | $3.00 \mathrm{e}-2$ |
| AFP | Albumin 1 | F | 50 | 28 | 5.06 | 3.98e-3 | 0.09 | $8.11 \mathrm{e}-1$ |
| AFP | Albumin 1 | E | 119 | 28 | 4.39 | 6.99e-4 | -0.20 | $4.35 \mathrm{e}-1$ |
| AFP | Albumin 3 | Y | 404 | 29 | 1.86 | 5.39e-3 | -0.09 | $5.02 \mathrm{e}-1$ |
| AFP | Albumin 3 | T | 460 | 28 | 4.33 | 9.19e-3 | -0.60 | 8.19e-2 |
| ANGPTL3 | Fibrinogen C-terminal | K | 377 | 27 | 2.28 | 5.53e-3 | -0.11 | $4.98 \mathrm{e}-1$ |
| ANGPTL3 | Fibrinogen C-terminal | H | 405 | 24 | 5.55 | 3.21e-3 | -0.33 | $3.74 \mathrm{e}-1$ |
| ARHGEF16 | PH | T | 586 | 20 | 6.13 | 3.57e-3 | -1.23 | $9.77 \mathrm{e}-3$ |
| ARHGEF16 | PH | H | 617 | 20 | 9.44 | $2.51 \mathrm{e}-3$ | -1.24 | $6.12 \mathrm{e}-2$ |
| ARHGEF6 | PH | M | 457 | 24 | 1.65 | 5.64e-3 | -0.08 | $4.86 \mathrm{e}-1$ |
| ARHGEF6 | PH | C | 463 | 24 | 7.97 | 7.66e-3 | -1.31 | $3.61 \mathrm{e}-2$ |


| protein | domain | reference <br> (human) <br> character | reference OrthoMaM position | non- <br> reference <br> characters | $\boldsymbol{b}_{\text {mls }}$ | $p_{\text {mls }}$ | $\boldsymbol{b}_{\text {mass }}$ | $\boldsymbol{p}_{\text {mass }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| ATM | FAT | C | 2074 | 27 | 6.23 | 2.32e-3 | -0.08 | $8.57 \mathrm{e}-1$ |
| ATM | FAT | Q | 2197 | 27 | 2.50 | 6.54e-3 | -0.04 | 8.30e-1 |
| ATR | FAT | S | 1876 | 27 | 5.65 | 7.50e-3 | -0.67 | $1.36 \mathrm{e}-1$ |
| ATR | FAT | Q | 1877 | 27 | 2.07 | $4.98 \mathrm{e}-3$ | -0.04 | $7.81 \mathrm{e}-1$ |
| BRCA1 | BRCT 2 | L | 1800 | 26 | 4.85 | 5.67e-3 | -0.87 | $2.38 \mathrm{e}-2$ |
| BRCA1 | BRCT 2 | A | 1843 | 26 | 1.59 | $4.89 \mathrm{e}-3$ | -0.02 | 8.72e-1 |
| C1R | Peptidase S1 | S | 553 | 22 | 3.59 | 5.92e-3 | -0.20 | $4.67 \mathrm{e}-1$ |
| C1R | Peptidase S1 | R | 669 | 23 | 5.66 | 2.50e-3 | -0.27 | $4.78 \mathrm{e}-1$ |
| CD200 | Ig-like V-type | P | 43 | 28 | 5.33 | 3.49e-3 | -0.35 | $3.64 \mathrm{e}-1$ |
| CD200 | Ig-like V-type | G | 114 | 29 | 5.09 | 5.12e-3 | -0.65 | $1.02 \mathrm{e}-1$ |
| CD83 | Ig-like V-type | S | 99 | 29 | 3.91 | 6.64e-3 | -0.14 | $6.17 \mathrm{e}-1$ |
| CD83 | Ig-like V-type | P | 112 | 29 | 11.57 | $1.38 \mathrm{e}-3$ | -1.68 | 2.02e-2 |
| CD93 | C-type lectin | L | 105 | 25 | 5.61 | 8.16e-3 | -1.05 | $3.19 \mathrm{e}-2$ |
| CD93 | C-type lectin | V | 117 | 25 | 1.41 | 3.93e-3 | -0.28 | $1.20 \mathrm{e}-2$ |
| CDCP1 | CUB | R | 527 | 25 | 4.73 | $2.93 \mathrm{e}-3$ | -0.39 | $2.80 \mathrm{e}-1$ |
| CDCP1 | CUB | G | 529 | 27 | 8.74 | $4.95 \mathrm{e}-3$ | -2.33 | $2.94 \mathrm{e}-3$ |
| CDON | Ig-like C2-type 5 | R | 437 | 22 | 3.34 | 7.66e-3 | -0.63 | $1.98 \mathrm{e}-2$ |
| CDON | Ig-like C2-type 5 | Q | 492 | 24 | 5.17 | 4.06e-3 | -0.66 | $6.80 \mathrm{e}-2$ |
| CFD | Peptidase S1 | D | 105 | 13 | 6.91 | $2.63 \mathrm{e}-3$ | -0.38 | $4.38 \mathrm{e}-1$ |
| CFD | Peptidase S1 | A | 177 | 16 | 4.53 | 7.46e-3 | -0.38 | $3.02 \mathrm{e}-1$ |
| CFTR | ABC transmembrane type-1 2 | L | 884 | 26 | 2.86 | 1.59e-3 | -0.50 | 1.41e-2 |
| CFTR | ABC transmembrane type-1 2 | F | 931 | 25 | 5.03 | 8.36e-3 | -1.35 | $1.49 \mathrm{e}-3$ |
| CLCA1 | VWFA | N | 423 | 27 | 5.58 | 7.66e-3 | -0.80 | $7.81 \mathrm{e}-2$ |
| CLCA1 | VWFA | G | 473 | 29 | 2.70 | $9.45 \mathrm{e}-3$ | -0.47 | $3.19 \mathrm{e}-2$ |
| CP | F5/8 type A 1 | I | 54 | 28 | 4.24 | $2.72 \mathrm{e}-3$ | -0.21 | $4.37 \mathrm{e}-1$ |
| CP | Plastocyanin-like 1 | I | 54 | 28 | 4.24 | 2.72e-3 | -0.21 | $4.37 \mathrm{e}-1$ |
| CP | Plastocyanin-like 1 | Q | 165 | 28 | 4.42 | 6.80e-3 | -0.55 | $1.21 \mathrm{e}-1$ |
| CP | F5/8 type A 1 | Q | 165 | 28 | 4.42 | 6.80e-3 | -0.55 | $1.21 \mathrm{e}-1$ |


| protein | domain | reference <br> (human) <br> character | reference OrthoMaM position | non- <br> reference <br> characters | $\boldsymbol{b}_{\text {mls }}$ | $\boldsymbol{p}_{\text {mls }}$ | $\boldsymbol{b}_{\text {mass }}$ | $p_{\text {mass }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| CP | F5/8 type A 3 | Q | 811 | 29 | 3.49 | 2.64e-3 | -0.24 | $2.95 \mathrm{e}-1$ |
| CP | F5/8 type A 3 | L | 1026 | 25 | 2.09 | 6.16e-3 | -0.47 | 1.24e-2 |
| CR2 | Sushi 11 | T | 751 | 21 | 3.72 | 8.68e-3 | -0.90 | 6.67e-3 |
| CR2 | Sushi 11 | H | 753 | 21 | 8.19 | 7.39e-3 | -1.87 | $8.39 \mathrm{e}-3$ |
| CTPS2 | Glutamine amidotransferase type-1 | N | 443 | 27 | 4.91 | 8.51e-3 | -0.04 | $9.24 \mathrm{e}-1$ |
| CTPS2 | Glutamine amidotransferase type-1 | K | 458 | 27 | 2.86 | 4.35e-3 | -0.24 | $2.40 \mathrm{e}-1$ |
| CUBN | EGF-like 4; calciumbinding (Potential) | P | 321 | 26 | 11.49 | $1.24 \mathrm{e}-4$ | -1.17 | 4.33e-2 |
| CUBN | EGF-like 4; calciumbinding (Potential) | Y | 340 | 25 | 1.24 | 5.82e-3 | -0.02 | 8.27e-1 |
| CUBN | CUB 1 | H | 529 | 24 | 4.08 | 3.58e-3 | -0.12 | $6.73 \mathrm{e}-1$ |
| CUBN | CUB 1 | E | 556 | 23 | 4.49 | 2.79e-3 | -0.25 | $4.16 \mathrm{e}-1$ |
| CUBN | CUB 4 | H | 847 | 24 | 8.57 | 1.88e-3 | -0.72 | 2.07e-1 |
| CUBN | CUB 4 | E | 886 | 24 | 4.33 | 4.79e-3 | -0.58 | $6.87 \mathrm{e}-2$ |
| CUBN | CUB 12 | R | 1793 | 29 | 3.35 | 3.97e-3 | 0.09 | $7.18 \mathrm{e}-1$ |
| CUBN | CUB 12 | S | 1839 | 28 | 3.08 | 1.55e-3 | -0.33 | $1.15 \mathrm{e}-1$ |
| CUBN | CUB 17 | L | 2355 | 27 | 3.65 | 8.25e-3 | -0.66 | $2.48 \mathrm{e}-2$ |
| CUBN | CUB 17 | S | 2371 | 27 | 6.68 | 2.13e-3 | -0.85 | $5.48 \mathrm{e}-2$ |
| DCHS1 | Cadherin 13 | P | 1357 | 23 | 10.15 | 5.05e-4 | -1.42 | $1.36 \mathrm{e}-2$ |
| DCHS1 | Cadherin 13 | G | 1361 | 22 | 3.42 | 5.73e-3 | -0.28 | $2.43 \mathrm{e}-1$ |
| EMB | Ig-like V-type 1 | E | 70 | 18 | 6.78 | $4.17 \mathrm{e}-3$ | -1.92 | $2.22 \mathrm{e}-3$ |
| EMB | Ig-like V-type 1 | I | 93 | 18 | 1.33 | 5.58e-4 | -0.30 | $1.62 \mathrm{e}-3$ |
| ERP27 | Thioredoxin | A | 71 | 29 | 3.12 | 9.70e-3 | -0.08 | $7.32 \mathrm{e}-1$ |
| ERP27 | Thioredoxin | T | 130 | 25 | 3.55 | 7.56e-3 | 0.01 | $9.74 \mathrm{e}-1$ |
| F11 | Apple 3 | F | 210 | 27 | 2.73 | 4.40e-3 | -0.16 | $4.41 \mathrm{e}-1$ |
| F11 | Apple 3 | S | 213 | 27 | 6.75 | 6.32e-3 | -0.99 | 6.87e-2 |
| F8 | F5/8 type A 3 | A | 1741 | 22 | 5.11 | 3.32e-3 | -0.49 | $1.76 \mathrm{e}-1$ |
| F8 | F5/8 type A 3 | D | 1956 | 27 | 6.37 | 1.82e-3 | -1.10 | $9.33 \mathrm{e}-3$ |
| FAT2 | Cadherin 14 | H | 1623 | 25 | 6.81 | 5.26e-4 | -0.10 | $8.05 \mathrm{e}-1$ |


| protein | domain | reference (human) character | reference OrthoMaM position | non- <br> reference <br> characters | $\boldsymbol{b}_{\text {mls }}$ | $p_{\text {mls }}$ | $\boldsymbol{b}_{\text {mass }}$ | $p_{\text {mass }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| FAT2 | Cadherin 14 | W | 1640 | 25 | 17.95 | 2.73e-4 | -2.38 | 2.19e-2 |
| FAT2 | Cadherin 15 | G | 1701 | 26 | 2.86 | $2.15 \mathrm{e}-3$ | 0.01 | $9.59 \mathrm{e}-1$ |
| FRAS1 | VWFC 2 | E | 81 | 26 | 3.06 | 8.28e-3 | -0.58 | $2.30 \mathrm{e}-2$ |
| FRAS1 | VWFC 2 | V | 89 | 27 | 1.50 | 8.50e-3 | -0.36 | 5.52e-3 |
| FREM1 | C-type lectin | A | 2080 | 29 | 2.83 | 2.47e-3 | -0.10 | 6.10e-1 |
| FREM1 | C-type lectin | Q | 2158 | 28 | 7.21 | 8.85e-4 | -0.76 | $9.62 \mathrm{e}-2$ |
| GALNT5 | Ricin B-type lectin | I | 807 | 24 | 0.97 | 9.60e-3 | 0.01 | 8.57e-1 |
| GALNT5 | Ricin B-type lectin | Y | 929 | 28 | 7.63 | 9.09e-3 | -1.87 | $4.16 \mathrm{e}-3$ |
| GDPD1 | GDPD | N | 145 | 25 | 3.06 | 9.99e-3 | -0.19 | $4.55 \mathrm{e}-1$ |
| GDPD1 | GDPD | M | 244 | 25 | 2.02 | 3.27e-3 | -0.09 | 5.02e-1 |
| HEPHL1 | Plastocyanin-like 3 | R | 443 | 26 | 3.94 | 9.01e-3 | -0.38 | $2.25 \mathrm{e}-1$ |
| HEPHL1 | Plastocyanin-like 3 | L | 444 | 26 | 5.07 | 3.66e-4 | -0.32 | $2.52 \mathrm{e}-1$ |
| IFNAR1 | Fibronectin type-III 3 | K | 413 | 22 | 4.38 | 7.21e-3 | -0.98 | $1.47 \mathrm{e}-2$ |
| IFNAR1 | Fibronectin type-III 3 | S | 417 | 22 | 3.96 | $2.32 \mathrm{e}-3$ | -1.00 | $2.18 \mathrm{e}-3$ |
| IL12RB1 | Fibronectin type-III 2 | A | 152 | 17 | 3.66 | 3.93e-3 | -0.01 | $9.58 \mathrm{e}-1$ |
| IL12RB1 | Fibronectin type-III 2 | T | 161 | 17 | 2.21 | $2.42 \mathrm{e}-3$ | -0.03 | $8.27 \mathrm{e}-1$ |
| IL1RL1 | Ig-like C2-type 2 | Y | 132 | 24 | 6.79 | $4.29 \mathrm{e}-3$ | -0.40 | $4.15 \mathrm{e}-1$ |
| IL1RL1 | Ig-like C2-type 2 | N | 186 | 26 | 4.14 | 8.80e-3 | -0.13 | $7.08 \mathrm{e}-1$ |
| IL6ST | Ig-like C2-type | Y | 57 | 29 | 9.59 | $9.30 \mathrm{e}-4$ | -1.71 | 5.04e-3 |
| IL6ST | Ig-like C2-type | L | 97 | 28 | 4.68 | 5.79e-3 | -0.28 | $4.41 \mathrm{e}-1$ |
| IQGAP1 | Ras-GAP | K | 1008 | 31 | 1.19 | $3.02 \mathrm{e}-3$ | -0.05 | $5.17 \mathrm{e}-1$ |
| IQGAP1 | Ras-GAP | A | 1104 | 28 | 2.58 | 3.01e-3 | -0.32 | $9.08 \mathrm{e}-2$ |
| ISG20L2 | Exonuclease | Q | 235 | 27 | 4.32 | 8.34e-3 | -0.39 | $2.61 \mathrm{e}-1$ |
| ISG20L2 | Exonuclease | P | 288 | 25 | 11.07 | 8.16e-3 | -1.12 | $2.27 \mathrm{e}-1$ |
| JAK1 | FERM | D | 145 | 25 | 2.14 | $1.70 \mathrm{e}-3$ | -0.05 | $7.51 \mathrm{e}-1$ |
| JAK1 | FERM | N | 309 | 28 | 6.69 | $9.58 \mathrm{e}-3$ | -0.71 | $2.10 \mathrm{e}-1$ |
| KIF18B | Kinesin-motor | V | 37 | 25 | 0.61 | 9.63e-3 | -0.03 | 5.51e-1 |
| KIF18B | Kinesin-motor | Q | 156 | 25 | 5.71 | 8.84e-3 | -0.88 | 5.58e-2 |
| KIF22 | Kinesin-motor | P | 41 | 24 | 6.57 | 5.33e-3 | -0.50 | $2.88 \mathrm{e}-1$ |
| KIF22 | Kinesin-motor | I | 76 | 26 | 1.05 | $5.23 \mathrm{e}-3$ | -0.07 | $3.56 \mathrm{e}-1$ |


| protein | domain | reference <br> (human) <br> character | reference OrthoMaM position | non- <br> reference <br> characters | $\boldsymbol{b}_{\text {mls }}$ | $\boldsymbol{p}_{\text {mls }}$ | $\boldsymbol{b}_{\text {mass }}$ | $\boldsymbol{p}_{\text {mass }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| KIRREL2 | Ig-like C2-type 2 | L | 176 | 22 | 4.45 | 8.17e-3 | -0.47 | 1.99e-1 |
| KIRREL2 | Ig-like C2-type 2 | T | 181 | 22 | 2.01 | 8.79e-3 | -0.02 | 8.89e-1 |
| KIRREL2 | Ig-like C2-type 5 | R | 458 | 20 | 6.68 | 4.39e-3 | -0.35 | $4.62 \mathrm{e}-1$ |
| KIRREL2 | Ig-like C2-type 5 | S | 480 | 21 | 4.15 | $4.38 \mathrm{e}-3$ | -0.45 | $1.43 \mathrm{e}-1$ |
| KIT | Ig-like C2-type 2 | K | 158 | 26 | 2.30 | 9.55e-3 | -0.12 | $5.33 \mathrm{e}-1$ |
| KIT | Ig-like C2-type 2 | D | 165 | 26 | 2.07 | 5.94e-3 | -0.07 | $6.75 \mathrm{e}-1$ |
| KLK6 | Peptidase S1 | S | 82 | 19 | 6.67 | 4.36e-4 | -1.37 | $2.56 \mathrm{e}-3$ |
| KLK6 | Peptidase S1 | T | 146 | 19 | 5.02 | 8.92e-4 | -1.15 | $2.05 \mathrm{e}-3$ |
| LAMA2 | Laminin IV type A 2 | E | 1263 | 27 | 1.97 | 6.77e-3 | -0.02 | $8.80 \mathrm{e}-1$ |
| LAMA2 | Laminin IV type A 2 | Q | 1364 | 24 | 7.00 | 8.16e-3 | -1.26 | $2.38 \mathrm{e}-2$ |
| LAMA3 | Laminin EGF-like 5 | S | 527 | 24 | 5.01 | $4.13 \mathrm{e}-3$ | -0.59 | $1.15 \mathrm{e}-1$ |
| LAMA3 | Laminin EGF-like 5 | H | 556 | 21 | 5.13 | 3.42e-3 | -0.13 | 7.12e-1 |
| LETMD1 | LETM1 | N | 260 | 28 | 3.77 | 7.70e-4 | -0.44 | $5.28 \mathrm{e}-2$ |
| LETMD1 | LETM1 | Q | 344 | 29 | 1.76 | $4.33 \mathrm{e}-3$ | -0.07 | 5.65e-1 |
| LGTN | SUI1 | R | 498 | 27 | 2.33 | 8.01e-3 | -0.42 | $2.68 \mathrm{e}-2$ |
| LGTN | SUI1 | I | 523 | 26 | 4.56 | $1.85 \mathrm{e}-3$ | -0.96 | $4.91 \mathrm{e}-3$ |
| LIFR | Fibronectin type-III 2 | S | 392 | 25 | 3.10 | 3.91e-3 | -0.43 | $4.75 \mathrm{e}-2$ |
| LIFR | Fibronectin type-III 2 | N | 402 | 25 | 5.40 | 2.24e-3 | -0.59 | 8.82e-2 |
| LRIT2 | Fibronectin type-III | N | 363 | 18 | 6.30 | 8.34e-3 | -1.27 | $3.51 \mathrm{e}-2$ |
| LRIT2 | Fibronectin type-III | E | 407 | 22 | 3.39 | $2.40 \mathrm{e}-3$ | -0.76 | 5.02e-3 |
| LTF | Transferrin-like 2 | D | 584 | 25 | 4.14 | 6.46e-3 | -1.01 | 3.06e-3 |
| LTF | Transferrin-like 2 | K | 675 | 24 | 2.01 | 5.48e-3 | -0.21 | $1.60 \mathrm{e}-1$ |
| MAPK13 | Protein kinase | A | 175 | 21 | 3.30 | $4.30 \mathrm{e}-3$ | -0.62 | $1.26 \mathrm{e}-2$ |
| MCF2 | DH | V | 586 | 25 | 2.06 | $1.93 \mathrm{e}-3$ | -0.31 | $2.22 \mathrm{e}-2$ |
| MCF2 | DH | S | 640 | 25 | 5.42 | $1.56 \mathrm{e}-3$ | -1.19 | 3.16e-3 |
| MFI2 | Transferrin-like 2 | S | 612 | 24 | 5.94 | $2.00 \mathrm{e}-3$ | -0.46 | $2.37 \mathrm{e}-1$ |
| MFI2 | Transferrin-like 2 | A | 699 | 25 | 5.49 | 3.81e-3 | -0.73 | 5.61e-2 |
| MTTP | Vitellogenin | P | 107 | 27 | 8.76 | $2.21 \mathrm{e}-3$ | -1.03 | $7.09 \mathrm{e}-2$ |
| MTTP | Vitellogenin | H | 181 | 29 | 5.76 | 5.41e-3 | -0.25 | $5.45 \mathrm{e}-1$ |
| MYO18A | Myosin head-like | Y | 536 | 30 | 6.88 | 2.81e-4 | -0.77 | $3.90 \mathrm{e}-2$ |


| protein | domain | reference <br> (human) <br> character | reference OrthoMaM position | non- <br> reference <br> characters | $\boldsymbol{b}_{\text {mls }}$ | $p_{\text {mls }}$ | $\boldsymbol{b}_{\text {mass }}$ | $\boldsymbol{p}_{\text {mass }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| MYO18A | Myosin head-like | D | 1078 | 26 | 3.48 | $4.60 \mathrm{e}-3$ | -0.71 | 1.01e-2 |
| MYO5C | Myosin head-like | E | 55 | 28 | 6.49 | $1.73 \mathrm{e}-3$ | -0.23 | $5.77 \mathrm{e}-1$ |
| MYO5C | Myosin head-like | S | 56 | 28 | 3.29 | 5.57e-3 | -0.58 | 2.09e-2 |
| MYO7B | MyTH4 1 | A | 1025 | 19 | 3.50 | 3.81e-3 | -0.75 | $7.18 \mathrm{e}-3$ |
| MYO7B | MyTH4 1 | P | 1072 | 20 | 11.83 | $4.44 \mathrm{e}-3$ | -2.67 | 5.12e-3 |
| MYO7B | FERM 2 | G | 2067 | 18 | 14.36 | 6.89e-3 | -2.95 | $2.26 \mathrm{e}-2$ |
| MYO7B | FERM 2 | Q | 2328 | 20 | 8.16 | 3.44e-3 | -0.80 | $2.11 \mathrm{e}-1$ |
| NIN | EF-hand 4 | E | 222 | 28 | 3.16 | 2.59e-3 | -0.07 | $7.32 \mathrm{e}-1$ |
| NIN | EF-hand 4 | H | 229 | 24 | 4.97 | 5.14e-3 | -0.14 | $6.98 \mathrm{e}-1$ |
| NLRP12 | NACHT | K | 376 | 18 | 1.84 | $9.21 \mathrm{e}-3$ | -0.46 | $9.69 \mathrm{e}-3$ |
| NLRP12 | NACHT | N | 394 | 19 | 6.45 | 3.66e-3 | -1.23 | $1.75 \mathrm{e}-2$ |
| NTN5 | NTR | N | 347 | 25 | 4.34 | $4.00 \mathrm{e}-3$ | -0.05 | $8.72 \mathrm{e}-1$ |
| NTN5 | NTR | R | 355 | 24 | 4.71 | 6.67e-3 | -0.15 | $6.77 \mathrm{e}-1$ |
| OBSCN | Ig-like 43 | R | 1818 | 21 | 6.13 | 8.02e-3 | -0.45 | $3.53 \mathrm{e}-1$ |
| OBSCN | Ig-like 43 | T | 1850 | 21 | 6.22 | 8.00e-3 | -1.36 | $1.09 \mathrm{e}-2$ |
| ORC1L | BAH | Y | 117 | 24 | 6.61 | $9.23 \mathrm{e}-3$ | -1.41 | $1.23 \mathrm{e}-2$ |
| ORC1L | BAH | A | 119 | 24 | 3.65 | 2.09e-3 | -0.52 | $3.61 \mathrm{e}-2$ |
| PBK | Protein kinase | N | 45 | 24 | 3.39 | 2.27e-3 | -0.18 | $4.43 \mathrm{e}-1$ |
| PBK | Protein kinase | K | 259 | 27 | 2.94 | $7.55 \mathrm{e}-3$ | -0.18 | $4.21 \mathrm{e}-1$ |
| PDCD11 | S1 motif 9 | M | 1038 | 28 | 4.91 | 5.90e-3 | -0.45 | $2.59 \mathrm{e}-1$ |
| PDCD11 | S1 motif 9 | I | 1046 | 28 | 1.24 | $4.38 \mathrm{e}-3$ | -0.12 | $1.99 \mathrm{e}-1$ |
| PDCD1LG2 | Ig-like V-type | V | 25 | 25 | 2.10 | 1.16e-3 | -0.07 | $6.00 \mathrm{e}-1$ |
| PDCD1LG2 | Ig-like V-type | T | 39 | 25 | 2.56 | 2.53e-3 | -0.07 | $6.70 \mathrm{e}-1$ |
| PGBD1 | SCAN box | R | 46 | 19 | 12.11 | $2.52 \mathrm{e}-3$ | -2.17 | $1.82 \mathrm{e}-2$ |
| PGBD1 | SCAN box | T | 124 | 20 | 10.18 | 4.67e-4 | -2.53 | $6.23 \mathrm{e}-4$ |
| PKD1L1 | REJ | Q | 1135 | 14 | 11.28 | 8.29e-3 | -3.51 | $4.00 \mathrm{e}-3$ |
| PKD1L1 | REJ | I | 1149 | 14 | 9.22 | $4.84 \mathrm{e}-3$ | -1.66 | $4.28 \mathrm{e}-2$ |
| PLA2G4A | PLA2c | E | 443 | 29 | 8.84 | $1.41 \mathrm{e}-4$ | -1.31 | $7.34 \mathrm{e}-3$ |
| PLA2G4A | PLA2c | T | 512 | 29 | 3.96 | 5.79e-3 | -0.66 | $3.15 \mathrm{e}-2$ |
| PRKDC | FAT | T | 3267 | 26 | 3.89 | $4.55 \mathrm{e}-3$ | -0.54 | $4.70 \mathrm{e}-2$ |


| protein | domain | reference (human) character | reference OrthoMaM position | non- <br> reference <br> characters | $\boldsymbol{b}_{\text {mls }}$ | $p_{\text {mls }}$ | $\boldsymbol{b}_{\text {mass }}$ | $\boldsymbol{p}_{\text {mass }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| PRKDC | FAT | T | 3483 | 27 | 4.15 | 4.49e-3 | -0.59 | 5.99e-2 |
| PRLR | Fibronectin type-III 2 | A | 185 | 29 | 2.13 | 8.17e-3 | -0.39 | $2.55 \mathrm{e}-2$ |
| PRLR | Fibronectin type-III 2 | S | 195 | 28 | 2.50 | 6.79e-3 | -0.42 | $3.50 \mathrm{e}-2$ |
| PTPRC | Tyrosine-protein phosphatase 1 | F | 711 | 27 | 6.97 | 6.13e-4 | -0.72 | 8.79e-2 |
| PTPRC | Tyrosine-protein phosphatase 1 | N | 741 | 26 | 4.20 | 5.84e-3 | -0.49 | $1.30 \mathrm{e}-1$ |
| RASSF6 | SARAH | Q | 308 | 31 | 1.14 | $4.00 \mathrm{e}-3$ | -0.04 | $6.01 \mathrm{e}-1$ |
| RASSF6 | SARAH | T | 312 | 30 | 4.75 | 3.44e-3 | -0.65 | 5.09e-2 |
| RECQL4 | Helicase C-terminal | N | 708 | 27 | 6.43 | 2.26e-3 | -1.13 | $1.07 \mathrm{e}-2$ |
| RECQL4 | Helicase C-terminal | V | 767 | 27 | 2.46 | 4.01e-3 | -0.21 | $2.26 \mathrm{e}-1$ |
| RIPK1 | Protein kinase | E | 107 | 29 | 3.01 | $2.84 \mathrm{e}-3$ | -0.38 | $5.43 \mathrm{e}-2$ |
| RIPK1 | Protein kinase | D | 180 | 30 | 4.04 | 6.11e-3 | -0.77 | $1.36 \mathrm{e}-2$ |
| ROS1 | Fibronectin type-III 3 | H | 571 | 25 | 5.32 | 9.02e-3 | -0.45 | $3.33 \mathrm{e}-1$ |
| ROS1 | Fibronectin type-III 3 | G | 631 | 26 | 6.78 | 3.52e-3 | -0.97 | $5.02 \mathrm{e}-2$ |
| ROS1 | Fibronectin type-III 7 | T | 1566 | 25 | 3.17 | 5.97e-4 | -0.27 | $1.29 \mathrm{e}-1$ |
| ROS1 | Fibronectin type-III 7 | G | 1616 | 23 | 4.49 | $2.69 \mathrm{e}-3$ | -0.24 | $4.05 \mathrm{e}-1$ |
| RPGRIP1 | C2 | A | 824 | 26 | 3.83 | 6.08e-3 | -0.58 | 6.10e-2 |
| RPGRIP1 | C2 | N | 843 | 25 | 4.23 | 1.04e-3 | -0.48 | $7.43 \mathrm{e}-2$ |
| RPS6KA6 | Protein kinase 2 | R | 518 | 26 | 3.62 | 3.90e-3 | -0.26 | $2.82 \mathrm{e}-1$ |
| RPS6KA6 | Protein kinase 2 | M | 595 | 25 | 3.51 | 8.33e-4 | -0.14 | $4.70 \mathrm{e}-1$ |
| SHBG | Laminin G-like 1 | P | 159 | 18 | 7.07 | $9.28 \mathrm{e}-3$ | -1.31 | $3.23 \mathrm{e}-2$ |
| SHBG | Laminin G-like 1 | P | 166 | 18 | 9.16 | $4.65 \mathrm{e}-3$ | -1.05 | $1.25 \mathrm{e}-1$ |
| SHROOM1 | ASD2 | G | 591 | 25 | 7.40 | $4.13 \mathrm{e}-3$ | -1.11 | $3.71 \mathrm{e}-2$ |
| SHROOM1 | ASD2 | P | 635 | 25 | 6.33 | 8.90e-3 | -0.42 | $3.88 \mathrm{e}-1$ |
| SNX25 | PXA | K | 3 | 15 | 8.69 | 6.08e-3 | -2.35 | $2.88 \mathrm{e}-3$ |
| SNX25 | PXA | K | 6 | 15 | 8.88 | 6.71e-3 | -2.36 | $3.63 \mathrm{e}-3$ |
| SNX25 | RGS | A | 293 | 25 | 2.73 | 3.01e-3 | -0.09 | $6.13 \mathrm{e}-1$ |
| SNX25 | RGS | H | 300 | 25 | 6.21 | $4.19 \mathrm{e}-4$ | -0.66 | 5.16e-2 |
| SPINK5 | Kazal-like 6 | V | 374 | 19 | 7.15 | $4.82 \mathrm{e}-3$ | -1.59 | 3.42e-3 |


| protein | domain | reference (human) character | reference OrthoMaM position | non- <br> reference <br> characters | $\boldsymbol{b}_{\text {mls }}$ | $p_{\text {mls }}$ | $\boldsymbol{b}_{\text {mass }}$ | $\boldsymbol{p}_{\text {mass }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| SPINK5 | Kazal-like 6 | R | 375 | 19 | 4.56 | 5.30e-4 | -0.75 | $4.00 \mathrm{e}-3$ |
| STK31 | Protein kinase | W | 605 | 21 | 9.91 | $3.33 \mathrm{e}-3$ | -0.21 | $7.60 \mathrm{e}-1$ |
| STK31 | Protein kinase | T | 811 | 19 | 3.48 | 5.25e-3 | -0.17 | $4.96 \mathrm{e}-1$ |
| SVEP1 | Pentaxin | K | 1460 | 25 | 0.76 | 3.70e-3 | -0.02 | $6.97 \mathrm{e}-1$ |
| SVEP1 | Pentaxin | K | 1466 | 24 | 2.64 | 6.72e-3 | -0.59 | $6.33 \mathrm{e}-3$ |
| SVEP1 | Sushi 16 | P | 2262 | 30 | 5.47 | 1.66e-3 | -0.21 | $5.28 \mathrm{e}-1$ |
| SVEP1 | Sushi 16 | Q | 2305 | 30 | 3.74 | 4.66e-3 | -0.03 | 8.96e-1 |
| SYPL1 | MARVEL | V | 77 | 26 | 4.97 | $2.48 \mathrm{e}-3$ | -0.88 | 1.36e-2 |
| SYPL1 | MARVEL | D | 81 | 26 | 8.10 | 3.52e-3 | -1.81 | $3.67 \mathrm{e}-3$ |
| TECTA | VWFD 2 | F | 735 | 26 | 2.88 | 2.66e-3 | -0.04 | $8.26 \mathrm{e}-1$ |
| TECTA | VWFD 2 | E | 794 | 24 | 1.93 | $4.89 \mathrm{e}-3$ | -0.03 | $8.33 \mathrm{e}-1$ |
| TFPI2 | BPTI/Kunitz inhibitor 2 | S | 101 | 21 | 4.40 | $3.93 \mathrm{e}-3$ | -0.55 | $9.23 \mathrm{e}-2$ |
| TFPI2 | BPTI/Kunitz inhibitor 2 | R | 132 | 22 | 6.59 | $9.78 \mathrm{e}-3$ | -1.23 | $2.35 \mathrm{e}-2$ |
| TGFBRAP1 | CNH | K | 67 | 25 | 1.16 | 9.37e-3 | -0.20 | $3.06 \mathrm{e}-2$ |
| TGFBRAP1 | CNH | I | 148 | 26 | 0.65 | $2.62 \mathrm{e}-3$ | -0.04 | $3.60 \mathrm{e}-1$ |
| TRIM25 | B30.2/SPRY | A | 446 | 23 | 4.42 | 6.80e-3 | -0.66 | $4.95 \mathrm{e}-2$ |
| TRIM25 | B30.2/SPRY | P | 450 | 21 | 7.38 | 8.83e-3 | -0.41 | $4.47 \mathrm{e}-1$ |
| TYK2 | FERM | D | 295 | 20 | 4.16 | $2.11 \mathrm{e}-3$ | -0.33 | $1.99 \mathrm{e}-1$ |
| TYK2 | FERM | A | 375 | 22 | 4.98 | 5.74e-3 | -0.43 | $2.44 \mathrm{e}-1$ |
| USH2A | Fibronectin type-III 6 | T | 1959 | 23 | 2.95 | $7.93 \mathrm{e}-3$ | -0.81 | $3.84 \mathrm{e}-3$ |
| USH2A | Fibronectin type-III 6 | R | 1962 | 23 | 7.73 | 6.45e-3 | -1.46 | $3.09 \mathrm{e}-2$ |
| USH2A | Fibronectin type-III 7 | K | 2079 | 26 | 3.22 | 2.28e-3 | -0.43 | $5.02 \mathrm{e}-2$ |
| USH2A | Fibronectin type-III 7 | Y | 2137 | 23 | 5.71 | $1.52 \mathrm{e}-3$ | -0.96 | $9.56 \mathrm{e}-3$ |
| USP48 | DUSP 2 | D | 616 | 28 | 3.37 | 9.12e-3 | -0.25 | $3.50 \mathrm{e}-1$ |
| USP48 | DUSP 2 | K | 669 | 25 | 1.78 | 3.38e-3 | -0.12 | $3.01 \mathrm{e}-1$ |
| ZNF541 | ELM2 | H | 1098 | 21 | 5.23 | $4.28 \mathrm{e}-3$ | -0.43 | $2.71 \mathrm{e}-1$ |
| ZNF541 | ELM2 | T | 1121 | 22 | 3.14 | 5.05e-3 | -0.29 | $2.18 \mathrm{e}-1$ |

## APPENDIX C (Chapter 2) Domains enriched in the Stachybotrys proteome

Lists of Stachybotrys protein domains that are significantly enriched (corrected p $<0.001$ ) in comparison to control sets, by Fisher's exact test. (D-1) Domains that are enriched in proteins exclusive to Stachybotrys, relative to Stachybotrys domains overall. (D-2) Domains that are overrepresented in the entire set of Stachybotrys proteins, relative to the entire set of Fusarium proteins. Positive $\log _{2}$ odds ratio indicates that domain is overrepresented in test group relative to control; conversely, negative odds ratio indicates underrepresentation. P -values shown were corrected for multiple testing with the Bonferroni method.
(D-1)

| CDD domain name | \# domains in Stachybotrysexclusive groups | \# other domains in Stachybotrysexclusive groups | \# domains in Stachybotrys proteomes | \# other domains in Stachybotrys proteomes | $\log _{2}$ <br> odds <br> ratio | p <br> (corrected) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Mito_carr | 0 | 4038 | 385 | 43133 | -Inf | $8.32 \mathrm{E}-12$ |
| WD40 | 7 | 4031 | 381 | 43137 | -2.35 | $1.63 \mathrm{E}-04$ |
| RRM | 8 | 4030 | 413 | 43105 | -2.27 | $7.49 \mathrm{E}-05$ |
| GAL4 | 150 | 3888 | 919 | 42599 | 0.84 | $4.64 \mathrm{E}-06$ |
| SDR_c | 140 | 3898 | 483 | 43035 | 1.68 | $3.33 \mathrm{E}-23$ |
| BRLZ | 33 | 4005 | 108 | 43410 | 1.73 | $2.88 \mathrm{E}-04$ |
| SANT | 31 | 4007 | 97 | 43421 | 1.79 | $3.09 \mathrm{E}-04$ |
| CypX | 158 | 3880 | 478 | 43040 | 1.87 | $7.63 \mathrm{E}-32$ |
| ANK | 242 | 3796 | 717 | 42801 | 1.93 | $1.34 \mathrm{E}-51$ |
| Abhydrolase_5 | 28 | 4010 | 75 | 43443 | 2.02 | $9.07 \mathrm{E}-05$ |
| HET | 173 | 3865 | 386 | 43132 | 2.32 | $2.39 \mathrm{E}-49$ |
| Inhibitor_I9 | 22 | 4016 | 46 | 43472 | 2.37 | $9.22 \mathrm{E}-05$ |
| Peptidases_S8_PCSK9_Pr oteinaseK_like | 22 | 4016 | 46 | 43472 | 2.37 | $9.22 \mathrm{E}-05$ |
| FAD_binding_4 | 45 | 3993 | 94 | 43424 | 2.38 | $5.02 \mathrm{E}-12$ |
| fCBD | 66 | 3972 | 136 | 43382 | 2.41 | 7.10E-19 |
| Amb_all | 27 | 4011 | 55 | 43463 | 2.41 | $1.54 \mathrm{E}-06$ |
| Ank_2 | 32 | 4006 | 64 | 43454 | 2.44 | $2.57 \mathrm{E}-08$ |
| GlcD | 85 | 3953 | 163 | 43355 | 2.52 | $1.29 \mathrm{E}-26$ |
| Acetyltransf_7 | 17 | 4021 | 30 | 43488 | 2.62 | $5.76 \mathrm{E}-04$ |
| CFEM | 34 | 4004 | 57 | 43461 | 2.69 | $1.25 \mathrm{E}-10$ |
| MPP_Dcr2 | 24 | 4014 | 40 | 43478 | 2.70 | $6.70 \mathrm{E}-07$ |
| Glyco_hydro_61 | 108 | 3930 | 148 | 43370 | 3.01 | $1.87 \mathrm{E}-44$ |
| DUF3632 | 15 | 4023 | 19 | 43499 | 3.09 | $1.37 \mathrm{E}-04$ |
| Glyco_hydro_6 | 16 | 4022 | 20 | 43498 | 3.11 | $4.18 \mathrm{E}-05$ |
| Methyltransf_18 | 14 | 4024 | 17 | 43501 | 3.15 | $2.74 \mathrm{E}-04$ |
| M28 | 16 | 4022 | 16 | 43502 | 3.43 | $4.78 \mathrm{E}-06$ |

(D-2)

| CDD domain name | \# domains in Stachybotrys proteomes | \# other domains in Stachybotrys proteomes | \# domains in Fusarium proteomes | \# other domains in Fusarium proteomes | $\log _{2}$ odds ratio | $\mathbf{p}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| nitrilases_CHs | 0 | 43518 | 23 | 36381 | -Inf | $8.00 \mathrm{E}-05$ |
| Helitron_like_N | 0 | 43518 | 23 | 36381 | -Inf | $8.00 \mathrm{E}-05$ |
| Dimer_Tnp_hAT | 32 | 43486 | 81 | 36323 | -1.60 | $1.27 \mathrm{E}-04$ |
| AA_permease_2 | 50 | 43468 | 103 | 36301 | -1.30 | $4.69 \mathrm{E}-04$ |
| MFS | 1552 | 41966 | 1990 | 34414 | -0.64 | $1.27 \mathrm{E}-34$ |
| PKS | 152 | 43366 | 46 | 36358 | 1.47 | $5.68 \mathrm{E}-07$ |
| PKS_AT | 149 | 43369 | 43 | 36361 | 1.54 | $1.75 \mathrm{E}-07$ |
| fCBD | 136 | 43382 | 35 | 36369 | 1.70 | $4.97 \mathrm{E}-08$ |
| Glyco_hydro_61 | 148 | 43370 | 33 | 36371 | 1.91 | $9.05 \mathrm{E}-11$ |

## APPENDIX D (Chapter 2) Putative polyketide synthases of Stachybotrys

Total counts of putative PKSs found in sequenced fungal genomes. Counts include hybrid NRPS/PKSs. We provided or verified counts for Stachybotrys, Fusarium spp, and A. nidulans; others are reprinted from Table 8 of Kubicek et al (2011).

| organism | PKSs |
| :--- | ---: |
| Stachybotrys chartarum 40293 | 37 |
| Stachybotrys chartarum 7711 | 36 |
| Stachybotrys chartarum 40288 | 35 |
| Aspergillus oryzae | 30 |
| Stachybotrys chlorohalonata 40285 | 28 |
| Aspergillus nidulans | 28 |
| Magnaporthe oryzae | 28 |
| Cochliobolus heterostrophus | 25 |
| Trichoderma virens | 22 |
| Trichoderma atroviridae | 19 |
| Botryotinia fuckeliana | 19 |
| Fusarium graminearum | 15 |
| Aspergillus fumigatus | 14 |
| Fusarium oxysporum | 13 |
| Fusarium solani | 13 |
| Trichoderma reesei | 13 |
| Fusarium verticillioides | 11 |
| Neurospora crassa | 7 |
| Saccharomyces cerevisiae | 0 |

## APPENDIX E (Chapter 2) Summary of selected putative Stachybotrys proteins

Each table below represents all proteins located in a single set of orthologous gene clusters among the four Stachybotrys strains. Alignment length refers to the length, in amino acids (aa), of each respective alignment of all protein orthologs, as shown in Appendix G. Hypothesized function is based on BLASTP results and conserved domains. See main text for discussion of specific proteins.

## F-1. Core trichothecene cluster, 9 products.

| symbol | alignment <br> length (aa) | hypothesized function |
| :--- | ---: | :--- |
| Tri3 | 524 | acetyltransferase |
| Tri4 | 547 | hydroxylase |
| Tri5 | 383 | terpene cyclase |
| Tri6 | 277 | transcription factor |
| Tri10 | 422 | transcription factor |
| Tri11 | 494 | hydroxylase |
| Tri14 | 367 |  |
| Tri17 | 2403 | reducing polyketide synthase (PKS) |
| Tri18 | 541 | hydroxylase |

F-2. Core atranone cluster, 14 products.

| symbol | alignment <br> length (aa) | hypothesized function |
| :--- | ---: | :--- |
| Atr1 | 234 | esterase, dehydrogenase, or enol lactonase |
| Atr2 | 540 | monooxygenase |
| Atr3 | 478 | monooxygenase |
| Atr4 | 524 | monooxygenase |
| Atr5 | 297 | esterase |
| Atr6 | 2439 | reducing PKS |
| Atr7 | 320 | short-chain reductase |
| Atr8 | 625 | BVMO |
| Atr9 | 253 | short-chain reductase |
| Atr10 | 276 | short-chain reductase |


| Atr11 | 133 | polyketide cyclase |
| :--- | ---: | :--- |
| Atr12 | 391 | methyltransferase |
| Atr13 | 381 | terpene cyclase |
| Atr14 | 461 | short-chain reductase |

## F-3. Satratoxin cluster 1, 10 products.

| symbol | alignment <br> length (aa) | hypothesized function |
| :--- | ---: | :--- |
| Sat1 | 294 | hydroxylase |
| Sat2 | 354 | short-chain dehydrogenase |
| Sat3 | 271 | ketoacyl reductase |
| Sat4 | 268 |  |
| Sat5 | 463 | acetyltransferase |
| Sat6 | 485 | lipase; $40 \%$ identity to Fusarium Tri8 |
| Sat7 | 470 | hydroxylase |
| Sat8 | 2602 | nonreducing PKS |
| Sat9 | 208 | transcription factor |
| Sat10 | 1930 |  |

## F-4. Satratoxin cluster 2, 6 products.

| symbol | alignment <br> length (aa) | hypothesized function |
| :--- | ---: | :--- |
| Sat11 | 526 | hydroxylase |
| Sat12 | 573 | acetyltransferase |
| Sat13 | 2383 | reducing PKS |
| Sat14 | 455 | acetyltransferase |
| Sat15 | 153 | transcription factor |
| Sat16 | 184 | acetyltransferase |

## F-5. Satratoxin cluster 3, 5 products.

| symbol | alignment <br> length (aa) | hypothesized function |
| :--- | ---: | :--- |
| Sat17 | 393 | hydroxylase |
| Sat18 | 401 | methyltransferase |


| Sat19 | 230 | acetyltransferase |
| :--- | :--- | :--- |
| Sat20 | 712 | transcription factor |
| Sat21 | 474 | transporter |

## APPENDIX F (Chapter 2) Selected draft sequences of putative Stachybotrys proteins

Alignments are in a slightly modified version of Phylip interleaved format. Length of each alignment is shown in amino acids (aa). These sequences are the unedited output of MAKER, so some minor errors are present. For example, a gap can indicate either sequence that is truly missing from the genome or simply a region that is missing from the annotation or was incorrectly annotated. Corrected sequence records will be placed in Genbank.

## Core trichothecene cluster, 9 products

```
Tri3, 524 aa
S40285
S40288
S40293
S7711
MGSLPELLLP PLTPEIHRWK ITKANPRLAQ RRGVGFEVIV GSEQLNRKGQ
MGSLPELRLP PLAPEIHRWK ISKTNPRLAQ RRGVGFEVIV GCEQLNRKGQ
MGSLPELRLP PLAPEIHRWK ISKTNPRLAQ RRGVGFEVIV GCEQLNRKGQ
MGSLPELRLP PLAPEIHRWK ISKTNPRLAQ RRGVGFEVIV GCEQLNRKGQ
YDLYLTVTLR MVESSTSTPV SLATLKEKFE LALLVARLEH PECGSSVRWD
YDLYLIVTLR MVESSTSTPV SLAILKEKFE LALLVARLEH PECGSSVRWD
YDLYLIVTLR MVESSTSTPV SLAILKEKFE LALLVARLEH PECGSSVRWD
YDLYLIVTLR MVESSTSTPV SLAILKEKFE LALLVARLEH PECGSSVRWD
DQPSPIFEYE SPENNEAAIA WAKGIVHALP TSSTAQQVWY DLEQERQKSA
DQPSPIFEYE SPENNEAALA WAKGIVHALP TSSTAQQVWY DLEQERQKSA
DRPSPIFEYE SPENNEAALA WAKGIVHALP TSSTAQQVWY DLEQERQKSA
DQPSPIFEYE SPENNEAALA WAKGIVHALP TSSTAQQVWY DLEQERQKSA
VSDRKAGKPV EIFLIARTPG KDAQIPQGAS IDVLFHMNHL YWDGIGARIF
VSDRKAGKPV EIFLVAHTPD KDARLPQGAS IDVLFHMNHL YWDGIGARIF
VSDRKAGKPV EIFLVAHTPD KDARLPQGAS IDVLFHMNHL YWDGIGARIF
VSDRKAGKPV EIFLVAHTPD KDARLPQGAS IDVLFHMNHL YWDGIGARIF
VGYLLRQLNN YIGAAGGQEP PTVHWGSEMS NFHTAQLDAM KVQVQSLGTE
VGYLLRQLSS YIGAAAGQEP PTVHWGSEMS NFHTAQLDAM KVQVESLGSE
VGYLLRQLSN YIGAAAGQKP PTVHWGSEMS NFHTAQLDAM KVQVESLGSE
VGYLLRQLSN YIGAAAGQEP PTVHWGSEMS NFHTAQLDAM KVQVESLGSE
FEARSHQYVN TLMQSLSCWG MPFKASDEAI PRAHTLTFTP AESTDIIRAV
FEARSHQYVN TLMQSLSCWG MPFKASDEAI PRAHTLTFTP AESTDIIRAV
FEARSHQYVN TLMQSLSCWG MPFKASDEAI PRAHTLTFTP AESTDIIRAV
FEARSHQYVN TLMQSLSCWG MPFKASDEAI PRAHTLTFTP AESTDIIRAV
KTRLGPHYTI SHLAQAATIV AMLDMYRHTA EILETDSFVA PTAVNARRYL
KTRLGPQYTI SHLAQAATIV AMLDMYRHTA DILETDSFVA PTAVNARRYL
KTRLGPQYTI SHLAQAATIV AMLDMYRHTA DILETDSFVA PTAVNARRYL
KTRLGPQYTI SHLAQAATIV AMLDMYRHTA DILETDSFVA PTAVNARRYL
RDDLKAGYMA GCVTGAVINV RNLKSLLVSL NDDQDVVVAA LARATKDVKA
RDDLKADYMA GCVTGAVINV GNLKSLLVSL NDDQDVVVGA LAKATKDVKA
RDDLKADYMA GCVTGAVINV GNLKSLLVSL NDDQDVVVGA LAKATKDVKA
RDDLKADYMA GCVTGAVINV GNLKSLLVSL NDDQDVVVGA LAKATKDVKA
SFDLWIHDQS QLALGLRVHS FEGAMLSKNP MPFDKVSGPF ISSDGINELY
SFDLWIHDQS QLALGLRVHS FEGAMLSKNP MPFDKTSGPF ISSDGINELY
SFDLWIHDQS QLALGLRVHS FEGAMLSKNP MPFDKTSGPF ISSDGINELY
SFDLWIHDQS QLALGLRVHS FEGAMLSKNP MPFDKTSGPF ISSDGINELY
IPTDISSATT GETFMKTDKF VFLLNQFLPY MALRLDSWKG TSMLTICYND
IPTDISSATT GETFMKTDKF VFLLNQFLPY MALRLDSWKG TSMLTICYND
IPTDISSATT GETFMKTDKF VFLLNQFLPY MALRLDSWKG TSMLTICYND
IPTDISSATT GETFMKTDKF VFLLNQFLPY MALRLDSWKG TSMLTICYND
GNFSQEETAT YLRAVADFML AFRL
GNFSQEETAT YLRAVADFML AFRL
GNFSQEETAT YLRAVADFML AFRL
GNFSQEETAT YLRAVADFML AFRL
```

Tri4, 547 aa
S40285 MPALSDLESI KAVPLWAAAG AVGGLYFVYI LGTCFYNVYL HPLRHIPGSK S40288 MPALSDLESI KAVPLWAAAG AVGGLYFVYI LGTCFYNVYL HPLRHIPGSK S40293 MPALSDLESI KAVPLWAAAG AVGGLYFVYI LGTCFYNVYL HPLRHIPGSK S7711 MPALSDLESI KAVPLWAAAG AVGGLYFVYI LGTCFYNVYL HPLRHIPGSK

LAVMGPYLEF YHEVIRKGQY LWEIEKMHEK YGPIVRVNPR EIHIKDSSFY LAVMGPYLEF YHEVIRKGQY LWEIEKMHEK YGPIVRVNPR EIHIKDSSFY LAVMGPYLEF YHEVIRKGQY LWEIEKMHEK YGPIVRVNPR EIHIKDSSFY LAVMGPYLEF YHEVIRKGQY LWEIEKMHEK YGPIVRVNPR EIHIKDSSFY

HTIYAAGSRK TNKDPSAVGA FDVPSSTAAT IDHDQHRARR GYLNPYFSKR HTIYAAGSRK TNKDPSAVGA FDVPSSTAAT IDHDQHRARR GYLNPYFSKR HTIYAAGSRK TNKDPSAVGA FDVPSSTAAT IDHDQHRARR GYLNPYFSKR HTIYAAGSRK TNKDPSAVGA FDVPSSTAAT IDHDQHRARR GYLNPYFSKR

SLADLEPTIH ERISKLTSRT EKHMTDGDVL TLDGIFSALT ADIICARFYG SLADLEPTIH ERISKLTSRT EKHMIDGDVL TLDGIFSALT ADIICARFYG SLADLEPTIH ERISKLTSRT EKHMIDGDVL TLDGIFSALT ADIICARFYG SLADLEPTIH ERISKLTSRT EKHMIDGDVL TLDGIFSALT ADIICARFYG

EHFDYLGVPD YHFVVRDGFQ GLTKLYHLAR FVPTLVSALK DLPEQVIRMF EHFDYLGVPD YHFVVRDGFQ GLTKLYHLAR FVPTLVSALK DLPEQVIRMF EHFDYLGVPD YHFVVRDGFQ GLTKLYHLAR FVPTLVSALK DLPEQVIRMF EHFDYLGVPD YHFVVRDGFQ GLTKLYHLAR FVPTLVSALK DLPEQVIRMF

LPALADLVVM RNEIHANGAS KFTSSQTADA KASALVGALA DKNIPPHERT LPALADLVVM RNEIHANGAS KFTSSQTADA KASALVGALA DKNIPPHERT LPALADLVVM RNEIHANGAS KFTSSQTADA KASALVGALA DKNIPPHERT LPALADLVVM RNEIHANGAS KFTSSQTADA KASALVGALA DKNIPPHERT

VSRLLDEGTV FLFAGTETTS RTMAITMYYL LTNPECLKKL REELETLPVT VSRLLDEGTV FLFAGTETTS RTMAITMYYL LTNPGCLKKL REELETLPVT VSRLLDEGTV FLFAGTETTS RTMAITMYYL LTNPECLKKL REELETLPVT VSRLLDEGTV FLFAGTETTS RTMAITMYYL LTNPECLKKL REELETLPVT

EDYKHSLQTL ESLPYLSGVV HEGLRLAFGP ITRSARVPMN KDLQYQDYNI EDYKHSLQTL ESLPYLSGVV HEGLRLAFGP ITRSARVPMN KDLQYQNYNI EDYKHSLQTL ESLPYLSGVV HEGLRLAFGP ITRSARVPMN KDLQYQNYNI EDYKHSLQTL ESLPYLSGVV HEGLRLAFGP ITRSARVPMN KDLQYQNYNI

PAGTPLSMST YFVHTDAELY PEPEKFKPER WIKAAEDGVP LKKFLTNFSQ PAGTPLSMST YFVHTDAELY PEPEKFKPER WIKAAEEGVP LKKFLTNFSQ PAGTPLSMST YFVHTDAELY PEPEKFKPER WIKAAEEGVP LKKFLTNFSQ PAGTPLSMST YFVHTDAELY PEPEKFKPER WIKAAEEGVP LKKFLTNFSQ

GSRQCIGIKY VAPCTPRSLE DVLTDLPLSS MSFAEMYLTI SRVARAFDFE GSRQCIGI-- ---------- ---------N MSFAEMYLTI SRVARAFDFE GSRQCIGI-- ---------- ---------N MSFAEMYLTI SRVARAFDFE GSRQCIGI-- ---------- ---------N MSFAEMYLTI SRVARAFDFE

LFETTAADLD MTYARIVAYP KEIPGKKEGL GEIRVKVTNR NHPVMVE LFETTAADLD MTYARIVAYP KEIPGKKEGL GEIRVKVTNR HHPVLVQ LFETTAADLD MTYARIVAYP KEIPGKKEGL GEIRVKVTNR HHPVLVQ LFETTAADLD MTYARIVAYP KEIPGKKEGL GEIRVKVTNR HHPVLVQ

| S40285 | METFPTEYFL GTAVRLLENV KYRDSNYTRE | ERVENLQYAY | NKAAAHFAQE |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
| S40288 | MEAFPTEYFL | GTAVRLLENV | KYRDSNYTRE | ERVENLQYAY | NKAAAHFAQE |
| S7711 | MEAFPTEYFL | GTAVRLLENV | KYRDSNYTRE | ERVENLQYAY | NKAAAHFAQE |
|  | MEAFPTEYFL | GTAVRLLENV | KYRDSNYTRE | ERVENLQYAY | NKAAAHFAQE |

RRSLLNEISD DHIPQPAFTG PCQCTFENCK STTVFTTGRD FRRHYRQHFK

RFFCRYEECP QSTDDPGDAG TRGFATRKDR ARHEAKHNPA IKCPWQSRNG RFFCRYEECP QSTDDPGDAG TRGFATRKDR ARHEAKHNPA IKCPWQNRNG RFFCRYEECP QSTDDPGDAG TRGFATRKDR ARHEAKHNPA IKCPWQNRNG RFFCRYEECP QSTDDPGDAG TRGFATRKDR ARHEAKHNPA IKCPWQNRNG

GTCTRTFSRM DNMRDHYRRI HGKSCKT GTCTRTFSRM DNMRDHYRRI HGKSCKT GTCTRTFSRM DNMRDHYRRI HGKSCKT GTCTRTFSRM DNMRDHYRRI HGKSCKT

Tri10, 422 aa

S40285
S40288
S40293
S7711

MTPITITFPK RTQEKETSLL MHYLDVVFPL QFPVHDRSYE GKREWLLAIL MTPITITFPK RTQEKETSLL MHYLDVVFPL QFPVHDRSYE GKREWLLAIL MTPITITFPK RTQEKETSLL MHYLDVVFPL QFPVHDRSYE GKREWLLAIL MTPITITFPK RTQEKETSLL MHYLDVVFPL QFPVHDRSYE GKREWLLAIL

TSSRSVYYAT LSLSLLHKES RLDDFES--- ---------- --ESQQLLDQ TSSRSVYYAT LSLSLLHKES RLDDFESVWQ SERTRYYILA LQESQQLLDQ TSSRSVYYAT LSLSLLHKES RLDDFESVWQ SERTRYYILA LQESQQLLDQ TSSRSVYYAT LSLSLLHKES RLDDFESVWQ SERTRYYILA LQESQQLLDQ

IDTADGVAKL KGNIHALAST VQLISIESSS LSLGDWQVHL LAGKALIPEL IDTADGVAKL KGNIHALAST VQLISIESSS LSLGDWQVHL LAGKALIPEL IDTADGVAKL KGNIHALAST VQLISIESSS LSLGDWQVHL LAGKALIPEL IDTADGVAKL KGNIHALAST VQLISIESSS LSLGDWQVHL LAGKALIPEL

VHGWTLVPKS GRFTSSVWTV LDAPQFSAAH DEDTLSFEYV GALQFLTNIL VHGWTLVPKS GRFTSSVWTV LDAPQFSAAH DEDTLSFEYV GALQFLTNIL VHGWTLVPKS GRFTSSVWTV LDAPQFSAAH DEDTLSFEYV GALQFLTNIL VHGWTLVPKS GRFTSSVWTV LDAPQFSAAH DEDTLSFEYV GALQFLTNIL

AMFGIFSCIS IGPAAASFAE YRYLLDQEGM IQMDQIIGCK NWVLLAILEV AMFGIFSCIS IGPASASFAE YRYLLDQEGM IQMDQIIGCK NWVLLAILEV AMFGIFSCIS IGPASASFAE YRYLLDQEGM IQMDQIIGCK NWVLLAILEV AMFGIFSCIS IGPASASFAE YRYLLDQEGM IQMDQIIGCK NWVLLAILEV

GELDKWKRVE QEHHRLSLKD LGNRATVIEE MIENGLRESS GSALVDLVTS GELDKWKRVE QEHHRLSLKD LGNRATVIEE MIETGLRESS GSALVDLVTS GELDKWKRVE QEHHRLSLKD LGNRATVIEE MIETGLRESS GSALVDLVTS GELDKWKRVE QEHHRLSLKD LGNRATVIEE MIETGLRESS GSALVDLVTS

IYATSTLTYM HTVVSGLNPN LREVQDSVAA TMVLLKQLPD VRIVKNLVWS IYATSTLTYM HTVVSGLNPN LREVQDSVAA TMVLLKQLPD VRIAKNLVWS IYATSTLTYM HTVVSGLNPN LREVQDSVAA TMVLLKQLPD VRIAKNLVWS IYATSTLTYM HTVVSGLNPN LREVQDSVAA TMVLLKQLPD VRIAKNLVWS

LVVTGCMASL GQEDFFRGLN AVAGTSVRGL RNCWGLATIW DRTWNMRDTI LVVTGCMASL GQEDFFRGLN AVAGTSVRGL RNCWGLATIW DRTWNMRDTI LVVTGCMASL GQEDFFRGLN AVAGTSVRGL RNCWGLATIW DRTWNMRDTI LVVTGCMASL GQEDFFRGLN AVAGTSVRGL RNCWGLATIW DRTWNMRDTI

TTTSHTVWED LINGQGPPNL LV TTTSHTVWED LINGQGPPNL LV TTTSHTVWED LINGQGPPNL LV TTTSHTVWED LINGQGPPNL LV

| Tri11, | aa |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| S40285 | MTVLLQAAAL | AAAVYTLSIP | IQSIYNLYFH | PLSRIPGPKL | WIAFPILGQI |
| S40288 | MTVLLQAAAL | AAAAYTLSIP | IQSIYNLYFH | PLSKIPGPKL | WIAFPILGQI |
| S 40293 | MTVLLQAAAL | AAAAYTLSIP | IQSIYNLYFH | PLSKIPGPKL | WIAFPILGQI |
| S7711 | MTVLLQAAAL | AAAAYTLSIP | IQSIYNLYFH | PLSKIPGPKL | WIAFPILGQI |
|  | ARVRGILDSY | MCAFHRVYGE | AVRYGPDEVS | IITEQAWKDI | YNHRPNQLER |
|  | ARVRGVLDSY | MCAFHRVYGE | AVRYGPDEVS | IITEQAWKDI | YNHRPNQLER |
|  | ARVRGVLDSY | MCAFHRVYGE | AVRYGPDEVS | IITEQAWKDI | YNHRPNQLER |
|  | ARVRGVLDSY | MCAFHRVYGE | AVRYGPDEVS | IITEQAWKDI | YNHRPNQLER |
|  | NILSTTRRPD | IFDAVEVDHD | RYRKAMSHAF | SPKGLQEQEP | IVKGYLDLLI |
|  | NILSTTRRPD | IFDAVEVDHD | RYRKAMSHAF | SPKGLQEQEP | IVKGYLDLLI |
|  | NILSTTRRPD | IFDAVEVDHD | RYRKAMSHAF | SPKGLQEQEP | IVKGYLDLLI |
|  | NILSTTRRPD | IFDAVEVDHD | RYRKAMSHAF | SPKGLQEQEP | IVKGYLDLLI |
|  | ERLNQVAANE | GKTDMVQWYN | FMLFDTIGDL | AFGQSFGGLR | DQVLHFSISF |
|  | ERLNQVAANE | GKTDMVQWYN | FMLFDTIGDL | AFGQSFGGLR | DQVLHFSISF |
|  | ERLNQVAANE | GKTDMVQWYN | FMLFDTIGDL | AFGQSFGGLR | DQVLHFSISF |
|  | ERLNQVAANE | GKTDMVQWYN | FMLFDTIGDL | AFGQSFGGLR | DQVLHFSISF |
|  | TFEAFKLLTY | MEAGARYPLL | LKFLELFTPK | SIIEARDRKE | EHAEATVKQR |
|  | TFEAFKLLTY | MEAGARYPLL | LKVLELFTPK | SIIEARDRKE | EHAEATVKQR |
|  | TFEAFKLLTY | MEAGARYPLL | LKVLELFTPK | SIIEARDRKE | EHAEATVKQR |
|  | TFEAFKLLTY | MEAGARYPLL | LKVLELFTPK | SIIEARDRKE | EHAEATVKQR |
|  | LENGSMHGRG | DFMDAMLRNR | GKPGGLNDRE | LIANASTLIT | AGSETTATIL |
|  | LENGSMHGRG | DFMDAMLRNR | GKPGGLNDRE | LIANASTLIT | AGSETTATIL |
|  | LENGSMHGRG | DFMDAMLRNR | GKPGGLNDRE | LIANASTLIT | AGSETTATIL |
|  | LENGSMHGRG | DFMDAMLRNR | GKPGGLNDRE | LIANASTLIT | AGSETTATIL |
|  | SGMTYWLLRN | PDNYKKVVHE | VRSAYSSDSE | ILMITTTTRL | PFMIACFQEA |
|  | SGMTYWLLRN | PDNYKKVVHE | VRSAYSSDSE | ILMITTTTRL | PFMIACFQEA |
|  | SGMTYWLLRN | PDNYKKVVHE | VRSAYSSDSE | ILMITTTTRL | PFMIACFQEA |
|  | SGMTYWLLRN | PDNYKKVVHE | VRSAYSSDSE | ILMITTTTRL | PFMIACFQEA |
|  | FRLYPPVPSC | LQRVTPETDM | TQISGYDIPP | NTKVGVHALA | AYTDPRNWHR |
|  | FRLYPPVPSC | LQRVTPETGM | TQISGYDIPP | NTKVGVHALA | AYTNPRNWHR |
|  | FRLYPPVPSC | LQRVTPETGM | TQISGYDIPP | NTKVGVHALA | AYTDPRNWHR |
|  | FRLYPPVPSC | LQRVTPETGM | TQISGYDIPP | NTKVGVHALA | AYTDPRNWHR |
|  | PDEFLPERWL | SEAEKNPASP | FYKDRRATLQ | PFSVGPRSCI | GRNMAEQEMR |
|  | PDEFLPERWL | PEVEKNPASP | FYKDRRATLQ | PFSVGPRSCI | GRNMAEQEMR |
|  | PDEFLPERWL | PEVEKNPASP | FYKDRRATLQ | PFSVGPRSCI | GRNMAEQEMR |
|  | PDEFLPERWL | PEVEKNPASP | FYKDRRATLQ | PFSVGPRSCI | GRNMAEQEMR |
|  | LILARLLWNF | DLALCPESKN | WKEQKTHYLW | EKHPLMCNVR | RRVF |
|  | LILARLLWNF | DLALCPESKD | WKEQKTHYLW | EKHPLMCSVR | RRVF |
|  | LILARLLWNF | DLALCPESKD | WKEQKTHYLW | EKHPLMCSVR | RRVF |
|  | LILARLLWNF | DLALCPESKD | WKEQKTHYLW | EKHPLMCSVR | RRVF |

Tril4, 367 aa
S40285 MLPQVLLSAL GLLGEANCSQ TSGHGSPNHH QCPQLPKGDL IYDVYMGYPE
S40288 MLPQVLLSTL GFLGKASCSQ TSGHGSPNYH QCPELPKGDL IYDVYMGYPE
S40293 MLPQVLLSTL GFLGKASCSQ TSGHGSPNYH QCPELPKGDL IYDVYMGYPE
S7711

NFMWDKRRCV AYVSNLYNAS LSIYDPYESR VLETFQFPGL SHPGNSAIDN NFMWDKRRCV AYVSNLYNAS LSIYDPYESR VLETFQFPGL SHPGNSAIDN

PLHTSGLVLR PDSYRAETLE IVVDNGDAFF SNGLNVSGPD YLLTMNLNTK PLHTSGLVLR PDSYRAETLE IVVDNGDAFF SNGLNVSGPD YLLTMDLSTK PLHTSGLVLR PDSYRAETLE IVVDNGDAFF SNGLNVSGPD YLLTMDLSTK PLHTSGLVLR PDSYRAETLE IVVDNGDAFF SNGLNVSGPD YLLTMDLSTK

EITHQLHLNN GLYAGYADAE LGTDGNTYVL GTYTANILRV TPDKKLSTFY EITHQLHLNN GLYAGYADAE LGTDGNTYVL GTYTANILRV TPDKKLSTFY EITHQLHLNN GLYAGYADAE LGTDGNTYVL GTYTANILRV TPDKKLSTFY EITHQLHLNN GLYAGYADAE LGTDGNTYVL GTYTANILRV TPDKKLSTFY

VEEPLAPPRL YGFTGITHVG DTLIANNNII GQFVRFSVHD EEGTPIIIKQ VEEPLAPPRL YGFTGITHVG DTLIANNNII GQFVRFSVHD DEGTPIIIKQ VEEPLAPPRL YGFTGITHVG DTLIANNNII GQFVRFSVHD DEGTPIIIKQ VEKPLAPPRL YGFTGITHVG DTLIANNNII GQFVRFSVHD DEGTPIIIKQ

TPYHNFTTSN VLNLPEKYED TILLATENAT PEHPSGGVGV FRSQDKLFHE TPYHNFTTSN VLNLPEKYED TILLATENAT PEHPSGGVGV FRSQDKLFHE TPYHNFTTSN VLNLPEKYED TILLATENAT PEHPSGGVGV FRSQDKLFHE TPYHNFTTSN VLNLPEKYED TILLATENAT PEHPSGGVGV FRSQDKLFHE

MEFLGFIPSR LNQALATSAR QMADRIYVVS VYTDGANITV AGHTSKFVFQ MEFLGFIPSR LNQALATSAR QMADRIYVVS VYTDGANITV AGHTSKFVFQ MEFLGFIPSR LNQALATSAR QMADRIYVVS VYTDGANITV AGHTSKFVFQ MEFLGFIPSR LNQALATSAR QMADRIYVVS VYTDGANITV AGHTSKFVFQ

DFTEEIDALV NAQSDEL
DFTEEIDALV NTQSDEL
DFTEEIDALV NTQSDEL
DFTEEIDALV NTQSDEL


VGIGCRFPAY ATNPGKLWDL LESGKFTWSK VPADRWNEEA FRRHSVDGIN VGIGCRFSGY ATNPGRLWDL LMSGKSTWSK VPADRWNEEA FRHHSPDGIN VGIGCRFSGY ATNPGRLWDL LMSGKSTWSK VPADRWNEEA FRHHSPDGIN VGIGCRFSGY ATNPGRLWDL LMSGKSTWSK VPADRWNEEA FRHHSPDGIN

HHQGGHFLCQ DIGRFDAEFF GITPQEAASI ---------- DPQQRLLLET NHQGGHFLDQ DIDRFDAELF GITPEEAASI ---------- DPQQRLLLET NHQGGHFLDQ DIDRFDAELF GITPEEAASI ---------- DPQQRLLLET NHQGGHFLDQ DIDRFDAELF GITPEEAASI NSRADHSSGQ DPQQRLLLET

TYEALENAGI RQDTIGGSET AVYMALSARD YDHNLDRGAT SVANHCVRSP TYEALENAGI RQDTINGSQT AVYTALSARD YDHNVDTGAT SVANPCVRSP TYEALENAGI RQDTINGSQT AVYTALSARD YDHNVDTGAT SVANPCVRSP TYEALENAGI RQDTINGSQT AVYTALSARD YDHNVDTGAT SVANPCVRSP

QQDVPANTIS RFFNLTGPSV NIDSGSDGGM AAVTHACQAL RLGRSDVALA RQDVPANRIS RLFNLTGPSV NMDSGSDGGM AAITHACQAL RLGRSDVALA RQDVPANRIS RLFNLTGPSV NMDSGSDGGM AAITHACQAL RLGRSDVALA RQDVPANRIS RLFNLIGPSV NMDSGSDGGM AAITHACQAL RLGRSDVALA

```
GASSLILNPD QVNGINDAHG VRIDGCVPRS SSEGSTHSRG EGVAALVIKR
GASNLILNPD QVDGIDDAHG VRVDGRVPLS SSEGSTHSRG EGVAALVIKR
GASNLILNPD QVDGIDDSHG VRVDGRVPLS SSEGSTHSRG EGVAALVIKR
GASNLILNPD QVDGIDDAHG VRVDGRVPLS SSEGSTHSRG EGVAALVIKR
LDDAIRDQNP IRAILHDTNI GEHSYALGSR ENSRRIEICT YDNRGRASAE
LDDAIRDQNP IRAILRDANI GQNSHALGSG EDSRRIEICS NGTPGKGGAE
LDDAIRDQNP IRAILRDANI GQNSHALGSG EDSRRIEICS NGTPGKGGAE
LDDAIRDQNP IRAILRDANI GQNSHALGSG EDSRRIEICS NGTPGKGGAE
LRNTQNVFSQ YQDINLSSFT NQIESTIGDT GCVSAFAAVI ASVLFLENTT
PRNLQSAFSQ HQDINLSSFT DQIKSTIGDT GCVSALAAVI ASVMFLENTT
PRNLQSAFSQ HQDINLSSFT DQIKSTIGDT GCVSALAAVI ASVMFLENTT
PRNLQSAFSQ HQDIKSSSFT DQIKSTIGDT GCVSALAAVI ASVMFLENTT
IPPDKTQNDA AGVVVNAFSS YGTKSHVILE RTTGLLISSS GEEDSSPRLF
ISPDATQNDV AGVVVNAFSS YGTKSHVVLE RTTRPVTTSS GEEESSSRLF
ISPDATQNDV AGVVVNAFSS YGTKSHVVLE RTTRPVTTSS GEEESSSRLF
ISPDATQNDV AGVVVNAFSS YGTKSHVVLE RTTRPVTTSS GEEESSSRLF
IFSASSQTSL VRMLAVYADW TREHAGNAST LRDLSYTLSQ RRSFLPWRFS
VFSASSQTSL VRKLAVHADW TRKHGGNAST LRDLSYTLSQ RRSLLPWRFS
VFSASSQTSL VRKLAVHADW TRKHGGNAST LRDLSYTLSQ RRSLLPWRFS
VFSASSQTSL VRMLAVHADW TRKHGGNAST LRDLSYTMSQ RRSLLPWRFS
CIAENQAELL ESLANGSKKQ DSLVRTTPGA KISFVFTGQG SQWAEMGREL
CIAESQAELL EALASGSKKT DSLVRITPGA KISFIFTGQG SQWAEMGREL
CIAESQAELL EALASGSKKT DSLVRITPGA KISFIFTGQG SQWAEMGREL
CIAESQAELL EALASGSKKT DSLVRITPGA KISFIFTGQG SQWAEMGREL
LLYPAFHDSF QRSREVLQGL GCSWDLVEEI LKTSAESRLH DAELAQPATT
LLYPAFHDSF QRSREILQDL GCSWDLVEET LKTSAESRLH EAELAQPATT
LLYPAFHDSF QRSREILQDL GCSWDLVEET LKTSAESRLH EAELAQPATT
LLYPAFHDSF QRSREILQDL GCSWDLVEET LKTSAESRLH EAELAQPATT
```

AIQIALVDLA TEWGIVPDSV IGHSSGEVAA AYAAGYLSQH QAIKVAYVQG
AIQIALVDLA TQWGVVPDSV IGHSSGEVAA AYAAGYLSQH QAIKVAYVQG
AIQIALVDLA TQWGVVPDSV IGHSSGEVAA AYAAGYLSQH QAIKVAYVQG
AIQIALVDLA TQWGVVPDSV IGHSSGEVAA AYAAGYLSQH QAIKVAYVQG
FASRLAEERF GKGSMLAVGV GEYGIEPYMD LLSHEGAVVA CQNSPNSTTI
FASRIAEERF GKGSMLAVGV GEYEVEPYMD LLSHEGAVIA CQNSPNSTTI
FASRIAEERF GKGSMLAVGV GEYEVEPYMD LLSHEGAVIA CQNSPNSTTI
FASRIAEERF GKGSMLAVGV GEYEVEPYMD LLSHEGAVIA CQNSPNSTTI
AGDDAAITEL SELVSQESIF NRKLNVDTAY HSHHMQAAAS KMHSALKDII
AGDDAAITEL SELLSRESIF NRKLNVDTAY HSHHMQTAAS MMQSALKDII
AGDDAAITEL SELLSRESIF NRKLNVDTAY HSHHMQTAAS MMQSALKDII
AGDDAAITEL SELLSRESIF NRKLNVDTAY HSHHMQTAAS MMQSALKDII
GAPSAKNGIE VFSTVTGSVK SDAFGADYWI ANLINKVRFC DGLQALCESK
SAPSTNNGIE LFSTVTGSVK SDAFGADYWI ANLINKVRFC DGLQALCESK
SAPSTNNGIE LFSTVTGSVK SDAFGADYWI ANLINKVRFC DGLQALCESK
SAPSTNNGIE LFSTVTGSVK SDAFGADYWI ANLINKVRFC DGLQALCESK
RPSPSCSPET SRIFIELGPH SALAGPIRQC IADMIAPISY SYTSALVRGT
RPSPLCGPES QRIFIELGPH SALAGPIRQC MTDMITPISY CYTSALIRGT

RPSPLCGPES QRIFIELGPH SALAGPIRQC MTDMITPISY CYTSALIRGT RPSPLCGPES QRIFIELGPH SALAGPIRQC MTDMITPISY CYTSALIRGT

GAARSALSMA GQVFKQGYSL DLAGVFASYE TSGHMSVMCD LPPYPWDHTR GAARSTLIMA GQVFNQGYPL NLAAVFASYE TIGYTSVISN LPPYPWDHTR GAARSTLIMA GQVFNQGYPL NLAAVFASYE TIGYTSVISN LPPYPWDHTR GASRSTLIMA GQVFNQGYPL NLAAVFASYE TIGYTSVISN LPPYPWDHTR

RYWNESRGSR DYRFRKHPYH DLIGLRMTDN SSIHPSWRHT VSLDNLPWLG RHWNESRASR DHRFRKHPYH DLLGLRMTDN SSLHPLWRHR VSLGNLPWLG RHWNESRASR DHRFRKHPYH DLLGLRMTDN SSLHPLWRHR VSLGNLPWLG RHWNESRASR DHRFRKHPYH DLLGLRMTDN SSLHPLWRHR VSLGNLPWLG

DHIVNHLVLF PCSGYLAMAV EACSQLTGDF HPGKRVERFS LNDVSFLKEL DHIVNHLVLF PCSGYLAMAV EACSQLIGDY YPGKNVEKFF LKDVSFLKEL DHIVNHLVLF PCSGYLAMAV EACSQLIGDY YPGKNVEKFF LKDVSFLKEL DHIVNHLVLF PCSGYLAMAV EACSQLIGDY YPGKNVEKFF LKDVSFLKEL

VIPEDHTSIE IQLCLTSIEH APSQASHTTT KYGFSITAYT SDGQWNEYCH VIPEDHNSIE IQLCLTSVAH FSSEASHSST RYGFSITAYT TDEQWNEYCH VIPEDHNSIE IQLCLTSVAH FSSEASHSST RYGFSITAYT TDEQWNEYCH VIPEDHNSIE IQLCLTSVAH FSSEASHSST RYGFSITAYT TDEQWNEYCH

GTVACEFAAA QPLLVADITQ ADLMHQLDPA LGNLKQAREF YEELGRLGTV GTIACEFAAG QPLLVADVTQ AHMMHQLDSA SGNLIQARDF YEELGRLGTV GTIACEFAAG QPLLVADVTQ AHLMHQLDSA SGNLIQARDF YEELGRLGTV GTIACEFAAG QPLLVADVTQ AHLMHQLDSA SGNLIQARDF YEELGRLGTV

YGSTFTGIEE MTIEGDSAAS YIVVPDVVSA MPSRQLSPHI IHPTTLDILL YGSTFKGIEE MTVDGDSAAS CIVIPDVVTT MPCRHLSPHI IHPTTLDILL YGSTFKGIEE MTVDGDSAAS CIVIPDVVTT VPCRYLSPHI IHPTTLDILL YGSTFKGIEE MTVDGDSAAS CIVIPDVVTT MPCRHLSPHI IHPTTLDILL

HTSMPLVHQK LGAGPVTLAH IKNMCITAAI DNTPGDAFRT VTNLGSSHAN HTSIPLVHQK LGVGPVTLAH IENMIITAAI DNKPGDAFRT VTNLVSIHSN HTSIPLVHQK LGVGPVTLAH IENMIITAAI DNTPGDAFRT VTNLVSIHSN HTSIPLVHQK LGVGPVTLAH IENMIITAAI DNTPGDAFRT VTNLVSIHSN

AAVADIFVFS DKAGASDAPV IYASGIELRS SSPGMDDTDT RDGLPEICYE AAVADLFVFS EKAGATDAPV LYASGIELRS SSPDMDDTNT PNGLPDICYE AAVAELFVFS EKAGATDAPV LYASGIELRS SSPDMDDTNT PDGLPDICYE AAVAELFVFS EKAGATDAPV LYASGIELRS SSPDMDDTNT PDGLPDICYE

MKWVLDERFI SAKRLQPLRP FSVSEDGLAH CCAFLAEYVK HKANKQSGLA MKWVLDERFI SAKQLQSLRP FSVSEDGLTG CCAFLAEYVK QKANKQSDLA MKWVLDERFI SAKQLQSLRP FSVSEDGLTG CCAFLAEYVK HKANKQSDLA MKWVLDERFI SAKQLQSLRP FSVSEDGLTG CCAFLAEYVK HKANKQSDLA

VIELVGPDAA SSATVAFVEA LHSSDARPIV YDFASLSGNF DGIQSALQDQ VIELAGPDAA SSATVAFLEA LRSSDARPTV YDFASSSGNF DGIQNALHDQ VIELAGPDAA SSATVAFLEA LRSSDARPTV YDFASSSGNF DGIQNALHDQ VIELAGPDAA SSATVAFLEA LRSSEARPTV YDFASSSGNF DGIQNALHDQ

DMSVFNFREL DIGADHLDPS FNEHYYNIVL ASNILRDTSN IRSILANARR DMSVFNFREL DIGADHLDPS FNEHYYNIVL ASNILRETSN IRSILINARR DMSVFNFREL DIGADHLDPS FNEHYYNIVL ASNILRETSN IRSILTNARR DMSVFNFREL DIGADHLDPS FNEHYYNIVL ASNILRETSN IRSILTNARR

```
LLKPDGVLLL VEDAASSQDS LSIEECADLM LDASFKMHLA ISDNQKRPQC
LLKPDGVLLL VEDATSGQDS LSIEECADLM LDASFKMQLA SPDNQKRPRC
LLKPDGVLLL VEDATSGQDS LSIEECADLM LDASFKMQLA SPDNQKRPRC
LLKPDGVLLL VEDATSGQDS LSIEECADLM LDASFKMQLA SPDNQKRPRC
TFFIARAFTK APTCIPKMIL VSQDSSRHEN FKHLATEMSN TLGRKVAHVV
TFFIARALTK APVLIPKIIL VSQDSSRHEN FKHFATEMSN TLGSNVTQVV
TFFIARALTK APVLIPKIIL VSQDSSRHEN FKHFATEMSN TLGSNVTQVV
TFFIARALTK APVLIPKIIL VSQDSSRHEN FKHFATEMSN TLGSNVTQVV
TELWHEMQPH DANAIYVVID DGAQPLLANV SQDHFRRVVD ILQKPAKVIW
KESWHDMQPH DANAIYVVID DGAQPLLANV SQNRFRHVVD LLQKPAKVIW
KESWHDMQPH DANAIYVVID DGAQPLLANV SQNRFRHVVD LLQKPAKVIW
KESWHDMQPH DANAIYVVID DGAQPLLANV SQNRFRHVVD LLQKPAKVIW
LSVQHNVESR FNPRKHFING VSRTAHKENR DLDMVTIDVQ QTLNQKTKPA
LCVQHSEKSS FNPKKHFING VSRTAHAENR DLDMVTIDVQ QTLDQKTEHA
LCVQHSEKSS FNPKKHFING VSRTAHAENR DLDMVTIDVQ QTLDQKTEHA
LCVQHSEKSS FNPKKHFING VSRTAHAENR DLDMVTIDVQ QTLDQKTEHA
ILQLLSSIFE SFGKKDILRE REYVFNGEDV LVPRLVPHAT LNHQISGKSE
ILQLLSNIVD SFGKKDILRE REYVFKGEDV LVPRLLPHAT LNHQISGKLE
ILQLLSNIVD SFGKKDILRE REYVFKGEDV LVPRLLPHAT LNHQISGKLE
ILQLLSNIVD SFGKKDILRE REYVFKGEDV LVPRLLPHAT LNHQISGKLE
TTIQTMPFSG SPVSLKMVDD KKGFVFVENA SHEQPLLDDF VEIESKAFGI
TTIQTIPFSK SPVSLRMIDD KKGFVFVENA SHGQPLLDNF VEIESKAFGI
TTIQTIPFSK SPVSLRMIDD KKGFVFVENA SHGQPLLDNF VEIESKAFGI
TTIQTIPFSK SPVSLRMIDD KKGFVFVENA SHGQPLLDNF VEIESKAFGI
PASYIKSAQT GNFFNEYTGV ITAVGCQVVA PKIGDRVVTI STESCANRLR
PANYTRSAQS GYFFNEYAGV VAAVGCQVLG PKIGDRVVTI STDSCANRLR
PANYTRSAQS GYFFNEYAGV VAAVGCQVLG PKIGDRVVTI STDSCANRLR
PASYTRSAQS GYFFNEYAGV VAAVGCQVLG PKIGDRVVTI STDSCANRLR
VPAGHVQVIP TQLSFTDAAT LPLAFMAVTH ALVDVANVQA KQMVLVDNAT VPAGHVQAIP RHLSFTDAAA LPLAFMAAIH ALVDVANIQA KQVLLVDNAT VPAGHVQAIP RHLSFTDAAA LPLAFMAAIH ALVDVANIQA KQVLLVDNAT VPAGHVQAIP RHLSFTDAAA LPLAFMAAIH ALVDVANIQA KQVLLVDNAT
SEYGQAALIV ARNLEATVIA AVARVDEASF LQNVFDISPS HIVARDSYLS SEYGQAALIV ARNLEATVIA AVARVDEAAF LQNVFEIQPS HIVARDSYLS SEYGQAALIV ARNLEATVIA AVARVDEAAF LQNVFEIQPS HIVARDSYLS SEYGQAALIV ARNLEATVIA AVARVDEAAF LQNVFEIQPS HIVARDSYLS
HRQMQRSLGL DGGIDVILGC GSTPVTTAVS RMLKPFGTFV SIQPRGGTSE HRQMQRILGL GGGIDVILGC GSTPVTTAIS RMLKPFGTVV NIQPRGGTSG HRQMQRILGL GGGIDVILGC GSTPVTTAIS RMLKPFGTVV NIQPRGGTSG HRQMQRILGL GGGIDVILGC GSTPVTTAIS RMLKPFGTVV NIQPRGGTSG
RHYGATCCSN ATVASFDIDS LLQAKPHKVP VLLQQVVKMV DQGVLLPPRS HHYGATFCSN ATVATFDIDS LLQARPHKLP VLLEQVVKMV DQGLLLPPRS HHYGATFCSN ATVATFDIDS LLQARPHKLP VLLEQVVKMV DQGLLLPPRS HHYGATFCSN ATVATFDIDS LLQARPHKLP VLLEQVVKMV DQGLLLPPRS
TVGLVLNNKL AKELTLIQKQ ENLAKHVIEV QKHSTVKVEK PSYQVPDLDT TVVLALNNKL EKELNLTQKH GNLVKHIIEV QEHSTVKVEK PSYQVPDLAT TVVLALNNKL EKELNLTQKH GNLVKHIIEV QEHSTVKVEK PSYQVPDLAT TVVLALNNKL EKELNLTQKH GNLVKHIIEV QEHSTVKVEK PSYQVPDLAT
```

DATYVVAGGL NDLSQRFLHL MAHAGARYLV TLSSSQVASQ AFHEFGKKLR DATYVVAGGL NDLSQRFLLW MAHAGARYLV TLSSSEEASE TFLEFRKKFK DATYVVAGGL NDLSQRFLLW MAHAGARYLV TLSSSEEASE TFLEFRKKFK DATYVVAGGL NDLSQRFLLW MAHAGARYLV TLSSSEEASE TFLEFRKKFK
SGNSHCSLVA LNCDVSKVHS VTAALSEIRG HDFPSVKGVI LLNTARNDSA DGNSHCSLMT VNCDVSKVHS ITAALSEIRE HGFPSVKGVI LLNTARNDSA DGNSHCSLVT VNCDVSKVHS ITAALSEIRG HGFPSVKGVI LLNTARNDSA DGNSHCSLMT VNCDVSKVHS ITAALSEIRG HGFPSVKGVI LLNTARNDSA
LAAMTADTFN TVTNAKVAGV LNLHTVFGSE NLDFFISVSS VTNIIGTEMQ LAAMTADTFN AVTNAKVAGV LNLHTVFGRE DLDFFISMSS VTNIIGAEGQ LAAMTADTFN AVTNAKVAGV LNLHTVFGRE DLDFFISVSS VTNIIGAEGQ LAAMTADTFN AVTNAKVAGV LNLHTVFGRE DLDFFISMSS VTNIIGAEGQ
ANGNAGDAFQ DALAHFDRDT GCFNMVLNIG GFEGAAHDNG SSIQASPREG AIGNAGDAYQ EALAHFDGDT GCFNMVLNIG GFEGAAPDNG PSIQASPREG AIGNAGDAYQ EALAHFDGDT GCFNMVLNIG GFEGAAPDNG PSIQASPREG AIGNAGDAYQ EALAHFDGDT GCFNMVLNIG GFEGAAPDNG PSIQASPREG
FDHISDQELT AYLDYALSAN TRRTGCHQSV IGLTPNSIAQ TFATNGAAQT FSHISDQELT AYLDYALSAN ARTTRCHQSV IGLMPDIIAR TIASNGAART FSHISDQELT AYLDYALSAN ARTTRCHQSV IGLMPDIIAR TIASNGAART FSHISDQELT AYLDYALSAN ARTTRCHQSV IGLMPDIIAR TIASNGAART
SMFTHVRRNA GALMDESEST ARERRFEHIV QEGASNEEIS AFVARSIGDK SMFTHVRRNA GALMDENDSA ARERRFEHMV QEGASKEEIS AFVARSIGNK SMFTHVRRNA GALMDENDSA ARERRFEHMV QEGASKEEIS AFVARSIGNK SMFTHVRRNA GALMDENDSA ARERRFEHMV QEGASKEEIS AFVARSIGNK
VAEFAAIDPM EVNFDSSILD YGLDSLMAIE LRNWIVRDFD APIRLPEVVD VAEFAAIDPM EVKFGSSILD YGLDSLMAIE LRNWMAREFD APIQLPEVVD VAEFAAIDPM EVKFGSSILD YGLDSLMAIE LRNWMAREFD APIQLPEVVD VAEFAAIDPM EVKFGSSILD YGLDSLMAIE LRNWMAREFD APIQLPEVVD
SPDIWTLSER VICCSQLTSS RSDTSKSSVI SGSEQDPLST LPTSRANTPE SPDIWTLSER VVNCSQLTTS RSDTSKSSVV SGSEQDPLST LPTSRANTPD SPDIWTLSER VVNCSQLTTS RSDTSKSSVV SGSEQDPLST LPTSRANTPE SPDIWTLSER VVNCSQLTTS RSDTSKSSVV SGSEQDPLST LPTSRANTPE
VKE
VKE
VKE
VKE
Tri18, 541 aa
S40285 MGSRGQPTAD STRSVPLDAS SPKAEQYAFP LPTLDPAEFR WHPSPKNNSI S40288 MGSSGQQTAD STRPVPPDAS SPKAEQYAFP LPTLDPAEFR WHPYPKNNSI S40293 MGSSGQQTAD STRPVPPDAS SPKAEQYAFP LPTLDPAEFR WHPYPKNNSI S7711 MGSSGQQTAD STRPVPPDAS SPKAEQYAFP LPTLDPAEFR WHPYPKNNSI
LQRKANGVEA LVGIKDANAV GTYDLYNNIV LRVGDISDLT LPRLKRAFVR LQRKANGVEA LVGIKDANAV GTYDLYNNIV LRVGDIPDLT LPRLKRAFVR LQRKANGVEA LVGIKDANAV GTYDLYNNIV LRVGDIPDLA LPRLKRAFVR LQRKANGVEA LVGIKDANAV GTYDLYNNIV LRVGDIPDLT LPRLKRAFVR
AMLDARFENP SIACYGVWGQ NKEPHLPHIQ YRPFKSHNEA RTWAYNSIYV

```
ALLDARFENP SIACYGVWGQ NKEPHLPHIQ YRPFKSHNEA RAWAYNSIYV
ALLDARFENP SIACYGVWGQ NKEPHLPHIQ YRPFKSHNEA RAWAYNSIYV
ALLDARFENP SIACYGVWGQ NKEPHLPHIQ YRPFKSHNEA RAWAYNSIYV
RATSLTSSEL RAERIEKRRA EAIPKSSNSL DVVISADVAH ERTILEPGTK
RATSLTSSEL RAERIEKRRA EAVPQPSNSL DIVISADVAH ERTILEPGTK
RATSLTSSEL RAERIEKRRA EAVPQPSNSL DIVISADVAH ERTILEPGTK
RATSLTSSEL RAERIEKRRA EAVPQPSNSL DIVISADVAH ERTILEPGTK
LDLMFLFNHL SWDGKARSFT SELVCRATQI LEKGLENTVP AYRWGEEKAR
LDLMFLFNHL SWDGKARSFT SELVHRATQI LEKGLENTVP AYRWGEEKAR
LDLMFLFNHL SWDGKARSFT SELVHRATQI LEKGLENTVP AYRWGEEKAR
VDLMFLFNHL SWDGKARSFT SELVHRATQI LEKGLENTVP AYRWGEEKAR
LDPPILDVML VGMETLGEDY KAVHRRLLES QMQVGLSWGL PVTNHPGDPL
LDPPILDVML VGMETLGDDY KAVHRKLLES QMQVGLSWGL PVTNHPGDPL
LDPPILDVML VGMETLGDDY KAVHRKLLES QMQVGLSWGL PVTNHPGDPL
LDPPILDVML VGMETLGDDY KAVHRKLLES QMQVGLSWGL PVTNHPGDPL
QLRYCMSAEE GKRILNAVKS RLGLKYNIGH LGHAATVLAL LKHHPIPASA
QLRYCMSVEE GKRIANAVKS RLGLKYNIGH LGHAATVLAM LKHHPIPASA
QLRYCMSVEE GKRIANAVKS RLGLKYNIGH LGHAATVLAM LKHHPIPASA
QLRYCMSVEE GKRIANAVKS RLGLKYNIGH LGHAATVLAM LKHHPIPASA
EDTAFLFSPL PVDGRGYLSE DRTTQRYGNA QASAVVEFQK LASWGIKKDD
EDTAFLFSPL PVDGRGYLSE DRTTQRYGNA QASAVVEFQK LASWGIKKDD
EDTAFLFSPL PVDGRGYLSE DRTTQRYGNA QASAVVEFQK LASWGIKKDD
EDTAFLFSPL PVDGRGYLSE DRTTQRYGNA QASAVVEFQK LASWGIKKDD
PEGLKAALDN LAKKIRDDYN FWLGQSDCLL PISVANHNFA SNLIATSSAT
PQGLKTALDK LAKKIRDDYN FWLGQADCLL PISVANHNFA SSLIATSSAT
PQGLKTALDK LAKKIRDDYN FWLGQADCLL PISVANHNFA SNLIATSSAT
PQGLKTALDK LAKKIRDDYN FWLGQADCLL PISVANHNFA SNLIATSSAT
PNVHAPAFCN DGRSENIISY EVLGLTGKKL FEVEDCFMGV EVIGYNAFIR
PKVHAPAFCN DGRSENIISH EVLGLTGKKL FEVEDCFMGV EVIGYNAFIR
PKVHAPAFCN DGRSENIISH EVLGLTGKKL FEVEDCFMGV EVIGYNAFIR
PKVHAPAFCN DGRSENIISH EVLGLTGKKL FEVEDCFMGV EVIGYNAFIR
MDTWKDAIRL TLCYNNGCFS DALAKEYTKD VAEYMLSYAD A
MDTWKDAIRL TLCYNNGCFS DALAKEYTKD VAKYMLEYAD A
MDTWKDAIRL TLCYNNGCFS DALAKKYTKD VAKYMLAYAD A
MDTWKDAIRL TLCYNNGCFS DALAKEYTKD VAKYMLAYAD A
```


## Core atranone cluster, 14 products

```
Atr1, 234 aa
S40285 MASIPGLLFS LTKPMDPTIP EAQFNDWYTN KHLVDTVNSG LASLAVRFKN
S40288 MASIPGLLFS LTKPMDPNIP EAQFNDWYTN KHLVDTVNFG LASLAVRFKN
    VNPSHQWPYL ALYRLQDLAK LYNMEFMSSL PTDSPAGWGV PNSKADIRIE
        VNPSHQWPYL ALYRLQDLAK LYDMEFMSSL PTDSPAGWGV PNSKADIRIE
        PRGYQLLTTL ERENAKTGVP KFVLTVEFRE SFMNAEAFVA SCQGLQLDDV
        PRGYQLLTTM ERENANTGVP KFVLTVEFRE STMNAEAFVA SCQSLQFDDV
        GKQPGYRRSM LYQAGRSLVT QEGKAGTEFR SAEQQQPSYL VVHEFDQMPT
        GKQRGYRRSM LYQAGRSLVP QEGKAGTEFR SAEQQQPAYL VVHEFDQMPA
        NTFQEQGASG LWEYMAEYGT GLYRTEPVPV KVYN
        HTFQEEGASG LWEYMAEYGT GLYRTEPVPV KVYN
Atr2, 540 aa
S40285 MAVISLFRII VDKWHVVLAC SACLGALLFQ ALRRQSNSTK DVPFIGMELG
S40288 MASMSLFRII VDEWRVVLAC SACLGALLFQ ALRRQSNSTK DVPFIGMELG
        SAEKRRKAYM TDARSLFRDG YQQFKDRVFG ITTTSENLVV VVPPRFLDEL
        SAEKRRKAYM TDARSLFRDG YQRFKDRVFG ITTTSENLVV VVPPRFLDEL
        GRLPDEVLSA SMAVADISQD KYTKMEITDP IISHAVRGNL TMSLSRLNDA
        GRLPDEVLSA SMAVADISQD KYTKMEITDP IISHAVRRNL TMSLS-----
        ILEELRKALS LLLPTCDEWT SVNISEKLQR IVAVISGRVF VGPELCGSDA
        ---------- ---------- ---------- -----------------------
        YLDAAIHIAH EASAAVQSIS TLPPWKRPFL SARLPELRAL RERQDKVHSV
        ---------- --SAAVQSIS TLPPWKRPFL SARLPELRAL RERQEKVYSV
        LRPVLEKRIQ MNEEDRPDDM LTWIISSQKK HGERSIETMA KVQTALHLAA
        LRPVLEKRIQ MNEADRPDDM LTWIISSQKK HGERSIETMA KVQTALHLAA
        IGTTSEMATN AFYNLAAMPE LVPELREEIR TVLEEHDGVV STKSLQAMKK
        IGTTSEMATN AFYNLAAMPE LVPELREEI- ---------- -----------
        LDSFLKETAR LYPPFLCKNF IPMPWWLPGG DNRISDANIV YPKAAFERKV
        ---------- ---------- ---------- ---------- ----- PAFERKV
        LRTFTLSNGQ VIPAGALIKV PSQAIMTDPA LFPDPDRFDA FRFYDLQQQK
        LRTFTLSNGQ VIPAGTLIKV PSQAIMTDPM LFPDPDRFDA FRFYDLQQQK
        NILKDGSVSV GASVNQFVNS NKNSLVFGYG RHACPGRFLA ADELKMILVY
        RGLKDGSVSV GPSVNQFVNS NKNSLVFGYG RHACPGRFLA ADELKMILVY
        FLQAYEIRLE EGESRRYRNL EFAAFSIPDP TKTIQMKKLQ
        FLQAYEIRLE EGETQRYRNL EFAAFSIPDP TKTIQMKKL-
```

Atr3, 478 aa
S40285 METLSQRITS MESVQLQGIA VAFVTASALY YVLPAAISHI QLSALPMLGK

```
S40288 METLSQRMTS MESVQLRGIA VAIVTASALY YVLPAAISHI QLSALPMLGK
TEVVVIPPKL LSELSKSPRT LSAEIAGNEF IAGKYTKVKA LTPILLHSIT
TEVVVIPPKL LSELSKSPRT LSAEIAGNEP VPELHQDWLS VNIRLV----
KYLIPSLGRN AVVMSEEVSN AVRLGIPTCN DWTGVNIYPK IMRMVTVSTG
------AGRN AVIMSEEVSN AVRLGIPPCN DWTAVKIYPK IMRMVTVSTG
RFLVGSELNR SEDYIDTVHN YALDVSSAQS AVHKMHPWIR PLLAEWLPEI
RFLVGSELNR SEEYIDTVHN YALDVSSAQS AVHKMHPWLR PLLAEWLPEI
RRLRKRTEEA FALFESLIKE RMKMQRELSE SELPDDLLQW MIANRHNYNN
RRLRKRTEEA FALFESLIKE RMDMQRELSE SELPDDLLQW MIANRHNYNN
EDAHDLVYSQ LGLTFTANHS TASTITNALY TLATMGDLID VIRDDITQAL
EDAHDLVYSQ LGLTFTANHS TASTITNALY TLATMGDLID VIRDDITQGL
AESGGQFTSK ALDSMWKFDS FIKETVRMNP LVMSVAVRKV VEPIKLPSGQ
EESGGQFTSK ALDSMWKFDS FIKETVRMNP LVMSVAVRKV VEPIKLPSGQ
VIPTGVTLET PLVAVNLDDQ IFPNADVFDP MRFYNLREKD RKQGDAREAE
VIPTGVTLET PLVAVNLDDQ IFPNADVFDP MRFYNLREND RKQGDARDAE
FNQLISSSTS HMSWGFGKHT CPGRAFAAQQ IKMILAHIIL RYDIKLVGDS
FNQLTSSSTS HMSWGFGKHT CPGRAFAAQQ IKMILAHIIL RYDIKLVGHS
TDRYENIPKG HLSLPDPTKD ILMKRREI
TDRYENIPKG HLSLPDPTKD ILMKRREI
Atr4, 524 aa
S40285 MRLDLLGPVA TRIITYLDSL TWVGMALPLF SLCWAISYAR GKAYPTVPGA
S40288 MGLDLLGPAA TRIATYLDSL TWVEIALPLF SLCWAISYAR GKGYPTVPGA
PVYGYNSRFE PSFMLKSRTY TGFYDILSNG YKMLKDVPFV IPRHDTNINI
PVYGYNSRFE PSFMLKSRTY TGFYDILSKG YTMLKDVPFV IPRHDTNINI
LPIKYLDEIR LMPKHILNSH LVLISQMTPK WTWLQPAADS DLVTRVLLTK
LPIKYLDEIR LMPKHILNSH LVLISQMTPK WTWLQPAADS DLVTRVLLTK
LNPDLQKYVD ITRLELDSAF KSDFPRHDEE WTEVDFQPLI RRVLTRISAK
LNPDLQKYVD ITRLELDSAF KSDFPRHDEE WTEVDFQPLI RRVLTRISAK
IFLGEPACLN EDWLRIAIGY TAGALEVTKD LHKFPSWTHF LVAPLLPSRR
IFLGEPACLN EDWLRIAIGY TAGALEVTKD LHKFPSWTHF LVAPLLPSRR
RLRRELDIAM KIVEKQIQLH EQAEKDGLKN YDTLLDWMLD NCSDKESSVE
RLRRELDIAM KIVEKQIQLH DQAERDGVKN DDTLLDWMLD NCSDKENGVE
AMTIFQCFIA MASIHTTEFS LANVLFDLCA HPEWFPVLRE ELDEVIRVHG
AMTIFQCFIA MASIHTTEFS LANVLFDLCA HPEWFPVLRE ELDEVIRAHG
NIGHRLPAKQ WLQKLEKMDS LLAETLRLCP TMLTSIQRLA LEKVQLKDGT
HIGEKLPAKQ WLQKLEKMDS LLAETLRLYP TMLTSIQRLA LEKVQLKDGT
VIPKGSRLAW ASLHHVTDPE VDGTLAAWDP MRNYRKRHSG SGENLTKFVA
```

|  | VIPKGARLAW | ASLHHVTDPD | VDGTLAAWDP | MRNYRKRHSS | SGENLNKFVA |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | GQINESTLGF | GYGNQACPGR | YFAVNEIKMM | LARLLLEFEF | KFPEGKSRPK |
|  | GQINESTLGF | GYGNQACPGR | YFAVNEIKMM | LARLLLEFEF | KFPEGKSRPK |
|  | VFFIGEIACL | DHDATLMMRN | VRTC |  |  |
|  | VFFVGEIACL | DHDATLMMRK | VRTC |  |  |
| Atr5, 297 aa |  |  |  |  |  |
| S40285 | MAVMTREDVE | FRTMDGLTLR | GWLYPSGMRG | PALVMTQGFN | ASKEYLLADV |
| S40288 | MTVMTREDVE | FRTVDGLTLR | GWLYPSGKRG | PALVMTQGFN | ASKEYLLADV |
|  | AVWFQKRGVT | SLLVDIRTTG | LSDGEPRNDI | DLDKQVEDCH | DAVSFLSRHP |
|  | AVWFQKRGVT | SLLVDIRTTG | LSDGEPRNDI | DLDKQVEDCH | DAVSFLSRHP |
|  | SVDPEMIVYW | GYSLGAVISL | CAAALDKRAA | AVIATAPNTD | FIFDPVKRAA |
|  | SVDPEMIVYW | GYSLGAVISL | CAAALDKRAA | AVIATAPNTD | FIFDPVKRAA |
|  | TLSLAMRDRL | SRLAGNPPLY | LKIIGEDGQN | PAGWYLGEER | RSPEELDALF |
|  | TLSLAMRDRV | SRLAGNPPLY | LKIIGEDGQN | PAGWYLGEER | RSPEELDALF |
|  | NSSNIMNQVT | IQSYYRLLRW | QPFGLMPSVS | PTPVMIVTPS | DDDLSKPENQ |
|  | NSSNIMNQVT | IQSYYRLLRW | QPFGLMPSVS | PTPVMVVTPS | DDDLSKPENQ |
|  | RKLFDIFQEP | KEFVLAENKG | HMNCISGEDG | EQFLQKQLEF | MKRMLKF |
|  | RKLFDIFQEP | KEFVLAENKG | HMNCISGVDG | EQFLQKQLEF | MKRMLKF |
| $\begin{aligned} & \text { Atr6, } 2439 \\ & \text { S40285 } \\ & \text { S40288 } \end{aligned}$ | aa |  |  |  |  |
|  | MDSEAPTPTS | SSFALPYAEP | IAIVSAACRL | PGHIQNPHQL | WQFLQAGGIA |
|  | MDSEAPTPTS | SSFALPYAEP | IAIVSAACRL | PGHIQNPHQL | WQFLQAGGIA |
|  | TSDVVPESRY | NVAGHFDGSG | RPGTLKTPGG | MFIEDIDLGA | FDAPFFHIGK |
|  | TSDVVPESRY | NVDGHFDGSG | RPGTLKTPGG | MFIEDIDLGA | FDAPFFHIGK |
|  | SDAVSMDPQQ | RQLLEVVYEC | LENGGITMQG | IDGDQIGCFV | ASYSADWHEM |
|  | SDAVSMDPQQ | RQLLEVVYEC | LENGGITMQG | IDGDQIGCFV | ASYAADWHEM |
|  | QSRHPASRAP | GTTAGTSRAI | LSNRISHFFN | IKGSSWTIDT | ACSGGLVGVD |
|  | QSRHPALRAP | GTTAGTSRAI | LSNRISHFFN | IKGSSWTIDT | ACSGGLVGVD |
|  | AACQYLRAGK | LNGAIVAAAQ | LWMSPEYNEE | LGTMRAAASS | TGRCHSFDAK |
|  | AACQYLRAGK | LNGAIVAAAQ | LWMSPEYNEE | LGTMRAAASS | TGRCHSFDAK |
|  | ADGYCRSEAV | NAVYLKRLSD | ALRDGDPVRA | VIRGTANNSD | GRTPGLHSPN |
|  | ADGYCRSEAV | NAVYLKRLSD | ALRDGDPVRA | VIRGTANNSD | GRTPGLHSPN |
|  | SDAQAAAIRA | AYADAGIDST | QYTKTAFMEC | HATGTPAGDP | SEVRGSASVL |
|  | ADAQAAAIRA | AYADAGIDST | QYTKTAFMEC | HATGTPAGDP | SEVKGSASVL |
|  | ASMRPPSDPL | IIGTIKSNLG | HAEPGAGISG | LMKAMMAVEK | GIIPGNPTFI |
|  | ASMRPPSDPL | IIGTIKSNLG | HAEPGAGISG | LMKAMMAVEK | GIIPGNPTFI |
|  | TPNPNIDFAG | LRVRASQRNM | RWPQSTKDYR | RASVASSGFG | GSNAHVVLDN |
|  | TPNPNIDFAG | LRVRASQRNM | RWPQSTKDYR | RASVASSGFG | GSNAHVVLDN |

```
AEHYMQHHFL SVQPQFRTYV SSYAETGDVL SMLSGFGLGA ANSSDKLAPL
AEHYMQHNFL AAQPQTRTYV SSYAESSDVL SMLAGFGLGG ANSSDTPAPL
PNVLVFSAHD ADSLKRQMGA LSAHLVDPRV AIKLSDLSYT LSERRSRHFH
PNVLVFSAHD ADSLKRQMEA LSAHLVDPRV AVKLSDLSYT LSERRSRHFH
RSFIVCRPNK GGNIETLPTD LAKYAMKPTS PVRIGFVFTG QGAQWSGMGA
RSFIVCRPNK GGNIETLPTD LAKYAKKPTS PVRIGFVFTG QGAQWSEMGA
DLIRLFPKTA KAVVDELDAA LQELPADVRP SWSLLAELTE PRSSEHLREP
DLIRLFPQTA KAMVDELDAV LQGLPADIKP SWSLLAELTE PRSSGHLREP
EFSQPLVTAL QLALLAVLKS WNVTADAVVG HSSGEIAAAC SAGLLTPGQA
EFSQPLVTAL QLALLAVLKS WNVTADVVVG HSSGEIAAAC SAGLLTPGQA
ILTAYFRGQA AKQVVMEGSM GMLAVGLGSA GVQKYLEDTS RAGKVVIACY
ILTAYFRGQA AKQVAMEGSM GMLAVGLGSA GVQKYLDDAS RAGKVVIACY
NSPASVTLSG PTSLLSELAQ VIQTDGHFAR LLQVNLPYHS HYMSAIGDRY
NSPASVTLSG PTSLLSELAQ VIQTDGHFAR LLQVNLPYHS HYMSAIGDRY
EKLLLDHGRL DEIQGETATR KIPMISSVST IVLEGSKSCS AAYWKSNMVS
EKLLLDYGRL DETQGETEAR NIPMISSVST AVLEGSESCS AAYWKSNMVS
AVQFDGACKR IVADQDLSAN LLIEIGPSAA LGGPIGQIIK QAGIDNVTYT
AVQFDGACKR TVTDQNLAAN LLIEIGPSAA LGGPIGQIIK EAGIENVTYA
SAAQRGTDSI LALFGVAGQL FLHDCPVSLD HVNTDETALT EPKPAVIIDL
SAAQRGADSI LALFGVAGQL FLHDSSVSLD RVNTDEAALI EPKPAVIIDL
PNYRWNHSTR YWHESLASKD WRFRNFPEHD LLGGKVLGTA WESPSWTKTL
PNYRWNHSTR YWHESLASKD WRFRNFPEHD LLGGKVLGTA WESPSWTKTL
RLEDVPWLRD HKIGSEILFP ASGYIAMAVE AARQATISTA RSQNKAAPSA
RLEDVPWLRD HKIGSEILFP ASGYIAMAVE AARQATISTA RSQNKAVPSA
HAYHYVLRDV HFERGLVLED ETDTTLMLSL APVARLGVKW WVFKVMSLAS
HAYHYVLRDV HFERGLVLED ETDATLMLSL APVARLGVKW WVFKVMSLAS
GGSSSSSDSW IEHSNGLVRL ALNASEPLPR VTPDNYSLPL QYPTPARFWY
GGSSSSSDSW IEHSNGLVRL ALNASEPLPQ ATPDNYSLPL QYPTPARFWY
KAFENAGYGY GPGFQKQSYI ECTEGSFSAR STIMLNPPLS KWEPQPNYPL
KAFDNAGYAY GPGFQKQSDI ECTEGSFSAR STIMLNPPLS KWEPQPDYPL
HPASMESCIQ ATLTSMYRGD RAGINNVLVP NAIDRIILSG DTWRSNEAVS
HPTSMESCIQ STLTSMYRGD RASINNVLVP NAIDRIILSG DIWRSNEAVS
VTTSESSSGI TSKPLSNASL FDPTNGVLII DLRGISMTSV GLQGNVCSFS
VTTSESSSGI TSKPLSNASL FDPTSGGLIV DLRGISMTSV GVQGNICSSP
TYTRVEWKPD ICHLDSDTKI RRAILDLTDG TGDFVQEVLD LAAHKKPNMR
TYTRVEWKPD ICHLDSDAKI RRAIRDLTGG TGDCVQEVLD LAAHKKPNMR
VLEVDLTGGQ PRSLWLSGNE TSRITRAATS EFNYASDRPE SVLSAQDLYS
```

NARCLLTEGG TIVLHVLDVS KYSKVGQESL REALSRGKFS KIRQAADGLF
NARCLLTEGG TMVLHVLNYG NDSKVEPESL RKALSQSKFS KIREAADGLF
VAEATDADTA YSQGKSLVVL HFSTSPVFSW SSAVITSLID KGWPITELTL
VAEATVADTA YTQPKSLVVL HFSTSHVSSW STAIITSLMD KGWPITELNL
EEGCRLTELP AKATILVMDE VNRPLFASME EYQLEAIQSI VQRDCSLLWV
EEGRRLTDLP AKATILVMDE VNQPIFASME QYQLETLQSI VQQECSLLWV
TQGSQMHVSS PLKAICHGVF RSVRSMDPNA RIVTLDVDSA AEDQLAKMAD
TQGSQMHVSS PLKAICHGVF RSVRSMEPNA RIVTLDVDSA AENQPEKTAD
ILHTVLLQVR VTPESLPADF EFVERGGLLY ISRLRPAQVD NESRSDGDKD
VLHTALLEVR ATPESLPADS EFVERGGLLY ISRLRPAQSD DDSRSDGDKD
GLQPVPVDLH STESTIGLVS GRPGILDTLH FAELGPGRLL VLGPEDIEVE
RHQPVPVDLH STEATVGLAL GRPGNLDTLH FAELGPGKVS VLDPEEVEVE
IFAASVDDGD YALAKNLDPE DSTRLGYGGA GIVTRTGDSI TDIRAGQRVA
IFAASVDYGD YAVAMNLVPG DPTRLGHGGA GIVTRTGDSI TDVRAGQRVA
LFHGGCVANR IVVARQVVFS VPDTMTFEDA ATLPTAFVPA IYSIYHLAQL
LFHGGSVANR VVVARKVVFP VPDAMTFEDA ATLPTAFVPA IYSIYHLARL
RQGQRVLIHS AANAVGIACV QLCQGLSCKP YVTVDSDEER KFLAEEVGVS
RQDQRVLIHS AANAVGIACV QLCQGLACKP YVTVNSDEEQ KFLAQEIGVS
SDHILLLNSE NFAREMQDSA QNHGFDVIIN TSQHHLPDQG WGVVSPGGVH
PDHILLSNSD NFAREMQHFA QNHGFDVIIN MSQEHLPDQG WDVVSPGGVH
VALGQTINDR SLLPMDYFTN NRSFCSLDIR TLPLDKLA-- -----------
VALCQSIGDR SLLPMDYFAN NRSFCSLDIR TLPLDKLARA CSQLSDLIHG
---------- ---------- ---------- RNVVISTGPD KDVRILVKPE
SCIKPVLPKA IFDYQKIQAA LQSCYGHDRR RSVVISNGPG KDVQILVKTA
KQQPRCTFAP EQTYLLVGKL KGVSGSLALH LARCGAKYLV IMSPKNSENS
EHQPGCTFAP DQPYLLVGKL EGVFGSLALH LARRGAKHLV IMCPRDAENS
ENISRSIRAM GCSLRFFEGD AASIDDMRRC YGQISGPIGG IVHGAAAQSF
ENISRSIRAM GCSLRFFEGD AASIDDMRRC YGQISASIGG IIHGAAAFTA
R------LMS HETYQATLAR SVLSAWNLHT VSLERDDSVP FFIMLSSTAG
RFPFLWPLMS HETYQESLAR NVQSAWNLHT VSLERNGSVP FFIMLSSTAG
VVGDEKQPHH AGSDVFHNAL ATYRCGLGLP STSINLGPIN DDALLPDSEK
VVGDEKQPHH AGSDVFRDAL AKYRCQLGLP STSINLGPIN DDALLLDSEE
TFKTLSSGVW FGVNEAVFRR IIDHSLSREH HGAQRHFELA SQAQIITGIA
TYKTLSSGVW LGINEAVFRR IIDHSLSQKH HGSKRHLELV SEAQIITGIA

```
VPQPGSSDIL HDVRLLGLKL AQSGNSSSAA SGRDDSQNRE MQTFLLCARS
VPQPESSPIL RDVRLLGLRL AQGGNASSAA SGRDDGQNRE MQTFLLCARS
TNPDPAVLLS SAVGVLQAQF TKMLRLNELM DPAYPLNTYG MDSLAAAEPR
TNPDPAVLLS SAVGVLQAQF TKMLRLNELL DPAYPLNTYG MDSLAAAEPR
SWVRTAFGVQ LTTLDVVNAA SLVVLCQKII SRMGLGKEV
SWVRTTFGVQ LTTLDVVNAA SLVVLCQKII SRMGLGKEV
```

Atr7, 320 aa
S40285 MSTLTIDPTS IPPLEGKTAV VTATPLVPGG ASGIGLAAAK IMLQKGATVY
S40288 MTTLTIDLSS IPPLEGKTAV VTATPLVPGG ASGIGLAAAK IMLQKGATVY
ALDRQEPIEA VPGLKFRRCD VTSWSALREV FDEIQQVHLA FANAGICDKS
ALDRQEPIEA VPGLKFRRCD VTSWSALRDV FDEMKQVHFA FANAGICDKS
PESYYDDVCD NGNLQEPDYS MIDVNLKAVL NFVKLARHSM RRHQVQGSIV
PESYYDDVYD NGNLQEPDYS MIDVNLKAVL NLVKLARHFM RKHQVQGSIV
ITASSTGLVP EQSAPVYSST KFAVIGLVRT LRSVLIQENI TINAVAPFVT
ITASSTGLVP EQSAPVYSST KFAVIGLVRT LRSVLIQENI TINAVAPFVT
TTGMAPAEAM VPLKNLGVQT SPADFVGLAL VYSAVARQTR RVEAYGKETE
TTGMAPAEAM VPLKNLGVQT SPADFVGLAL VYSAVARQTR RVEAYGKETA
EDILEHGRWN GRVILTLGDK YTEVEEEFSK SRPLWTGGEV LQSIRLQQAV
ESILEDGRWN GRVILTLGDK YTEVEEEFSK SRSLWTGGEV LEGIRLQQAV
LDFRHGGVAI KSNRPSNQLN
LDFRHGGVAI KSNRPSNQLN
Atr8, 625 aa
S40285 MAVEKVQAFE KVSIPTEKQP GSEDLGFDPA ELQKKYEAER NLRIQNGGVS
S40288 MAVEKVQALE NVSTPAEKEP GSKDLGFDPA ELQKKYEAER NLRIKNGGVS
QYRSAWKSGF GYYLEDPNAD ANFSRDPISA RYDVVIMGGG FSGLLVAARL
QYRSAWKSGF GYYLEDPNAD ANFSRDPIDA RYDAVIMGGG FSGLLVAARL
VQQGITNFTI LDKSADFGGT WYWSRYPGAQ CDVDSTIYLP LLEEVGYIPK
VQQGITNFAI LDKSADFGGT WYWSRYPGAQ CDVDSTIYLP LLEEVGYIPK
EKYSFGPEIL EHAQRIAKHF GLYPKALFQT EVKTCHWSEE DSLWTVQTDR
EKYSFGPEIL EHAQRIAKHF DLYPKALFQT EVKTCHWSEE DSLWTVQTDR
GDNLRAQFIV SAFGISHMPK LPGISGIENF QGKSFHASRW DYNYTGGDST
GDNLRAQFIV SAFGISHMPK LPGISGIENF QGKSFHASRW DYNYTGGDST
GNMTKLADKR VGIIGTGATA IQVVPKLAES AKELYVFQRT PSSVDVRNNR
GNMTRLADKR VGIIGTGATA IQVVPKLAES AKELYVFQRT PSSVDVRNNR
PTDAEWAKTL RPGWQQERID NFYAITTGEN VTEDLIDDGW TEIFRLVAAP
PTNAEWAKTL RPGWQQERID NFYAITTGEN VTEDLIDDGW TEIFRLVAAP
FFASADIEQS LENRMEQVQI ADFKKMESVR ARVDSLVKDP ATAASLKPWY

```
    FFASADVEQS LENRMEQVQI ADFKKMESVR ARVDSLVKDP ATAASLKPWY
    NQFCKRPCFH DEYLQAFNHP NVTLVDTRGH GVDAVTTKGV LAQGKEYELD
    NQFCKRPCFH DEYLQAFNHP NVTLVDTRGH GVDGVTTKGV LAQGKEYELD
    CLIYSTGYEW YTEWEQRTRS QVYGRNGLTI TKKWSQGITT YHGWGVHGFP
    CLIYSTGYEW YTEWEQRTRS QVYGRNGLTI TKKWSQGITT YHGWGVHGFP
    NFMVLSSAQV NNVPNYTHMV GYLSRHLAYI VRTCKDRGIK SVEPTATAES
    NFMVLSSAQV NNVPNYTHMV GYLSRHLAYI IRTCKDRGIK SVEPTANAES
    KWVQQVVEQG AARRDQMKLC TPGYLNHEGD ITEKTDRLYS YNGSGDSKFQ
KWVQQVVEQG AARRDQMKLC TPGYLNHEGD ITEKTDRLYS YNGSGDTKFQ
IILDKWRDDG KLVGLSIDCA TEADL
IILDKWREEG KLVGLSIDGA TEADF
Atr9, 253 aa
S40285 MPTIRGQSIL IIGGSSGIGA AVAKYACGDG VKVSVASSNK GRVEKALKKI
S40288 MPTIRGQSIL IIGGSSGIGA AVAEYACSDG VKVSIASSNR ARVEKAAKKI
    QALVPASEIL GFTVDLSQYD LESRLEKLFK EVVDATGGPL DHVVMTAGTG
        QASVPAAKIL GFTVDLGQYD LESRLEQLLK DVVDATGGPL DHVIVTAGTG
        NMVSLSEYTA KAFQESAPLH FIAPLMVGKV APRFMNRHWK SSITFTSGAF
        NMVSLSEYTA TAFQDCAPLH FIAPLMVGKV APRFMNQHWK SSIIFTSGAF
        GKKPAKGYCV IASAVGALDA ATRALALELA PIRVNAVSPG PTVTEMFGPP
        GKKPAKGYCV IASAVGALDA ATRALALELA PIRVNAVSPG PTVTEMFGPP
        SEALDKAVAA MGAQSLLGKL GRPEDVAEAY IYLMRDANTT GTIVDSNGGA
        SEALDKAVAA MGAQSLLGKL GRPEDVAEAY LYLMRDTNTT GTIVDSNGGA
        FLQ
        FLQ
Atr10, 276 aa
S40285 MARQSAEPPT DDGQSAKEIV VITGGNTGIG FEVARQLLCN YGNRFYVIIG
S40288 MARQSAEPPT NKGQSAKEIV VITGGNTGIG FEVARQLLCN HGDRFYVIIG
    SRTLGKGHTA VAALKQQGYE AVQAVQLDVT KEASIAAAAK IIGEQFGRID
    SRTLAKGHTA VAELKQQGYE AVQAVQLDVT EEASIKAATK TIGEQFGRID
    VLHVNAGVLL EPTDINAKPV PFSETIMETM RTNVAGAAAT VEGFTPLLSI
    VLHVNAGILL EPTDVNGKSV PFSETIMETM RTNVAGAAAT VEGFTPLLSN
    GSNPRVVFMT STAASAQLMH QYSSMTTAPA LSASKAAENI IMIYYYHKYP
    GSNPRVVFMT STAASAQLMH QYSSMTTAPA LSASKAAENI IMIYYYHKYP
    NWKVNACYPG YRDTAMMRRY NASSLSKAYR QPDPVEEGAY NAVRLSLLGK
    NWKVNASYPG YRDTAMMRRY NASSLSKAYR QPDPIEEGAY NAVRLSLLGK
    DGETGTFTEY KGVGEDGQRQ YSALPW
    DGETGTFTEY KGVSEDGQRQ YTTLPW
```

```
Atr11, 133 aa
S40285 MASRKATVQS IVESFNERDI DKMTAPVSKN FVYQLLPKSL ERGPMDVAGF
S40288 MASRKATVQS IVESFNERDI DKMTAPVSDN FVYQLLPKSL ERGPMDVAGF
    RGLFEATKSY FNNFKFEVVD TFEDSAADKM ILWANVTSDT HVGKFATEVM
    RGLFEATKSY FNNFKFEVVD TFEDSAADKM IVWANVTSDT HVGKFATEVM
    LIFYFDTTGK IYKWIEWIDS AVGKEFEQKL QGQ
    LIFYFDKAGK IYRWIEWIDS AVGKEFEQKL QGQ
Atr12, 391 aa
S40285 MASSVATLVK SLDKINAADF ESDEAARVNA IAAAQKMIHR LQSGVERGIE
S40288 MASSVASLVE SLDKINVDDF ESDEAARVNT IVAAQMMIHR LQSGVEWGIE
    LTHQRSTVFP IIDVFEDLGL WEAWASQGHE ISLEGLAQLS NTPLALNLLR
    LTHQRSTVFP IIDVFEDLGL WEAWASQGHE ISLEGLAQLR NTP-------
    RLCRLLTAAD IFEEKSEDCY TPTELSLYMG DKTKGSQVSQ GSAPGWVGSY
    RLCRLLTVAD IFEEKSEDCY MPTELSLYLR DKTKGSQVSQ GSAPGWVGSY
        TNLPIFLKET AYQEPLDPKK SAYSKTAGKS FWEELSQDPL QQENFGRFMS
        TNLPIFLKET SYQEPLDPKK SAYSKTAGKS FWEELSQDPL QQENFGRFMS
        SWAKFKVPWP AFYDTESLVR GAEPGMPILV DIGGNDGTDV ERFLAKHPGV
        SWAKFTVPWP AFYDTESLLR GAKPGKPILV DVGGNDGTDV ERFLAKHPGV
        AAGSLILQDR PAALKLAKVD QKIELMPHDF FTPQPVIGSR AYFFHAVLHD
        ATGSLILQDR PAALKLAKVD QKIDLMPHDF FTTQPVIGSR AYFFHAVLHD
        WDDAHALDIL RNTVPAMRKG YSKLLILDIA IPRTGASLIQ AAMDISMMSL
        WDDAHALDIL KNTVSAMQKG YSKLLILDIA IPRAGASLIQ AAIDISMMSL
        LSSLERPITT WEILLKKAGL KIVKFWPDPR RYETLIEAEL E
        LSSLERPITT WVTLLKKAGL KIVKLWPDPR RYETLIEAEI D
Atr13, 381 aa
S40285 MALEEISERL QVSDFPTLGM AANYDLRRHK FESLANDGSH EMRADVRRWV
S40288 MALDEISERL QVSDFPTLGM AANYDLRRHK FESLANDGSH EMRADVRRWV
    GNPSDFGGCN PINGHIIALT MPMIKPDRVK IAGYIYECWF LYSWDLTTTL
    GNPSDFGGCN PINGHIIALT MPMIKPERVK IAGYIYECWF LYSWDLTTTL
    TGADGFFHDD ILEGTNEGVS DTDAFGLGTA DQDAKARDGR KQIQAKMMYL
    TRVDGFFHDD ILEGTNEGVS DTDAFGLGTA DQDAKARDGR KQIQAKMMYR
    LETTDKACAK HLQKVWSNML VTTIQHKSRD FETLKEYIDF RIRDCGALFG
    LETTDKACAK HLQKVWSNML VTTIQHKSRD FETLEEYIDF RIRDCGALFG
    EGVMLFGMGL ALTEKDREDV ASTIYPCYAA LGLTNDYFSF DREWEEAKRT
    EGVMLFGMGL ALTEKDREDV ASTIYPCYAA LGLTNDYYSF DREWEEAQRS
    GEAKFSNAVR LFMDWQSTGA AAAKEVVRKA IIEYEREFLE LREKFVKANP
    GEAKFSNAVR LFMDWQSTDA ATAKEVVRKA IIEYEREFLE LREKFVKANP
KAERLHKFLE AMVYQISGHV VWSINCPRYN PSFRYDPNSG VENQVLAERR
EAERLHQFLE AMVYQISGHV VWSLNCPRYN PSFRYDPNSG VENQLLAERR
```

```
GKSSSKKPSV MIEEIDEKSH LASETGPAMI A
GKSSSKKPSA LIEDINEKSH LASESGPTMI A
```



## Satratoxin cluster 1, 10 products

```
Sat1, 294 aa
S40293 MWASFPRPEA IPPGYVGETQ HQHRSIMLLN GKSRSWIFLY ERLPAPSHDR
S7711 MWASFPRPEA IPPGYVGETQ HQHRSIMLLN GKSRSWIFLY ERLPAPSHDR
    VKCIAEDVIE FADSFADWSI WNNTKLEDVV DHSTAGMSNL EEGIVKNFSH
    VKCIAEDVIE FADSFADWSI WNNTKLEDVV DHSTAGMSNL EEGIVKNFSH
    GRIVLVGDAC HKFTSNAGLG LNNGIQDIVA GCNSIRKVVT ESGFDLPDVK
    GRIVLVGDAC HKFTSNAGLG LNNGIQDIVA GCNSIRKVVT ESGFDLPDVK
    ALEATFKTYY EMRLGPFNDD FIHSKMMTRM QAWANTWYFL FTRYLFFIFS
    ALEATFKTYY EMRLGPFNDD FIHSKMMTRM QAWANTWYFL FTRYLFFIFS
    EWILFGFTML RRVCIGLVLT MHLAKSRLLA LLNGFIRSGY HSFIWISAIR
    EWILFRFTML RRVCTGLVLT MHLAKSRLVA LLNGFIRSGY HSFIWISAIR
    PCNDQLLNQL LAGAIQIEIL CSLNTWRISS CRAPLLLVFD QARG
    PCNDQLLNQL LAGAIQIEIL CSLNTWRISS CRAPLLLVFD QARG
Sat2, 354 aa
S40293 MPSLQVIRAA VAELPQGSPI VAAVAGGTTG IGSYLAKALA TTFASHGSKL
S7711 MPSLQVIRAA VAELPQGSSI VAAVAGGTTG IGSYLAKALA TTFASHGSKL
    RVYIVGRNAG RAKTVISECQ KISPGSDWRF IHATDLALIS EVDKSSAEII
    RVYIVGRNAG RAKTVISECQ KISPGSDWRF IHATDLALIS EVDKSSAEII
    KQETEAPFHG ELARLDLLYM THAIPILGHK RTTEEGLDAL ESTIYYSRIR
    KQETEAPFHG ELARLDLLYM THAIPILGHK RTTEEGLDAL ESTIYYSRIR
    FILQLLPLLT ASPRVAHVIS VYAGGMENGV KPDEEPIGFV PAEIYHFNTV
    FILQLLPLLT ASPRVAHVIS VYAGGMENGV KPDEEPIGFV PAEIYHFNTV
    RKYTTFMKTF VFEELAEKHA ERLSLIHIYP GLVDGPGFTQ MPRWFRVLFT
        RKYTTFMKTF VFEELAEKYA ERLSLIHIYP GLVDGPGFTQ MPRWFRVLFT
        LMKPLTSLYM TRSEDCGMVM AYLATSRFSA KGSGQDAPTS TDTLAPKSSL
        LMKPLTSLYM TRSEDCGMVM AYLATSRFSA KGSGQDAPTS TDTLAPKSSL
        GVVGGGAYSL GQRADSQTPQ IMFEKSRKPD TSKKAWDHTI RTLDDIAKKN
        GVVGGGAYSL GQRADSQTPQ IMFEKSRKPD TSKKAWDHTI RTLDDIAKKN
    ATIA
    ATIA
Sat3, 271 aa
S40293 MSEALIGGGA KKVYILSRRR DVLESAAAKH EGILIPIQCD VTSKASLQSA
S7711 MSEALIGGGA KKVYILSRRR DVLESAAAKH EGILIPIQCD VTSKASLQSA
VDIVTKDSGY VNLLIANSGT LGPTNRLDHD LSIHELRKNV FDNVSFEDFN
VDIVTKDSGY VNLLIANSGT LGPTNRLDHD LSIHELRKNV FDNVSFEDFN
NTLSVNTTGA YFTMLAFLEL LDAGNKNALK GGFGGPSTEG GAPSIQSQVI
```

```
    NTLSVNTTGA YFTMLAFLEL LDAGNKNALK GGFGGPSTEG GAPSIQSQVI
    FTSSLGAYSR DRLSPPAYSA SKSALSHLAK HASTNLAKYG IRVNVLAPGL
    FTSSLGAYSR DRLSPPAYSA SKSALSHLAK HASTNLAKYG IRVNVLAPGL
    FPSEIATLMT ANRDPATENL GDRMFIPARK FGGAEEMGGT VLYLASRAGS
    FPSEIATLMT ANRDPATENL GDRMFIPARK FGGAEEMGGT VLYLASRAGS
    YCNGLILVND GGRLSVMLSE Y
    YCNGLILVND GGRLSVMLSE Y
Sat4, 268 aa
S40293 MNGIYALQQT FVKFSLLALY HRLFWVNRHF VRSVWLVGIV QGCWGIAILL
S7711 MNGIYALQQT FVKFSLLALY HRLFWVNRHF VRSVWLVGIV QGCWGIAILL
    VHIFLCTPME KIWTPWMVEG TCVDVNTLFA IYEALNSVLD FIVAGLAIWM
    VHIFLCTPME KIWTPWMVEG TCVDVNTLFA IYEALNSVLD FIVAGLAIWM
    LPSLQIRKST RWHLAGLFVL GAFSGFIGII KIVEAYDSAQ RNFQAVIWNV
    LPSLQIRKST RWHLAGLFVL GAFSGFIGII KIVEAYDSAQ RNFQAVIWNV
    VQMSISIICC CAPIYRSILP KMGMSSIPSW ASWSLRGSSR RSKAVASTAD
    VQMSISIICC CAPIYRSILP KMGMSSIPSW ASWSLRGSSR RSKAVASTAD
    GTSKFSMRSY QGEGKAGGTS VSGNWINLDG SSQRALAWVD AESHGKDQST
    GTSKFSMRSY QGEGKAGGTS VSGNWINLDG SSQRALAWVD AESHGKDQST
    YQDIPMGRMK VERSVEVI
    YQDIPMGRMK VERSVEVI
Sat5, 463 aa
S40293 MSTMAKSPEA NNLHQDVIAQ FPILNGYTHT VGAFSQPLNV SRLFIIDEIQ
S7711 MSTMAKSPEA NNLHQDVIAQ FPILNGYTHT VGAFSQPLNV SRLFIIDEIQ
TAYDELRVQI PWLAHQVVVV DAGPGKSGYI TTAPWPSSAP PNDVTYEEKD
TAYDELRVQI PWLAHQVVVV DAGPGKSGYI TTAPWPSSAP PNDVTYEEKD
DAFPSLNTLI KSGGSFLATK DLVGYPGLPE PHGLHPTPVA TIRLVFITGG
DAFPSLNTLI KSGGSFLATK DLVGYPGLPE PHGLHPTPVA TIRLVFITGG
VLVVLSTHHN IVDGIGLMQM WDYLDILMGG GAISRODARS ANADRARVLP
VLVVLSTHHN IVDGIGLMQM WDYLDILMGG GAISRQDARS ANADRARVLP
LIAPGEPVKD YSHLIRPDPW PLPPPPKTEW RLFKMHPWAL AEIRSRARDG
LIAPGEPVKD YSHLIRPNPW PLPPPPKTEW RLFKMHPWAL AEIRSRARDG
TDQRASARPA SSDDALTAFC WQRVSAMRLA SGRVTGDQVS KFGRAVNGRS
TDQRASARPA SSDDALTAFC WQRVSAMRLA SGRVTGDQVS KFGRAVNGRS
AMGLDSSYLF HMMLHTETRL PIEQIARSTL AELSTQLRKD LDAARTEWSV
AMGLDSSYLF HMMLHTETRL PIEQIARSTL AELSTQLRKD LDAARTEWSV
RSYATFLAGV ADKTRLLYGG ITNPQTDLGG TSTMHWASRR PIRLGLLGDC
RSYATFLAGV ADKTRLLYGG ITNPQTDLGG TSTMHWASRR PIRLGLLGDC
```

```
    HLIRKPEGMP LPGCLYFMPS GGTSGVVQLL LCLPKEELDA LQEDAEWKHY
    HLIRKPEGMP LPGCLYFMPS GGTSGVVQLL LCLPKEELDA LQEDAEWKHY
    TESGGRRVDG PRL
    TESGGRRVDG PRL
Sat6, 485 aa
S40293 MPQDPNTTLQ MSSSKPSLSD LSVSADPVLG KADNQVRDSL ALPSIEGGEE
S7711 MPQDPNTTLQ MSSSKPSLSD LSVSADPVLG KADNQVRDSL ALPSIEGGEE
    GVMRPLAWLF GLCAIQQASG ATLLRNDVST VEPLPPTQDP WYRAPPGFEK
    GVMRPLAWLF GLCAIQQASG ATLLRNDVST VEPLPPTQDP WYRAPPGFEK
    KQPGDVLRIR QAPGNLTTVV SNSSAAFHIL FRTTNARSEP AWAVTTLFLP
    KQPGDVLRIR QAPGNLTTVV SNSSAAFHIL FRTTNARSEP AWAVTTLFLP
    KKLYRAPSRN AALLSFQLAD NSANPDSAPS LGLYWRLAQD NPMLGLRSDT
    KKLYRAPSRN AALLSFQLAD NSANPDSAPS LGLYWRLAQD NPMLGLRSDT
    SFISNLLSEG WLVNIPDQSG PEAAFGASRQ AGHATIDAIR AIQHLCSLTG
    SFISNLLSEG WLVNIPDQSG PEAAFGASRQ AGHATIDAIR AIQHLCSLTG
    ATGINAAIWG YSGGTFATGA AAELMPTYAP NINIVGAVLG GMVTDVSGGF
    ATGINAAIWG YSGGTFATGA AAELMPTYAP NINIVGAVLG GMVTDVSGGF
    DSLNRSPIAA TIIATLLGVT AQFPEERAYL ESRLVPETRD EFMSVLDINV
    DSLNRSPIAA TIIATLLGVT AQFPEERAYL ESRLVPETRD EFMSVLDINV
    FDALVHFAGR DIYAFFIDGA ADIEAPILQN LFEAQSRIGF GDIPPMPMFI
    FDALVHFAGR DIYAFFIDGA ADIEAPILQN LFEAQSRIGF GDIPPMPMFI
    YKAIADEVVP IGPTDVTVQR WCDGGADITY ERNTVGGHIA EIENGKPRAI
    YKAIADEVVP IGPTDVTVQR WCDGGADITY ERNTVGGHIA EIENGKPRAI
    QWLWSIFDES YSAQSPECRI RDVTVEVPVQ VVGRV
    QWLWSIFDES YSAQSPECRI RDVTVEVPVQ VVGRV
Sat7, 470 aa
S40293 MSTSTSEPGA IAGLPLGAEV RTDGDATGLS VAIVGGGIVG IALALGLVER
S7711 MSTSTSEPGA IAGLPLGAEV RTDGDATGLS VAIVGGGIVG IALALGLVER
GVRVSVYERA QELPEIGVGF AFNGAARKSM ARLSPLVIAA LERVANENEQ
GVRVSVYERA QELPEIGVGF AFNGAARKSM ARLSPLVMAA VERVANENEQ
AYDNYWDGYT STAEDDESST ASKRGKLLFR MPNSNMAWWS CLRSQFLNEM
AYDNYWDGYT STAEDDESST ASKRGKLLFR MPNSNMAWWS CLRSQFLNEM
LQALPPGTVT FGKELDSYND PFDTSDPVRL RFTDGTTAAA NVLIGSDGLR
LQALPPGTVT FGKELDSYDD PFDTSDPVRL RFTDGTTAAA NVLIGSDGLR
SRVRQQLFAT SHPEVCNPTY THKTCYRAVI PMAAAESAMG LSKPHNHCMH
SRVRQQLFAT SHPEVCNPTY THKTCYRAVI PMAAAESAMG LSKPHNHCMH
TGPRAHVLSY PIAQHKLVNV VLFVTHDEPW VDGTGDEAIS VPRMTRPGDK
TGPRAHVLSY PIAQHKLVNV VLFVTHDEPW VDGTGDEAIS VPRMTRPGDK
```

KVLQNRLADW RPEVRNLVAQ LPDAPTAWGI FDTAEHPVPF YAAGRVGLVG KVLQNRLADW RPEVRNLVAQ LPDAPTAWGI FDTAEHPVPF YAAGRVGLVG

DAAHASSPHH GAGAGFGVED ALALAVALGM ATEKKQSVAA ALQAFNDVRY DAAHASSPHH GAGAGFGVED ALALAVALGM ATEKKQSVAA ALQAFNDVRY

DRTQWLIRSS KETGDIYEWK HFGVGGDPVK IRAELEGRQK TIWDYDVDAM DRTQWLIRSS KETGDIYEWK HFGVGGDPVK IRAELEGRQK TIWDYDVDAM

AEEVKTRYEA RVTSETTAHQ
AEEVKTRYEA RVTSETTAHQ

Sat8, 2602 aa
S40293 MATTLLLFGP QAASMSKQSI TQLQVALRDQ EWAFDALSNV QPIIQRASTS
S7711 MATTLLLFGP QAASMSKQSI TQLQVALRDQ EWAFDALSNV QPIIQRASTS

ISGLDQISLD ERLADLTRWL KHGPKDQEEL AEIPNIMLAP LTTLSHLVQY
ISGLDQISLD ERLADLTRWL KHGPKDQEEL AEIPNIMLAP LTTLSHLVQY

RRYIERHYPN ESDAHAALLQ QKPVATLGFC NGLLAAFATT SSATLNDWER RRYIERHYPN ESDAHAALLQ QKPVATLGFC NGLLAAFATT SSATLNDWER

YAAVATRLAL LVGAVIDAAD ELQPHGPAAS YGVSWRDIDG ARQLEQILSP YAAVATRLAL LVGAVIDAAD ELQPHGPAAS YGVSWRDIDG ARQLEQILSP

FPGDAYVSVW YDRSRATVTV SKHLVRTVLH LVEAAGMAVV PVRLRGRYHS FPGDAYVSVW YDRSRATVTV SKHLVRTVLH LVEAAGMAVV PVRLRGRYHS

RQHAEVAEAL IRLCDAEPDL LALPDARNLC LPTYSNVGHG EVVREGRLHE RQHAEVAEAL IRLCDAEPDL LALPDARNLC LPTYSNVGHG EVVREGRLHE

IALQAMLVQQ CDWYSTLSGI TDESQVQVVC LSEVSTLPPS LTFKLKPQME IALQAMLVQQ CDWYSTLSGI TDESQVQVVC LSEVSTLPPS LTFKLKPQME

YFAPLEEKTA PKDNFSGRAD GGSQFSFSML ENSTSPPSPA ATSSNSHCEY YFAPLEEKTA PKDNFSGRAD GGSQFSFSML ENSTSPPSPA ATSSNSHCEY

SVDPRDIAIV GMSVKVAGAD DVVEYESILR GGVSQHQQVR KNRVPFGYNS SVDPRDIAIV GMSVKVAGAD DVVEYESILR GGVSQHQQVR KNRVPFGYNS

FRPEEPGHKW YGNFVRDVDA FDHKFFRKSS RESAAMDPQQ RLVLQAAYQA FRPEEPGHKW YGNFVRDVDA FDHKFFRKSS RESAAMDPQQ RLVLQAAYQA

VEQSGYYASG TEPDQHIGVY LGTCATDYEQ NANCHAPGAF TVTGLLRGFI VEQSGYYASG TEPDQHIGVY LGTCATDYEQ NANCHAPGAF TVTGLLRGFI

AGRISHFFGW TGPAMTYDTA CSGSAVAIHS AVQALVSGEC SAALAGGVNT AGRISHFFGW TGPAMTYDTA CSGSAVAIHS AVQALVSGEC SAALAGGVNT

IGNEVWFQNL AGAQFLSPTG QCKPFDDAAD GYCRGEGIAC VVLKPMAKAI IGNEVWFQNL AGAQFLSPTG QCKPFDDAAD GYCRGEGIAC VVLKPMAKAI

ADGNQIFGRI ASSAVHQSVN CTPLFVPNVP SLSRLFGDVM RQARLEPHDI ADGNQIFGRI ASSAVHQSVN CTPLFVPNVP SLSRLFGDVM RQARLEPHDI

```
SFVEAHGTGT PVGDPVEYES IRAILGGPLR DKPLSLGSAK GLVGHTESTS
SFVEAHGTGT PVGDPVEYES IRAILGGPLR DKPLSLGSAK GLVGHTESTS
GVVSLVKVLL MMQSGFIPPQ ASYSKLSHRI APSASAMIQV STTLQPWTDS
GVVSLVKVLL MMQSGFIPPQ ASYSKLSHRI APSASAMIQV STTLQPWTDS
YKAALINNYG ASGSNAAMVV TQGPAQTARS PRGEADGAHL PFWIPGFDSA
YKAALINNYG ASGSNAAMVV TQGPAQTARS PRGEADGAHL PFWIPGFDSA
RIAAYCARLS AFIEANRSTI HLADIAYNIS RQSNRTLSHA LLFRCNSIDS
RIAAYCARLS AFIEANRSTI HLADIAYNIS RQSNRTLSHA LLFRCNSIDS
LVGQLSSAAA PQTVQVKPSR PVILCFGGQM STFVGLNREI YDSSPILRDH
LVGQLSSAAA PQTVQVKPSR PVILCFGGQM STFVGLNREI YDSSPILRDH
LSQCDAAIRA LGFGSIFPSI FATIPIEDTV LLQTVLFSFQ YACAKSWIDC
LSQCDAAIRA LGFGSIFPSI FATIPIEDTV LLQTVLFSFQ YACAKSWIDC
GVRPTAVVGH SFGEITALCI AEVLSLDDTI KLVTRRAKVV RDSWGADRGV
GVRPTAVVGH SFGEITALCI AEVLSLDDTI KLVTRRAKVV RDSWGADRGV
MMAVEGEVDQ VERLLEEANK DLDTHSPASI ACYNGLRNFT LAGSTLAMER
MMAVEGEVDQ VERLLEEANK DLDTHSPASI ACYNGLRNFT LAGSTLAMER
VALALSSSAY ASIRGKKLNV TNAFHSALVD PLLQELEQAG SDLTFNKARI
VALALSSSAY ASIRGKKLNV TNAFHSALVD PLLQELEQAG SDLTFNKARI
KVERATKEST TGEPCAPKFV GEHMRNPVFF RQAAQRLARD NPSAVWIEAG
KVERATKEST TGEPCAPKFV GEHMRNPVFF RQAAQRLARD NPSAVWIEAG
SATKITAMAR RSLDSNAESH FQGITVTGED GLDKLTEATL SLWKQGLNVA
SATKITAMAR RSLDSNAESH FQGITVTGED GLDKLTEATL SLWKQGLNVA
FWAHHGPQAT RDHQPLLLPP YQFEKSRHWL DVKAPPVMLA DTAQGDNGPL
FWAHHGPQAT RDHQPLLLPP YQFEKSRHWL DVKAPPVMLA DTAQGDNGPL
FGLLTFVGFQ DAEERRARFK INTESERYKS LVIPHIIART APICPATLEY
FGLLTFVGFQ DAEERRARFK INTESERYKS LVIPHIIART APICPATLEY
SLAIQALLTL RDHKHFESRD MHPVIRDMRN DAPLCLNSDQ STWLDLEANK
SLAIQALLTL RDHKHFESRD MHPVIRDMRN DAPLCLNSDQ STWLDLEANK
TSPRSLVWKV FTAPVSRQLD SHNDSDETLC AQGKLDLLSS SETTEFAQYE
TSPRSLVWKV FTAPVSRQLD SHNDSDETLC AQGKLDLLSS SETTEFAQYE
QLATYDACVS LLQDDDGDVS GLQGRSVYRS LADVVDYGVH YQKVRRVSGR
QLATYDACVS LLQDDDGDVS GLQGRSVYRS LADVVDYGVH YQKVRRVSGR
NSESAGIVRG ASGGNWLSDL PIIDSFSQVA GVWVNCLADR TPGSDDLFLA
NSESAGIVRG ASGGNWLSDL PIIDSFSQVA GVWVNCLADR TPGSDDLFLA
TGCETIMTSP TFLHADRGGK SWHVWAKHHR ESERSYRTDV LVFDATNGQL
TGCETIMTSP TFLHADRGGK SWHVWAKHHR ESERSYRTDV LVFDATNGQL
```

```
ADVFLGIAYT RIPRHSMTRL LSKLSEPSAL QAQAALPSST GHEGLTAKTA
ADVFLGIAYT RIPRHSMTRL LSKLSEPSAL QAQAALPSST GHEGLTAKTA
SSQRLGQDTL KQTVGQIIAS LSGVEAAQIT DESALADIGI DSLAGMELAR
SSQRLGQDTL KQTVGQIIAS LSGVEAAQIT DESALADIGI DSLAGMELAR
DIESVLGCKL DLEELLFTHD TFGAFVRYIS KVVNGEDDLG TPSHSDNDSH
DIESVLGCKL DLEELLFTHD TFGAFVRYIS KVVNGEDDLG TPSHSDNDSH
VTGTTATPNS SSASSDTHHG NSKLQIAVAQ SSQADASSSS PLPPQHVISS
VTGTTATPNS SSASSDTHHG NSKLQIAVAQ SSQADASSSS PLPPQHVISS
FEQVKLSTDQ RIREEKADNT DDIIVSRSNL LCVALVVEAF EQLGCPLRGV
FEQVKLSTDQ RIREEKADNT DDIIVSRSNL LCVALVVEAF EQLGCPLRGV
PAGEALKRIQ HAPQHARLVD WLYRFLEDEA RLINTEGTLI LRTSNGAPNK
PAGEALKRIQ HAPQHARLVD WLYRFLEDEA RLINTEGTLI LRTSNGAPNK
TSQAIFQDLE HANDRWIESH RLANYAGKNL ADVVSGKKEG IHVLFGSAEG
TSQAIFQDLE HANDRWIESH RLANYAGKNL ADVVSGKKEG IHVLFGSAEG
RELVRGLYSG LPFNCLFYKQ VRDTISLIVE KVKDDFQGPL RILEMGAGTG
RELVRGLYSG LPFNCLFYKQ VRDTISLIVE KVKDDFQGPL RILEMGAGTG
GTTQVLAPFL ATLDIPVEYT MTDLSPYMVA QAQRSFGTKY PFMHFAVHDI
GTTQVLAPFL ATLDIPVEYT MTDLSPYMVA QAQRSFGTKY PFMHFAVHDI
EKPPAESLLG TQHIIVASNA VHATANLADS AANIRSTLRP DGILLLVEMT
EKPPAESLLG TQHIIVASNA VHATANLADS AANIRSTLRP DGILLLVEMT
ESLPFVDIVF GLLEGWWRFA DGREHAIVPA EQWEARLRDA GYGHVDWTDG
ESLPFVDIVF GLLEGWWRFA DGREHAIVPA EQWEARLRDA GYGHVDWTDG
VFSENRLQKV ILAMASELPD GLPVSSGVPE PVQPALEVTT TVAREANAEA
VFSENRLQKV ILAMASELPD GLPVSSGVPE PVQPALEVTT TVAREANAEA
YVTQYSADFT YDGESSGNIE AHEAQDSRIV VVTGATGSLG SHMVASFAES
YVTQYSADFT YDGESSGNIE AHEAQDSRIV VVTGATGSLG SHMVASFAES
PSVTSVVCIN RRNSGKATAL ERQQEAFTSR GITLSPDAFG KLRVFATDTA
PSVTSVVCIN RRNSGKATAL ERQQEAFTSR GITLSPDAFG KLRVFATDTA
QPQLGLPLEE YEWLVTHATH IVHNAWPMSA SRPIQAFQPQ FKTMSRLLDL
QPQLGLPLEE YEWLVTHATH IVHNAWPMSA SRPIQAFQPQ FKTMSRLLDL
AAAIAQQSTS RCVVFQLISS IGVVGSAPMI DTRVPERRVP VSYTLPNGYC
AAAIAQQSTS RFVVFQLISS IGVVGSAPMI DTRVPERRVP VSYTLPNGYC
EAKWVCEQLL NETLHQYPER FRAMVVRPGQ IAGSSVNGVW NPVEHFPALV
EAKWVCEQLL NETLHQYPER FRAMVVRPGQ IAGSSVNGVW NPVEHFPALV
RSSQALRAFP ALGGTLQWIP VDVAAGTVAD LALNQQAGEP VYHIDNPVGQ
RSSQALRAFP ALGGTLQWIP VDVAAGTVAD LALNQQAGEP VYHIDNPVGQ
SWSDMVPILA DELNIPGERI IPLGEWVRKV KRSSLLETEN PASRLPDFFE
```

```
    SWSNMVPILA DELNIPGERI IPLGEWVRKV KRSSLLETEN PASRLPDFFE
    QHFERMSCGG LILDVALATK RSGTLAAQGA VSADTARKYI QTWKDMKFLD
    QHFERMSCGG LILDVALATK RSGTLAAQGA VSADTARKYI QTWKDMKFLD
    RY
    RY
Sat9, 208 aa
S40293 MASAALFYDS RATIARRLTL HCQYMARAVL FAQCRSAETM LTFILDLSWL
S7711 MASAALFYDS RATIARRLTL HCQYMARAVL FAQCRSAETM LTFILDLSWL
    FPDENGMRDN TCCYIVATIT MALDLLRDRV LAVAVSLDVE LLPYVYIVVT
    FPDENGMRDN TCCYIVATIT MALDLLRDRV LAVAVSLDVE LLPYVYIVVT
    HTRLHLLASL LNYPPVHLDV RRMVSEAALH SACEVLRAAV RGEDQLKYIP
    HTRLHLLASL LNYPPVHLDV RRMVSEAALH SACEVLRAAV RGEDQLKYIP
    NNLVIMICYA SCISHVPKVR RLVAQLLQFS WTMQGLFTHC VSLLVATLAA
    NNLVIMICYA SCISHVPKVR RLVAQLLQFS WTKQGLFTHC VSLLVATLAA
    KSGSQNSR
    KSGSQNSR
Sat10, 1930 aa
```



```
S7711 MSIQFFSYDV GGLIVKEVRL LILWRRSALP NGRTLFARMT QALRIASSDK
    KYRSIFDRTS LLAFFATPHR STQHQSPESV ALALLNQCYC GLISPWISIF
    KYRSIFDRTS LLAFFATPHR STQHQSPESV ALALLNQCYC GLISPWISIF
    PPNFSKVVAR SEVEFRPPTR AHILNVFQDP GPASPIKDSV VVHKSCAVLG
    PPNFSKVVAR SEVEFRPPTR AHILNVFQDP GPASPIKDSV VVHKSCAVLG
    VDGEVLIGLD CSHYTLARLL KARDKRYLLR QASHAALRHG KAFQQVVGLF
    VDGEVLIGLD CSHYTLARLL KARDKRYLLR QASHAALRHG KAFQQVVGLF
    FLDSIRTFDA EGPKFECRKV VSQLASLSQL QSWRQGSVDS RVLWFGTPAM
    FLDSIRTFDA EGPKFECRKV VSQLASLPQL QSWRQGSVDS RVLWFGTPAM
    LDPTSLFRTL RSQIQEENQL GDPIFIRVDS TLHRHNELSE PQILASMCQQ
    LDPTSLFRTL RSQIQEENQL GDPIFIRVDS TLHRHNELSE PQILASMCQQ
    ILRQQPQLTS ALQDLLLNVE DAAVGSRDCW KQRTLWNCLL VLLYHPKDAE
    ILRQQPQLTS ALQDLLLNVE DAAVGSRDCW KQRTLWNCLL VLLYHPKDAE
    TFCFIDATSS LQTKNLAGQL DSVMKESEMP LRLIVSCRST AKQTPEASTQ
    TFCFIDATSS LQTKNLAGQL ESVMKESEMP LRLIVSCRST AKQTPEASTQ
    VDVDLSDAGF DEPLRQDLEE WIRESLECGL TDSTLREALL TQILSSGDFH
    VDVDLSDAGF DEPLRQDLEE WIRESLECGL TDSTLREALL TQILSSGDFH
    LARHALEFFA STGSWLTKWS VPSVWAMLSK QSAAELFIED NIRRHGQWLL
    LARHALEFFA STGSWLTKWS VPSVWAMLSK QSAAELFIED NIRRHGQWLL
```

```
IPMLWALEAF EPMQVDEIDV ALMLEDDGVA GQVEDFINLL PGISTIRRGV
IPMLWALEAF EPMQVDEIDV ALMLEDNGVA GQVEDFINLL PGISTIRRGV
FVIADHARPA FDYLWGKYFA TYQHHVYLAK SCVAALRHHL RVTPAIPQPR
FVIADHVRPA FDYLWGKYFA TYQHHVYLAK SCVAALRHHL RVTPAIPQLR
EDKSSDAAAR LCTYAAMNWV RHFSLQTNSE TTKYVPHPTI ITANETDPGS
EDKSSDAAAR LCTYAAMNWV RHFSLQRNSE TTKYVPHPTI ITANETDPGS
PNEHAGVSEA FLEDPELSRL WITHLRRALD LDGLDEELGH LILPETLGSR
PNEHAGVSEA FLEDPELSRL WITHLRRALD LDGLDEELGH LILPETLGSR
LGICTGWALR ISRQLASMRL SSERDVTNSL LVIGSETDDL AMVQSCLSAD
LGICTGWAIR ISRQLASMRL SSERDVTNSL LVIGSETDDL AMVQSCLSAD
PSPTEHTLGY ALAAASDPIK EKLLQQVGEP SDEFLYRALL SSICFGNVSV
PSPTEHTLGY ALAAASDPIK EKLLQQVGEP SDEFLYRALL SSICFGNVSV
TKDLLVRITD KVRVAQVTPL EGSKLQWPQA NESSESAETF RHTPLGVATA
TEDLLVRITD KVRVAQVTPL EGSKLQWPQA NESSESAETF RHTPLGVATA
YGDADVIDLL INHDISWWDL EERSPPPGTW NALHHAALGG QRNIMCKLLL
YGDADVIDLL INHDISWWDL EERSPPPGTW NALHHAALGG QRNIMCKLLL
QQRKGVLNSS ARIPNTVTES GNTPLILAAS RGFHKIVALL LEDGSMRGYG
QQRKGVLNSS ARIPNTVTES GNTPLILAAS RGFHKIVALL LEDGSMRGYG
VDVNIQNEQR SSALLAAARY GFSQTLEMLL TYEGIDYSKT DSNGASILHL
VDVNIQNEQR SSALLAAARY GFSQTLEMLL TYEGIDYSKT DSNGASILHL
ALVNDREAAA LQILAHKDIF SNEMEYQEAN MEANPVNKFE DDDSFSESSV
ALVNDREAAA LQILAHKDIF SNEMEYQEAN MEANSVNNFE DDDSFSESSV
DTTDVVYTVP ARPRISLHQK DGSGLTSLTI AIWRNLKSIV EILIAMDADA
DTTDVVYTVP ARPRISLHQK DGSGLTSLTI AIWRNLKSIV EILIAMDADA
NGPEGEFEAP LVAAAEVGSF ELFTMFTKIG ATKTEAALNT ISTGRTRPLH
NGPEGEFEAP LVAAAEVGSF ELFTMFTKIG ATKTEAALNT ISTGRTRPLH
AACAMGHLEV VRELLKDSVT QLSHTDSNQR TPLCAAISRD QNHVISVLLD
AACAMGHLEV VRELLKDSVT QLSHTDSNQR TPLCAAISRD QNHVISVLLD
RETETGLQEG LWEAARSGKA HILDQLLRRG AEINAQDEYG NTALQWASYY
RETETGLQEG LWEAARSGKA HILDQLLRRG AEINAQDEYG NTALQWASYY
NKPRCVERLL LGGARLDLLD CDNVNALGDA ARSGSAEPLK LLVDVGVDVN
NKPRCVERLL LGGARLDLLD CDNVNALGDA ARSGSAEPLK LLVDVGVDVN
AEAGGDTALC RAIWAEEVEC VSVLLQGGAK FILSSAQSRF ENLLTFAVQV
AEAGGDTALC RAIWAEEVEC VSVLLQGGAK FILSSAQSRF ENLLTFAVQV
SSPEILRLLL KAPEERDLAP TLRSACAMQS TSQLEVLLEF YDPAKVDLGS
SSPEILRLLL KAPEERDLAP TLRSACAMQS TSQLEVLLEF YDPAKVDLGS
GWTILHLAAV HGTLAGLTKV LDHATGRAAL NYGPKKVGTP FEMAAFSSKE
```

```
GWTILHLAAV HGTLAGLTKV LDHATGRAAL NYGPKKVGTP FEMAAFSSKE
SLSKVEHLYS NAALPGLVQP SSRFGTALNA ASYRLNDPVV VYLLQKMQLE
SLSKVEHLYS NAALPGLVQP SSRFGTALNA ASYRLNDPVV VYLLQKMQLE
DINASGARYG NAIQNMLASA WMDTERSLKL LGILLEAGVS LTPTSADRHG
DINASGARYG NAIQNMLASA WMDTERSLKL LGILLEAGVS LTPTSADRHG
TALHTAALFS PKPLVEKVLE TSRMLADERD GEGRLPIHLS ALQEEWASMM
TALHTAALFS PKPLVEKVIE TSRMLADERD GEGRLPIHLS ALQEEWASMM
LLSTTTSTIR SVDKMGRNAV HLAAAAGARS VLEKIFEVEE NEDLLLEADF
LLSTTTSTIR SVDKMGRNAV HLAAAAGARS VLEKIFEVEE NEDLLLEADF
DGWTPFHWAC RGEDDDCARF LIETARKIFD SKWDSMKHEL VTTDEKTWTP
DGWTPFHWAC RGEDDDCARF LIEKARKIFD SKWDSMKHEL VTTDEKTWTP
LDVARFHQRR EVELLLSLGM TTSDAENWMP DQSQNLGSYC DSCACQIWHE
LDVARFHQRR EVELLLSLGM TTSDAENWMP DQSQNLGSYC DSCACQIWHE
EHHSSALHCK RLYLRFNGWS RMCQLAPTAK RKYTPTLLGY KTCFKVADNL
EHHSSALHCK KLYLRFNGWS RMCQLAPTAK RKYTPTLLGY KTCFKVADNL
MKARLAKVLV PHSQGPLQRK GRGKGEGEED EEGIATVENY PVSQSCGVEM
VKARLAKVLV PHSQGPLQRK GRGKGEGEED EEGIATVENY PVSQSCGVEM
IRAFVIDDRR IQPDATRNLN HEVSVGSEDQ TQMSLGTGRL FVQSVDSPLE
IRAFVIDDRR IQPDATRNLN HEVSVGSEDQ TQMSLGTGRL FVQSVDSPLE
MVMDVAAIFL SSPKSAHKQD ETTRAFATAK
MVMDVAAIFL SSPKSAHKQD ETTRAFATAK
```


## Satratoxin cluster 2, 6 products

```
Sat11, 526 aa
S40293 MTIPTSFEML KGMHIKDAFL LIAMLYLGYL LCICFYNIYL HPLRHIPGSK
S7711 MTIPTSFEML KGMHIKDAFL LIAMLYLGYL LCICFYNIYL HPLRHIPGSK
    LAVMGPYLEF YHEVIRQGQY LWEIEKMHDK YGPIVRVNER EIHIRDSSYY
    LAVMGPYLEF YHEVIRQGQY LWEIEKMHDK YGPIVRVNER EIHIRDSSYY
    HTIYAAGSRK TNKDAATVGA FDVPNSTAAT VDHDQHRARR GYLNPYFSKR
    HTIYAAGSRK TNKDAATVGA FDVPNSTAAT VDHDQHRARR GYLNPYFSKR
    SLANLEPTIH ERISKLLNRL EQHQNNDDII TLDGIFSALT ADVICSRFYG
    SLANLEPTIH ERISKLLNRL EQHQNNDDII TLDGIFSALT ADVICSRFYG
    KHFDYLSIPD YHFVVRDGFQ GLTKLYHLGR FLPTLVTILK CLPQQIIRLI
    KHFDYLSIPD YHFVVRDGFQ GLTKLYHLGR FLPTLVTILK CLPQQIIRLI
    LPNLADLIVM RDEIQANGIA QFTSSQTADS KASALVGALG DKNIPPHERT
    LPNLADLIVM RDEIQANGIA QFTSSQTADS KASALVGALG DKNIPPHERT
    VARLLDEGTV FLFAGTETTS RTLAVTMFYL LTNPDCLKKL RAELDTLPST
    VARLLDEGTV FLFAGTETTS RTLAVTMFYL LTNPDCLKKL RAELDTLPST
    EDYQHSLSTL ESLPYLSGVV HEGLRLAFGP ITRSARVPMN VDLQYKEYTI
        EDYQHSLSTL ESLPYLSGVV HEGLRLAFGP ITRSARVPMN VDLQYKEYTI
        PAGTPLSMST YFVHTDKELY PEPEKFKPER WIQAAEENIP LKKFLTNFSQ
        PAGTPLSMST YFVHTDKELY PEPEKFKPER WIQAAEENIP LKKFLTNFSQ
        GSRQCIGISM SFAEMYLTIS RVARAYNFEL YETTAADLDM TYARIVPYPK
        GSRQCIGISM SFAEMYLTIS RVARAYNFEL YETTAADLDM TYARIVPYPK
        EIPGKTEGLG EIRVKIVGKN HSQIEE
        EIPGKTEGLG EIRVKIVGKN HSQIEE
Sat12, 573 aa
S40293 ---------- ---MSNASSR EASITSRSSS TSGNNSLPED RGAVVQLPTL
S7711 MLDDDCSPTS SSEMSNASSR EASITSRSSS TSGNNSLPED RGAVVQLPTL
    NPSDYRWHPF PGDSSVLQRK AIGVEALVGI RDANSRGEYD FYNNIVLRVG
    NPSDYRWHPF PGDSSVLQRK AIGVEALVGI RDANSRGEYD FYNNIVLRVG
    NALELTLTRL KRAFVKAMLD ARFENPSIAC YGVWGQNKEQ YLPHIQYKSF
    NALELTLTRL KRAFVKAMLD ARFENPSIAC YGVWGQNKEQ YLPHIQYKSF
    KSQSEALAWA NNCIIIQATS LTGSELRAER LKKRRAQAVP QPSNPLDIII
    KSQSEALAWA NNCIIIQATS LTGSELRAER LKKRRAQAVP QPSNPLDIII
    YADVANQRNR LEPGTEVNIL FLFNHLIWDG KGRYFTSELV QRATTILDQE
    YADVANQRNR LEPGTEVNIL FLFNHLIWDG KGRYFTSELV QRATTILDQE
KENIMPTHRW GEEKSRLDPP ILDVMLVNLD KMGPDYDLAH RKLLNSQLQV
KENIMPTHRW GEEKSRLDPP ILDVMLVNLD KMGPDYDLAH RKLLNSQLQV
```

|  | GLSWGLPLTR | NPGEPLQIRH | CISREDSTKI | TDAVRARLGP | KYNIGHLGHA |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | GLSWGLPLTR | NPGEPLQIRH | CISREDSTKI | TDAVRARLGP | KYNIGHLGHA |
|  | ATVLSLLKNN | PIPPSTQDTA | FLFSPLPVDG | RPYLLEERKT | PRYGNAQAAA |
|  | ATVLSLLKNN | PIPPSTQDTA | FLFSPLPVDG | RPYLLEERKT | PRYGNAQAAA |
|  | VVELQKLASW | GIKSDNLNGV | KVALDDLAKK | VKEDYDYWLT | NLVAWRFKSS |
|  | VVELQKLASW | GIKSDNLNGV | KVALDDLAKK | VKEDYDYWLT | NLVAWRFKSS |
|  | CTSEFIAFGS | AIYQTPYLDP | GAPKVKVGTG | TSTDMVFLKA | FCNDGRAESI |
|  | CTSEFIAFGS | AIYQTPYLDP | GAPKVKVGTG | TSTDMVFLKA | FCNDGRAESI |
|  | IAYTMHGPSG | KELFQVDDCF | GGVDVLGSNA | FIRMDTWKDA | IRLTLCYNSG |
|  | IAYTMHGPSG | KELFQVDDCF | GGVDVLGSNA | FIRMDTWKDA | IRLTLCYNSG |
|  | CFSDAVANSF | TTDVAQYMLA | YSW |  |  |
|  | CFSDAVANSF | TTDVAQYMLA | YSW |  |  |
| Sat13, | aa |  |  |  |  |
| S40293 | MSGPNPVPLA | IVGIACRFPG | DATNPEKFWD | LLANARSGWS | RVPNDRWNEE |
| S7711 | MSGPNPVPLA | IVGIACRFPG | DATNPERFWD | LLANARSGWS | RVPNDRWNEE |
|  | AFWHPDPDDT | NGTNNHMGGH | FLNQDLARFD | AGFFNVTPQE | AASMDPQQRL |
|  | AFWHPDPDDT | NGTNNHMGGH | FLNQDLARFD | AGFFNVTPQE | AASMDPQQRL |
|  | LLETTYEALE | SAGIPQEHIR | GSNTAAYMAM | FTRDYDRNVY | KDMMSIPKYH |
|  | LLETTYEALE | SAGIPQEHIR | GSNTAAYMAM | FTRDYDRNVY | KDMMSIPKYH |
|  | VTGTGDAILA | NRISHLFDLR | GPSVTMDTGC | SGGLTAISHA | CQALRSGLSD |
|  | VTGTGDAILA | NRISHLFDLR | GPSVTMDTGC | SGGLTAISHA | CQALRSGLSD |
|  | IGLAGAVNLI | LTPDHMVGMS | NLHMLNVNGR | SFSFDSRGAG | YGRGEGVATL |
|  | IGLAGAVNLI | LTPDHMVGMS | NLHMLNVNGR | SFSFDSRGAG | YGRGEGVATL |
|  | VIKRLDDAIR | DKDPVRAILR | DAAINQDGYT | AGITLPSGRA | QQALERRVWD |
|  | VIKRLDDAIR | DKDPVRAILR | DAAINQDGYT | AGITLPSGRA | QQALERRVWD |
|  | VLNLDPATVG | YVEAHGTGTL | AGDSAELEGI | SKIFCENRDH | GSPLIVGSVK |
|  | VLNLDPATVG | YVEAHGTGTL | AGDSAELEGI | SKIFCENRDH | GSPLIVGSVK |
|  | SNIGHTECVS | GIAAVIKSTL | ILENGTIPPN | INFEQPRESL | DLRNKKIKVP |
|  | SNIGHTECVS | GIAAVIKSTL | ILENGTIPPN | INFEQPRESL | DLRNKKIKVP |
|  | NALMPWPQTT | GTARISVNSF | GYGGTNAHAV | LERAERVIDT | TCPEEDDAPQ |
|  | NALMPWPQTT | GTARISVNSF | GYGGTNAHAV | LERAERVIDT | TCPQEDDAPQ |
|  | LFIFSAASQT | SLLGMLAANR | DWVSENRERA | WVMRDLAYTL | SQRRSLLPWR |
|  | LFIFSAASQT | SLLGMLAANR | DWVSENRERA | WVMRDLAYTL | SQRRSLLPWR |
|  | FSCVAANRSE | LLETLSSVPQ | NANSIARITP | GSRISFIFTG | QGAQWAGMGR |
|  | FSCVAANRSE | LLETLSSVPQ | NANSIARITP | GSRISFIFTG | QGAQWAGMGR |
|  | ELLSMPTFNS | SLQRSNEILQ | DLGCSWDLIE | EVSKQKPESR | LHEPELSQPL |
|  | ELLSMPTFNS | SLQRSNEILQ | DLGCSWDLIE | EVSKQKPESR | LHEPELSQPL |

```
TTAIQIALVD LFREWGIVPD SVIGHSSGEI GAAYTAGHIA HCQAIKVAYF
TTAIQIALVD LFREWGIVPD SVIGHSSGEI GAAYTAGHIA HCQAIKVAYF
RGFSSAWAAQ AHKRGAMLAV GLGEYDVEPY LEQLEQGHAS IACQNSPNST
RGFSSAWAAQ AHKRGAMLAV GLGEYDVEPY LEQLGQGHAS IACQNSPNST
TVSGDDAAIS ELSEILTKES IFNRKLNITV AYHSHHMQTA ACQYKAALEP
TVSGDDAAIS ELSEILTKES IFNRKLNITV AYHSHHMQTA ACQYKAALEP
LLTNPSLDTG IEMFSTVTGS IKKDAFNSNY WVENLVSKVR FCDGLQALCE
LLTNPSLDTG IEMFSTVTGS IKKDAFNSNY WVENLVSKVR FCDGLQALCE
STQASPLGSS KAERIFIEIG PHSALAGPTR QCIADLITPL PYSYTSGLLR
STQASPLGSS KAERIFIEIG PHSALAGPTR QCIADLITPL PYSYTSGLLR
ETGAVKSALA MVGHIFNRGY SLNLAAISAS NKTSOYATVL SNLPSYHWDH
ETGAVKSALA MVGHIFNRGY SLNLAAISAS NKTSQYATVL SNLPSYHWDH
TRRHWNESRI SREYRFRKHP YHDLLGLRMT EVSPLRPSWR HMIGTKGLPW
TRRHWNESRI SREYRFRKHP YHDLLGLRMT EVSPLRPSWR HMIGTKGLPW
LADHVVDDLV IFPGSGYLAM AIEACSQLAD DRYPGREIER FSLNDIFFLK
LADHVVDDLV IFPGSGYLAM AIEACSQLAD DRYPGREIER FSLNDIFFLK
GLIIPDDGAR VEVQLSLNPI EPADKDTRMN VMQHEFSVTA FTDEARWNEH
GLIIPDDGAR VEVQLSLNPI EPADKDTRMN VMQHEFSVTA FTDEARWNEH
CRGNIVVVFK TSSATERLVA NGFTRGDMAA QLDPVSGKLT HAGQLYPELR
CRGNIVVVFK TSSATERLVA NGFTRGDMAA QLDPVSGKLT HAGQLYPELR
KAGNSYGLTF NGIQRMKIGA DSASSDVIIP DVVSRMPACH MRPHIIHPTT
KAGNSYGLTF NGIQRMKIGA DSASSDVIIP DVVSRMPACH MRPHIIHPTT
LDILLHTTLP LVHQKLGVGS VMPVHIRNMD VSADIESTPR KMFRVVTTLT
LDILLHTTLP LVHQKLGVGS VMPVHIRNMD VSADIESTPR KMFRVVTTLT
SSHARAADTE LFVFSEEGHV DDTPVVSAAG MELRSFVARD SNDAGSSDGH
SSHARAADTE LFVFSEEGHV DDTPVVSAAG MELRSFVARD SNDAGSSDGH
RDICSELKWI PDERFITAKH LQVLQPSILT KDALARCYAL MAQYLKQMAI
RDICSELKWI PDERFITAKH LQVLQPSILT KDALARCYAL MAQYLKQMAI
KHSDLSVLEL GGDDTTSGAT KTFLEVFHAG GTAPAMYDFC TSLKDFDVIQ
KHSDLSVLEL GGDDTTSGAT KTFLEVFHAG GTAPAMYDFC TSLKDFDVIQ
RKLEAFDCEK VHKVEMKRIE LDAVSENRYD VVLSCNTIYN AADVKSVLSH
RKLEAFDCEK VHKMEMKRIE LDAVSENRYD VVLSCNTIYN AADVKSVLSH
ARKLLKLDGV LLFVEDMSSR ESRSSSEWSK LMSEASFKMQ LAVTDNDATR
ARKLLKLDGV LLFVEDMSSR ESRSSSEWSK LMSEASFKMQ LAVTDNDATR
QLTFFATRAV EDAIASVHNV SIVSGCNLPL HIQNFLPQIE SELGSKGMQV
QLTFFATRAV EDAIASVHNV SIVSGCNLPL HIQNFLPQIE SELGSKGMQV
```

```
    TRSCWDKLPP NGTDIYIIVD DGSRPILSGI NQDRFRIVTG LLQKTARIIW
    TRSRWDKLPP NGTDIYIIVD DGSRPILSGI NQDRFRIVTG LLQKTARIIW
    LSVQDDETFR FNPRKHLITG LSRTAHAENE GLDMVTIDVQ ETLNQKTQPE
    LSVQDDETFR FNPRKHLITG LSRTAHAENE GLDMVTIDVQ ETLNQKTQPE
    VIGFLSQVVG LFDCKHITRE REYVYNGTDI LIPRLIPHQR LNLQVSGKIG
    VIGFLSQVVG LFDCKHITRE REYVYNGTDI LIPRLIPHQR LNLQVSGKIG
    TSIEAMAFTN SSVPLKLSDG QNRLVFVENM DHKQALCHDY VEIETKAVGL
TSIEAMAFTN SSVPLKLSDG QNRLVFVENM DHKQALCHDY VEIETKAVGL
PPGFNGVQSG NTVYEYAGII IAVGSEVSTL KAGDRAVAYS STPCANVLRV
PPGFNGVQSG NTVYEYAGII IAVGSEVSTL KAGDRAVAYS STPCANVLRV
PAIQAQLIPS NLSFKDAAAM PRALMAVSHA LVHIANVQPG QVVFVDDAAT
PAIQAQLIPS NLSFKDAAAM PRALMAVSHA LVHIANVQPG QVVFVDDAAT
EIGLAAICVA QNLGSTLIAA VSTKEEAAFI KNTFKVPSRH IVPRDSYFGQ
EIGLAAICVA QNLGSTLIAA VSTKEEAAFI KNTFKVPSRH IVPRDSYFGQ
RQVRTLVRPN GGLDVILGCG KSPVTAVTSE LLKPFGLLVH VRNRASDPKR
RQVRTLVRPN GGLDVILGCG KSPVTAVTSE LLKPFGLLVH VRNRASDPKR
YDGTGYPPNL TVASFDIDSL LQASTKNSAE LFQKVMEMVN RGMIPPSQSI
YDGTGYPPNL TVASFDIDSL LQASTKNSAE LFQKVMEMVN RGMIPPSQSI
VAIEAGIKIE EAISLAQKQG SMKKCVLEFN ENSIVNVETS FHHIPSLKPH
VAIEAGIKIE EAISLAQKQG SMKKCVLEFN ENSIVNVETS FHHIPSLKPH
ATYVVAGGLG DLGQRLLRLM AQAGARHLVS LSRKGAGSKE FRGLEKELKG
ATYVVAGGLG DLGQRLLRLM AQAGARHLVS LSRKGAGSKE FRGLEKELKG
VHPGCSLLAI DCDILREESV SAALAEIKQQ GFPTVKGVVQ SAVILKDATL
VHPGCSLLAI DCDILREESV SAALAEIKQQ GFPTVKGVVQ SAVILKDATL
DSMTAELFNS VVSVKAEGTL NLHRVFIQEE LAFFISFSSV MSIIGGKAQA
DSMTAELFNS VVSVKAEGTL NLHRVFIQEE LAFFISFSSV MSIIGGKAQA
NYNAGNAVQD AFAQFERRNP HCFYMSLNIG GIKDAAVNND AIVQSIRRQG
NYNAGNAVQD AFAQFERRNP HCFYMSLNIG GIKDAAVNND AIVQSIRRQG
LTQISHEELS SYLKYAFSDD ARKTGCKQPV IGFTAETIVS TTAVNGTAHT
LTQISHEELS SYLKYAFSDD ARKTGCKQPV IGFTAETIVS TTAVNGTAHT
PMFTHVRQKP TAKTTVGNVN EKRSFKDVVN SGTNKGEISE FVARSICDKI
PMFTHVRQKP TAKTTVGNVN EKRSFKDIVN SGTNKGEISE FVARSICDKI
ADLTGIDLAE VNLDSGISDY GLDSLVSIEL RNWLMREFDS PIQSSEVLDS
ADLTGIDLAE VNLDSGISDY GLDSLVSIEL RNWLMREFDS PIQSSEVLDS
HGIRDLAQKV VSRSRLVTTE TDVVHTVNGE APT
HGIRDLAQKV VSRSRLVTTE TDVVHTVNGE APT
Sat14, 455 aa
```

```
S40293 MATIPIRLQA LATDQTVLKL PHPYKTEFAV RKASNASTKL PVYNLVPKPF
S7711 MATIPIRLQA LATDQTVLKL PHPYKTEFAV RKASKASTKL PVYNLVPKPF
    PTRPLPFELH NDHLVFTDAI HLKSSELPPD SNNGAWARAR RAPCVTLYWD
    PTRPLPFELH NDHLVFTDAI HLKSSELPPD SNNGAWARAR RAPCVTLYWD
    GVEVPTLKQA WLVVYAFFTM RPGMDSFRLE LDGNSAANLA RQIKDVLLGI
    GVEVPTLKQA WLVVYAFFTM RPGMDSFRLE LDGNSAANLA RQIKDVLLGI
    DHPIKARQQQ EPCAKTKENT LLILRSTFWQ GAGCPFGPRP VWCPQESPSS
    DHPIKARQQQ EPCAKTKENT LLILRSTFWQ GAGCPFGPRP VWCPQESPSS
    LLPSTCLSSF PLAPFHRTST ISLAGDPEDF DRCQQSWHPI RPAKPAPGSI
    LLPSTCLSSF PLAPFHRTST ISLAGDPEDF DRCQQSWHPI RPAKPAPGSI
    IYSRWIPYLG EMFSMVALDP EDSEHVRLFH EWQSDPRVLQ GWTETKTLDQ
    IYSRWIPYLG EMFSMVALDP EDSEHVRLFH EWQSDPRVLQ GWTETKTLDQ
    HRRYLEALHK DPHQLTVLAK WDDSPFAYFE LYWAKENRLG GYIDAGDFDR
        HRRYLEALHK DPHQLTVLAK WDDSPFAYFE LYWAKENRLG GYIDAGDFDR
        GRHSFVGDVR FRGPLRVSAW WSSLMHYLFL DDPRTMYIVG EPRDTHSTVL
        GRHSFVGDVR FRGPLRVSAW WSSLMHYLFL DDPRTMHIVG EPRDTHSTVL
        MYDFIHGFGL DRFIDLPSKR SAFMRCSRDR FFQSFPLEDS EKVIGGTSIR
        MYDFIHGFGL DRFIDLPSKR SAFMRCSRDR FFQSFPLEDS EKVIGGTSIR
    VVQKL
    VVQKL
Sat15, 153 aa
S40293 MTTPPGWKVS GQNEISRPFD ILEAWFHRIV GGGNLTRERD SFGSNYVVKL
S7711 MTTPPGWKVS GQNEISRPFD ILEAWFHRIV GGGNLTRERD SFGSNYVVKL
    GFPGSVADPI PYLRRAWLVT RYLHPQLGAT YSSKSLDDLR YIIRPLDEQI
    GFPGSVADPI PYLRRAWLVT RYLHPQLGAT YSSKSLDDLR YIIRPLDEQI
    WLQTTFFVEQ GPSATYSSAE DAVSKYLSKS TTTAHWIPAT SEFMISPTAS
    WLQTTFFVEQ GPSATYSSAE DAVSKYLSKS TTTAHWIPAT SEFMISPTAS
    SPL
    SPL
Sat16, 184 aa
S40293 ---------- ---------- ---------- -------------------------
S7711 MVELNPVTIT NDNATPRGHV LKLILVESRD IIRAVKTRLC PQYTISYLAQ
    ------MLDT YSSKSELSKP DFFVALTAVN GRRYLREDLE SNYLAGYVTG
    AATVIAMLDT YSSKSELSKP DFFVALTVVN GRRYLREDLE SNYLAGYVTG
    APIKIEKLRS LLVSLDDSKD IIVSALEKAA KDAKRRLDMW IYDQSQLATG
    APIKIEKLRS LLVSLDDSKD IIVSALEKAA KDAKRRLDMW IYDQSQLATG
    FRIHSFKGAM SSENPELFIK TAVPYLSSYG INEV
    FRIHSFKGAM SSENPELFKK TAVPYLSSYG INEV
```


## Satratoxin cluster 3, 5 products

```
Sat17, 393 aa
S40293 MAASPVLATT SHPIGHEAAV VTDADLDRHY AVKLAGKLND EMAWVGQQFT
S7711 MAASPVLATT SHPIGHEAAV VTDADLDRHY AVKLAGKLND EMAWVGQQFT
    GEEDFVVCLS EADVAEVNAA LTAFQGMFLK PDYYTGLKPG YLSPETFKLP
    GEEDFVVCLS EADVAEVNAA LTAFQD---- ----TGLKPG YLSPETFKLP
    KLGPKLRLLS QRIHEQEGFI VLRGLQPWRY RRLENTIVFT GIASYIGNRR
    KLGPKLRLLS QRIHEQEGFI VLRGLQPWRY RRLENTIVFT GIASYIGNRR
    GVQCADGPVM THIFDYSTEV EEKEKLNDGY LGHANRTSYL PFHTDDGHII
    GVQCADGPVM THIFDYSTEV EEKEKLNDGY LGHANRTSYL PFHTDDGHII
    SLYCLQAADI GGRTLLASSH AIYNHLLETR PDVIETLKEE WIWDSFIPEK
        SLYCLQAADI GGRTLLASSH AIYNHLLETR PDVIETLKEE WIWDSFIPEK
        PSFIRPLLLE QDGKLICNYR IRPFLGTPGY PRNAALGPLP AHQEEALNTV
        PSFIRPLLLE QDGKLICNYR IRPFLGTPGY PRNAALGPLP AHQEEALNTV
        AEIAEKLSLK FEFKTGDIQF LNNLSILHAR EEFHCAKGDT TRRHLLRLVQ
        AEIAEKLSLK FEFKTGDIQF LNNLSILHAR EEFHCAKGDT TRRHLLRLVQ
        MDDELAWRLP PGLSKDMDKM FQHDLEEEKF IWSPEPL--- ---
        MDDELAWRLP PGLSKDMDKM FQHDLEEEKF IWSPEPLPYV IGQ
Sat18, 401 aa
S40293 MKLVEIAEDI LSKANAYTNN TGLTSSQRFQ LREEIRYQAN GILSAIDGPE
S7711 MKLVEIAEDI LSKANAYTNN TGLTSSQRFQ LREEIRYQAN GILSAIDGPE
    QTMKAIARSY TTCTALKVCV DLKLASHLPL SDARSLSQLA QICGCDSRVL
    QTMKAIARSY TTCTALKVCV DLKLASHLPL SDARSLSQLA QICGCDSLVL
    RPMLRLLAKN GIFEQVDAET WQHTELSAVM AQPPFQALEE KYRSVAHLPR
    RPMLRLLAKN GIFEQVDAET WQHTELSAVM AQPPFQALEE KYRSVAHLPR
    LLQAVSHQFP TPGRTAFNQV YCTSLDFYTY SNELDHAAAR NFAFSMKELA
    LLQAVSHQFP TPGRTAFNQV YCTSLDFYTY SNELDHAAAR NFAFSMKELA
    RNQIPFVQQS YPLETIDPES HFIDVAGGVG YLSFFLAGSF PKATFEVQDH
    RNQIPFVQQS YPLETIDPES HFIDVAGGVG YLSFFLAGSF PKATFEVQDH
    PFIIEEAHSV CPSELRDRIT FRAHNILHPQ PEIAKEINGR LVFLVKIILH
    PFIIEEAHSV CPSELRDRIT FRAHNILHPQ PEIAKEINGR LVFLVKIILH
    DHGDDDCRLM LRNLVSVMKQ GDRILIIDTV IPETGGSLSS ANSDIIIMSM
    DHGDDDCRLM LRNLVSVMKQ GDRILIIDTV IPETGGSLSS ANSDIIIMSM
    FGSGHRTLEE FRALIHHCGE DLVIETFASG DEEYDGMMVI EVRKAEPVLD
    FGSGHRTLEE FRALIHRCGE DLVIETFASG DEEYDGMMVI EVRKAEPVLD
```

```
        N
        N
Sat19, 230 aa
S40293 MATATPPPQD FPPYPPFTSL RLAAARDVAQ MANLSVQGFK DSEIFRYERP
S7711 MATATPPPQD FPPYPPFTSL RLAAARDVAQ MANLSVQGFK DSEIFRYERP
    GHDQYPEDAV AYFANLYRDR LEDPRAVVIV AEDWDGAERV VVGVGCWILP
    GHDQYPEDAV AYFANLYRDR LEDPRAVVIV AEDWDGAERV VVGVGCWILP
    QDSPRTGQFV VPCVGDREPA LDRDLCCRRL ELFNAVTKAT EERYLDGKVI
    QDSPRTGQFV VPCVGDREPA LDRDLCCRRL ELFNAVTKAT EERYLDGKVI
    CDKFVVHPSY QRRGHGTAML RWSLRLCTQD TVDQGVIPSH VGEPVYLSLG
    CDKFVVHPSY QRRGHGTAML RWSLRLCTQD TVDQGVIPSH VGEPVYLSLG
    FEVIGEMHVP DEGDTQGFTQ RVAVYKARQT
    FEVIGEMHVP DEGDTQGFTQ RVAVYKARQT
Sat20, 712 aa
S40293 MPNLPGSSDS TQRHQRNPGI DELVCSSTKP NAAQENADTE LAQEKHPQLL
S7711 MPNLPGSSDS TQRHQRNPGT DELVCSSTKP NAAQENADTE LAQEKHPQLL
    SPQTDIPPVC SQPNVSFAQW WDQNFFLDAA LTG------- ---------HM
    SPQTDIPPVC SQPNVSFAQC WDQNFFLDAA LTGQNSMTLL GVFDLPNSHM
    NLTETLSSQL GLEPSQNAFG QSSFDPFFPS SEPSVHSTDN PWPSLPTQLA
    NLTETLSSQL GLEPSQNAFG QGSFDPFVPS SEPSVHSTDN PWPSLPTQLA
    FQPTNNNTSS LALLGPDPEQ LSTLPSPWTG PLEEWPPLDL GQDFAALLSP
    FQPTNNNTSS LALLGPDPEQ LSTLPSSWTG PLDEWPPLDL GQDFAALLSP
    TYQALEATPR HTHAHAHQPP RATRHITSQQ SPEPYVQVHS TAKIVDRFLV
    TYQAFEATPR HTHAHAHQPP RATRHITSQQ SPEPYVQVHS TAKIVDRFLV
    PIAPKPILVE RDGPVSGASL PSNPPTALSS TGTRKRKRFN KADRERVNQM
    PIAPKPILVE RDGPVSGASL PSNPPTALSS TGTRKRKRFN KADRERVNQM
    RKLGSCFRCR MYKENCDPGL PCKNCMRVQV TRRTFFGPCI RIKWEEVHTF
    RKLGSCFRCR MYKENCDPGL PCKNCMRVQV TRRTFFGPCI RIKWEEVHTF
    RAGDGDLGQI RATLQTFQWT LGGQVKSIDV QWPFRDDKVK PPILSIECQQ
    RAGDGDLGQI RATLQTFQWT LGGQVKSIDV QWPFRDDKVK PPILSIECQQ
    FLPKHEHVAE EYSVAGQAYK ILLPPWACSN TKAASKKVEA FVRQCQAPLE
FLPKHEHVAE EYSVAGQAYK ILLPPWACSN TKAASKKVEA FVRQCQAPLE
EEIRHTLNDP ILLLTLDEAR RYRNETGSKL VATALEIYAG AMMNSRYPAS
EEIRHTLNDP ILLLTLDEAR RYRNETGSKL VATALEIYAG AMMNSRYPAS
TESDIFGVVD QLHTPYFFDK VPLPPQLTCQ IQIMVAQVML DKQKNALKRL
TESDIFGVVD QLHTPYFFDK VPLPPQLTCQ IQIMVAQVML DKQKNALKRL
QERALSKNRH KVWYECYLTI FILLATIELV YQVQLRFVKA KQGVSDRNAT
QERALSKNRH KVWYECYLTI FILLATIELV YQVQLRFVKA KQGVSDRNAT
```

```
        NLSYVTQYMI EEWEESILTL VGLFHCVMNG GLPFTQSWED GGENHRLTEL
        NLSYVTQYMI EEWEESILTL VGLFHCVMNG GLPFTQSWED GGENHRLTEL
        DDKALVYVRS LKAEIEQRRG ELIALRNRRG RWRYEQPLAA ICQLFLPSQD
        DDKALVYVRS LKAEIEQRRG ELIALRNRRG RWRYEQPLAA ICQLFLPSQD
    GDKGEGRAAP PS
    GDKGEGRAAP PS
Sat21, 474 aa
S40293 MLRNTHLVVP FILYLLFRLS HFLLEVPTVR MIELAACHQH LRLDHGPLNE
S7711 MLRNTHLVLP FILYLLFRLS HFLLEVPTVR MIELAACHQH LRLDHGPLNE
    AACKTPPVQE HVSLVVGWKM TFDSIPGLMS ILYFGTLADK SGHRAILRLC
    AACKTPPVQE HVSLVVGWKM TFDSIPGLMS ILYFGTLADK SGHRAILRLC
    CVGYLLAILW VLITCLFHQV FPVELVLLSS LFLFIGGGQL VFAAVITAFV
    CVGYLLAILW VLITCLFHQV FPVELVLLSS LFLFIGGGQL VFAAVITAFV
    ADLFPPPSRT KFLFLLAAMP HMDKVASPAL ATKLMEQNLF LPSLVSMAIV
    ADLFPPPSRT KFLFLLAAMP HMDKVASPAL ATKLMEQNLF LPSLVSMAIV
    VICVALLQMS DVGRETAASK VVGSTSDQTE PFLRSSSNSS QESGTAAPAI
    VICVALLQMS DVGRETAASK VVGSTSDQTE PFLRSSSNSS QESGTAAPAI
    DPEQARGPFR QLKNIICWVY REPVLFICYL CFFLKSNAMA SEAFIFQYLS
    DPEQARGPFR QLKNIICWVH REPVLFICYL CFFLKSNAMA SEAFIFQYLS
    EKFGWPLRET TVMRLALSSG AVISTLIICP LANATLHNRG VASARINIGA
    EKFGWPLRET TVMRLALSSG AVISTLIICP LANATLHNRG VASARINIGA
    VHASSIVLVA SFIMAWQASS STAFIFSMLA AGFGEGLEPA LQGVLAAASQ
    VHASSIVLVA SFIMAWQASS STAFIFSMLA AGFGEGLEPA LQGVLAAASQ
    TKAKGSIFAL MCTCSLLGDM TGGPLMSALM SIGRGGNGVS DGYCFLASAL
    TKAKGSIFAL MCTCSLLGDM TGGPLMSALM SIGRGGNGVS DGYCFLASAL
    VFGAVIVLAH LLWALGAEEM LGED
    VFGAVIVLAH LLWALGAEEM LGED
```


## APPENDIX G (Chapter 2)

## Parameters used in Stachybotrys genome annotation

This appendix shows the two parameter files, maker_opts.ctl and maker_bopts.ctl, that were used by MAKER during the second and final pass of our annotation. These specific files were used for strain 7711, but parameters were the same for the other three assemblies.

## maker_opts.ctl

```
#-----Genome (these are always required)
genome=$HOME/sch/genomes03/S7711-1e3.fa #genome sequence (fasta file or
fasta embeded in GFF3 file)
organism_type=eukaryotic #eukaryotic or prokaryotic. Default is
eukaryotic
```

\#-----Re-annotation Using MAKER Derived GFF3
maker_gff=/home/jrs/sch/makers14.1/S7711/genome2.gff \#MAKER derived
GFF3 file
est_pass=0 \#use ESTs in maker_gff: 1 = yes, $0=$ no
altest pass=0 \#use alternate organism ESTs in maker gff: $1=y e s, 0=$
no
protein_pass=0 \#use protein alignments in maker_gff: $1=$ yes, 0 = no
rm_pass=0 \#use repeats in maker_gff: 1 = yes, 0 = no
model_pass=1 \#use gene models in maker_gff: 1 = yes, $0=$ no
pred pass=0 \#use ab-initio predictions in maker gff: $1=$ yes, $0=$ no
other_pass=0 \#passthrough anyything else in maker_gff: $1=y e s, 0$ = no
\#-----EST Evidence (for best results provide a file for at least one)
est= \#set of ESTs or assembled mRNA-seq in fasta format
altest= \#EST/cDNA sequence file in fasta format from an alternate
organism
est_gff= \#aligned ESTs or mRNA-seq from an external GFF3 file
altest_gff= \#aligned ESTs from a closly relate species in GFF3 format
\#-----Protein Homology Evidence (for best results provide a file for at
least one)
protein=/home/jrs/sch/one.fa:S40285,/home/jrs/sch/two.fa:S40288,/home/j
rs/sch/three.fa:S40293,/home/jrs/fusarium/fgdb/FGDB_v32.prot:f_graminea
rum,/home/jrs/fusarium/fusarium_oxysporum_f._sp._lycopersici_4287_2_pro
teins.fasta:f oxysporum,/home/jrs/fusarium/fusarium verticil̄íioides 760
0_3_proteins. $\bar{f} a s t a: f$ verticillioides,/home/jrs/h4/d̄̄/uniprot_sprot. $\bar{f} a s t$
a:swiss \#protein sequence file in fasta format (i.e. from mutiple
oransisms)
protein_gff= \#aligned protein homology evidence from an external GFF3
file
\#-----Repeat Masking (leave values blank to skip repeat masking)
model_org=all \#select a model organism for RepBase masking in
RepeatMasker
rmlib= \#provide an organism specific repeat library in fasta format for
RepeatMasker
repeat_protein=/home/jrs/maker-2.26-beta/data/te_proteins.fasta
\#provide a fasta file of transposable element proteins for RepeatRunner
rm_gff= \#pre-identified repeat elements from an external GFF3 file
prok_rm=0 \#forces MAKER to repeatmask prokaryotes (no reason to change
this), $1=$ yes, $0=$ no

```
softmask=1 #use soft-masking rather than hard-masking in BLAST (i.e.
seg and dust filtering)
#-----Gene Prediction
snaphmm= #SNAP HMM file
gmhmm=$HOME/sch/gm01/mod/es.mod #GeneMark HMM file
augustus_species=fusarium_graminearum #Augustus gene prediction species
model
fgenesh_par_file= #FGENESH parameter file
pred_gff= #ab-initio predictions from an external GFF3 file
model_gff= #annotated gene models from an external GFF3 file
(annotation pass-through)
est2genome=0 #infer gene predictions directly from ESTs, 1 = yes, 0 =
no
protein2genome=0 #infer predictions from protein homology, 1 = yes, 0 =
no
unmask=0 #also run ab-initio prediction programs on unmasked sequence,
1 = yes, 0 = no
#-----Other Annotation Feature Types (features MAKER doesn't recognize)
other gff= #extra features to pass-through to final MAKER generated
GFF3 file
#-----External Application Behavior Options
alt_peptide=C #amino acid used to replace non-standard amino acids in
BLAST databases
cpus=1 #max number of cpus to use in BLAST and RepeatMasker (not for
MPI, leave 1 when using MPI)
#-----MAKER Behavior Options
max_dna_len=1000000000 #length for dividing up contigs into chunks
(increases/decreases memory usage)
min_contig=1 #skip genome contigs below this length (under 10kb are
often useless)
pred_flank=200 #flank for extending evidence clusters sent to gene
predīctors
pred_stats=1 #report AED and QI statistics for all predictions as well
as models
AED_threshold=1 #Maximum Annotation Edit Distance allowed (bound by 0
and 1)
min_protein=0 #require at least this many amino acids in predicted
proteins
alt_splice=0 #Take extra steps to try and find alternative splicing, 1
= yes, 0 = no
always_complete=0 #extra steps to force start and stop codons, 1 = yes,
0 = no
map_forward=1 #map names and attributes forward from old GFF3 genes, 1
= yēs, 0 = no
```

```
keep_preds=1 #Concordance threshold to add unsupported gene prediction
(bound by 0 and 1)
split_hit=10000 #length for the splitting of hits (expected max intron
size for evidence alignments)
single_exon=0 #consider single exon EST evidence when generating
annotations, 1 = yes, 0 = no
single_length=250 #min length required for single exon ESTs if
'single_exon is enabled'
correct_est_fusion=0 #limits use of ESTs in annotation to avoid fusion
genes
tries=2 #number of times to try a contig if there is a failure for some
reason
clean try=0 #remove all data from previous run before retrying, 1 =
yes, \overline{0}= no
clean_up=0 #removes theVoid directory with individual analysis files, 1
= yes, 0 = no
TMP=/home/jrs/h9/tmp #specify a directory other than the system default
temporary directory for temporary files
```


## maker_bopts.ctl

```
#-----BLAST and Exonerate Statistics Thresholds
blast_type=ncbi+ #set to 'ncbi+', 'ncbi' or 'wublast'
pcov blastn=0.8 #Blastn Percent Coverage Threhold EST-Genome Alignments
pid_\overline{blastn=0.85 #Blastn Percent Identity Threshold EST-Genome Aligments}
eval blastn=1e-10 #Blastn eval cutoff
bit_blastn=40 #Blastn bit cutoff
depth_blastn=0 #Blastn depth cutoff (0 to disable cutoff)
pcov_blastx=0.2 #Blastx Percent Coverage Threhold Protein-Genome
Alignments
pid_blastx=0.2 #Blastx Percent Identity Threshold Protein-Genome
Aligments
eval_blastx=1e-06 #Blastx eval cutoff
bit_blastx=30 #Blastx bit cutoff
depth_blastx=0 #Blastx depth cutoff (0 to disable cutoff)
pcov_tblastx=0.8 #tBlastx Percent Coverage Threhold alt-EST-Genome
Alignments
pid_tblastx=0.85 #tBlastx Percent Identity Threshold alt-EST-Genome
Aligments
eval tblastx=1e-10 #tBlastx eval cutoff
bit tblastx=40 #tBlastx bit cutoff
depth_tblastx=0 #tBlastx depth cutoff (0 to disable cutoff)
pcov_rm_blastx=0.5 #Blastx Percent Coverage Threhold For Transposable
Element Masking
pid_rm_blastx=0.4 #Blastx Percent Identity Threshold For Transposbale
Element Masking
eval_rm_blastx=1e-06 #Blastx eval cutoff for transposable element
masking
bit_rm_blastx=30 #Blastx bit cutoff for transposable element masking
ep_score_limit=20 #Exonerate protein percent of maximal score threshold
en_score_limit=20 #Exonerate nucleotide percent of maximal score
th\overline{reshol\overline{d}}\mathbf{}/\mp@code{l}
```


## BIBLIOGRAPHY

Alexander NJ, McCormick SP, Hohn TM (1999) TRI12, a trichothecene efflux pump from Fusarium sporotrichioides: gene isolation and expression in yeast. Mol Gen Genet 261:977-984.

Arnaud MB, Cerqueira GC, Inglis DO, Skrzypek MS, Binkley J, et al (2012) The Aspergillus Genome Database (AspGD): recent developments in comprehensive multispecies curation, comparative genomics and community resources. Nucleic Acids Res 40:D653659.

Arnold K, Bordoli L, Kopp J, Schwede T (2005) The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling. Briefings Bioinf 22:195-201.

Adachi J, Hasegawa M (1996) MOLPHY version 2.3: Programs for molecular phylogenetics based on maximum likelihood. Computer Science Monographs. Tokyo: Institute of Statistical Mathematics, 28:1-150.

Andersen B, Nielsen KF, Jarvis BB (2002) Characterization of Stachybotrys from waterdamaged buildings based on morphology, growth and metabolite production. Mycologia 94:392-403.

Andersen B, Nielsen KF, Thrane U, Szaro T, Taylor JW, Jarvis BB (2003) Molecular and phenotypic descriptions of Stachybotrys chlorohalonata sp. nov. and two chemotypes of Stachybotrys chartarum found in water-damaged buildings. Mycologia 95:1227-1238.

Angiuoli SV, Salzberg SL (2011) Mugsy: fast multiple alignment of closely related whole genomes. Bioinformatics 27:334-342.

Belville C, Jamin SP, Picard J-Y, Josso N, di Clemente N (2005) Role of type I receptors for anti-Müllerian hormone in the SMAT-1 Sertoli cell line. Oncogene 24:4984-4992.

Belville C, Maréchal J-D, Pennetier S, Carmillo P, Masgrau L, et al (2009) Natural mutations of the anti-Müllerian hormone type II receptor found in persistent Müllerian duct syndrome affect ligand binding, signal transduction and cellular transport. Hum Mol Genet 18:3002-3013.

Bininda-Emonds OR, Cardillo M, Jones KE, MacPhee RD, Beck RM, et al. (2007) The delayed rise of present-day mammals. Nature 446:507-512.

Blom N, Gammeltoft S, Brunak S (1999) Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 294:1351-1362.

Boeckmann B, Bairoch A, Apweiler R, Blatter M-C, Estreicher A, et al. (2003) The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nuc Acids Res 31:365-370.

Brown DW, Dyer RB, McCormick SP, Kendra DF, Plattner RD (2004) Functional demarcation of the Fusarium core trichothecene gene cluster. Fungal Genet Biol 41:454-462.

Burns DS, Jimenez-Krassel F, Ireland JL, Knight PG, Ireland JJ (2005) Numbers of antral follicles during follicular waves in cattle: evidence for high variation among animals, very high repeatability in individuals, and an inverse association with serum follicle-stimulating hormone concentrations. Biol Reprod 73:54-62.

Cardoza RE, Malmierca MG, Hermosa MR, Alexander NJ, McCormick SP, et al (2011) Identification of loci and functional characterization of trichothecene biosynthesis genes in filamentous fungi of the genus Trichoderma. Appl Environ Microbiol 77:4867.

Cherry JM, Adler C, Ball C, Chervitz SA, Dwight SS, et al (1998) SGD: Saccharomyces Genome Database. Nucleic Acids Res 26:73-79.

Cox RJ (2007) Polyketides, proteins and genes in fungi: programmed nano-machines begin to reveal their secrets. Org Biomol Chem 5:2010-2026.

Cruse M, Telerant R, Gallagher T, Lee T, Taylor JW (2002) Cryptic species in Stachybotrys chartarum. Mycologia 94:814-822.

Degenkolb T, Dieckmann R, Nielsen KF, Gräfenhan T, Theis C, et al (2008) The Trichoderma brevicompactum clade: a separate lineage with new species, new peptaibiotics, and mycotoxins. Mycol Progress 7:177-219.
de Magalhães JP, Budovsky A, Lehmann G, Costa J, Li Y, et al (2009) The Human Ageing Genomic Resources: Online databases and tools for biogerontologists. Aging Cell 8:65-72.
de Magalhães JP, Costa J (2009) A database of vertebrate longevity records and their relation to other life-history traits. J Evol Biol 22:1770-1774.
de Magalhães J, Costa J, Church G (2007) An Analysis of the Relationship Between Metabolism, Developmental Schedules, and Longevity Using Phylogenetic Independent Contrasts. J Gerontol A Biol Sci Med Sci 62:149-160.
di Clemente N, Wilson C, Faure E, Boussin L, Carmillo P, et al (1994) Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone. Mol Endocrinol 8:1006-1020.

Durlinger ALL, Visser JA, Themmen APN (2002) Regulation of ovarian function: The role of anti-Müllerian hormone. Reproduction 124:601-609.

Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, et al (2007) Comparative protein structure modeling using MODELLER. Curr Protoc Protein Sci pp 2.9.1-2.9.31.

Huang DW, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nuc Acid Res 37:1-13.

Finch CE (1990) Longevity, Senescence, and the Genome. Chicago: University of Chicago Press. 922 p.

Finch CE, Gosden RG (1986) Animal models for the human menopause. In: Mastroianni L, Paulsen CA, editors. pp 3-34. New York: Plenum.

Foote A (2008) Mortality rate acceleration and post-reproductive lifespan in matrilineal whale species. Biol Lett 4:189-191.

Fraaije MW, Kamerbeek NM, van Berkel WJH, Janssen DB (2002) Identification of a Baeyer-Villiger monooxygenase sequence motif. FEBS Lett 518:43-47.

Freckleton RP, Harvey PH, Pagel M (2002) Phylogenetic analysis and comparative data: A test and review of evidence. Am Naturalist 160:712-726.

Gnerre S, MacCallum I, Przybylski D, Ribeiro FJ, Burton JN, et al (2011) High-quality draft assemblies of mammalian genomes from massively parallel sequence data. Proc Nat Acad Sci USA 108:1513-1518.

Goldsmith EJ, Akella R, Min X, Zhou T, Humphreys JM (2007) Substrate and docking interactions in serine/threonine protein kinases. Chem Rev 107:5065-5081.

Gorelick PB (2004) Risk factors for vascular dementia and Alzheimer disease. Stroke 35:2620-2622.

Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O (2010). New algorithms and methods to estimate maximum-likelihood phylogenies: Assessing the performance of PhyML 3.0. Systematic Biol 59:307-321.

Henikoff S, Henikoff JG (1992) Amino acid substitution matrices from protein blocks. Proc Nat Acad Sci USA 89:10915-10919.

Hinkley SF, Mazzola EP, Fettinger JC, Lam Y-F, Jarvis BB (2000) Atranones A-G, from the toxigenic mold Stachybotrys chartarum. Phytochemistry 55:663-673.

Hiramoto-Yamaki N, Takeuchi S, Ueda S, Harada K, Fujimoto S, et al. (2010) Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent mechanism. J Cell Biol 190: 461-477.

Holt C, Yandell M (2011) MAKER2: an annotation pipeline and genome-database management tool for second-generation genome projects. BMC Bioinformatics 12:491.

Imbeaud S, Faure E, Lamarre I, Mattei M-G, di Clemente N, et al (1995) Insensitivity to anti-mullerian hormone due to a mutation in the human anti-mullerian hormone receptor. Nature Genet 11:382-388.

Jaiswal RS, Singh J, Adams GP (2009) High-resolution ultrasound biomicroscopy for monitoring ovarian structures in mice. Reprod Biol Endocrinol 7:69.

Jarvis BB, Lee YW, Cömezoglu SN, Yatawara CS (1986) Trichothecenes produced by Stachybotrys atra from Eastern Europe. Appl Environ Microbiol 51:915-918.

Jarvis BB (2003) Stachybotrys chartarum: a fungus for our time. Phytochemistry 64:5360.

Jobson RW, Nabholz B, Galtier N (2010) An evolutionary genome scan for longevityrelated natural selection in mammals. Mol Biol Evol 27:840-847.

Jones DT (1999) Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol 292:195-202.

Kanapuru B, Ershler WB (2009) Inflammation, coagulation, and the pathway to frailty. Am J Med 122:605-613.

Katoh K, Toh H (2008) Recent developments in the MAFFT multiple sequence alignment program. Brief Bioinf 9:286-298.

Keller NP, Turner G, Bennett JW (2005) Fungal secondary metabolism -- from biochemistry to genomics. Nat Rev Microbiol 3:937-947.

Kelley DR, Schatz MC, Salzberg SL (2010) Quake: quality-aware detection and correction of sequencing errors. Genome Biol 11:R116.

Kevenaar ME, Themmen APN, Rivadeneira F, Uitterlinden AG, Laven JSE, et al (2007) A polymorphism in the AMH type II receptor gene is associated with age at menopause in interaction with parity. Hum Reprod 22:2382-2388.

Kim EB, Fang X, Fushan AA, Huang Z, Lobanov AV, et al. (2011) Genome sequencing reveals insights into the physiology and longevity of the naked mole rat. Nature 479:223-227.

Kirkwood T (1977) Evolution of ageing. Nature 270:301-304.
Knighton DR, Zheng J, TenEyck LF, Ashford VA, Xuong N-H, et al (1991) Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253:407-414.

Kroken S, Glass NL, Taylor JW, Yoder OC, Turgeon BG (2003) Phylogenomic analysis of type I polyketide synthase genes in pathogenic and saprobic ascomycetes. Proc Nat Acad Sci USA 100:15670-15675.

Kubicek CP, Herrera-Estrella A, Seidl-Seiboth V, Martinez DA, Druzhinina IS, et al (2011) Comparative genome sequence analysis underscores mycoparasitism as the ancestral life style of Trichoderma. Genome Biol 12:R40.

Kuhn DM, Ghannoum MA (2003) Indoor mold, toxigenic fungi, and Stachybotrys chartarum: infectious disease perspective. Clin Microbiol Rev 16:144-172.

Lapointe J, Hekimi S (2009) When a theory of aging ages badly. Cell Mol Life Sci 67:18.

Li L, Stoeckert CJ Jr, Roos DS (2003) OrthoMCL: identification of ortholog groups for eukaryotic genomes. Genome Res 13:2178-2189.

Li R, Zhu H, Ruan J, Qian W, Fang X, et al (2010) De novo assembly of human genomes with massively parallel short read sequencing. Genome Res 20:265-272.

Li S, Hartman GL, Jarvis BB, Tak H (2002) A Stachybotrys chartarum isolate from soybean. Mycopathologia 154:41-49.

Li Y, de Magalhães J (2011) Accelerated protein evolution analysis reveals genes and pathways associated with the evolution of mammalian longevity. AGE:1-14. doi:springerlink. pp. 10.1007/s11357-011-9361-y.

Ma L-J, van der Does HC, Borkovich KA, Coleman JJ, Daboussi M-J, et al (2010) Comparative genomics reveals mobile pathogenicity chromosomes in Fusarium. Nature 2010, 464:367-373.

Marchler-Bauer A, Lu S, Anderson JB, Chitsaz F, Derbyshire MK, et al (2011) CDD: a Conserved Domain Database for the functional annotation of proteins. Nucleic Acids Res 39:D225-229.

Mason JM, Arndt KM (2004) Coiled coil domains: Stability, specificity, and biological implications. ChemBioChem 5:170-176.

Massingham T, Goldman N (2012) All Your Base: a fast and accurate probabilistic approach to base calling. Genome Biol 13:R13.

Manev H, Uz T, Sugaya K, Qu T (2000) Putative role of neuronal 5-lipoxygenase in an aging brain. FASEB J 14:1464-1469.

McCormick SP, Alexander NJ (2002) Fusarium Tri8 encodes a trichothecene C-3 esterase. Appl Environ Microbiol 68:2959-2964.

McCormick SP, Stanley AM, Stover NA, Alexander NJ (2011) Trichothecenes: from simple to complex mycotoxins. Toxins (Basel) 3:802-814.

Orme D, Freckleton R, Thomas G, Petzoldt T, Fritz S, et al (2011) Accessed 19 Feb 2013. caper: Comparative Analyses of Phylogenetics and Evolution in R. Available:http://cran.r-project.org/web/packages/caper/index.html.

Palma GA, Argañaraz ME, Barrera AD, Rodler D, Mutto AA, Sinowatz F (2012) Biology and Biotechnology of Follicle Development. Sci World J 2012:938138. doi:10.1100/2012/938138.

Parra G, Bradnam K, Korf I (2007) CEGMA: a pipeline to accurately annotate core genes in eukaryotic genomes. Bioinformatics 23:1061-1067.

Pei J, Grishin NV (2001) AL2CO: Calculation of positional conservation in a protein sequence alignment. Bioinformatics 17:700-712.

Pérez VI, Buffenstein R, Masamsetti V, Leonard S, Salmon AB, et al (2009) Protein stability and resistance to oxidative stress are determinants of longevity in the longest-living rodent, the naked mole-rat. Proc Nat Acad Sci USA 106:30593064.

Pestka JJ, Yike I, Dearborn DG, Ward MDW, Harkema JR (2008) Stachybotrys chartarum, trichothecene mycotoxins, and damp building-related illness: new insights into a public health enigma. Toxicol Sci 104:4-26.

Qu T, Uz T, Manev H (2000) Inflammatory 5-LOX mRNA and protein are increased in brain of aging rats. Neurobiol Aging 21:647-652.

Ranwez V, Delsuc F, Ranwez S, Belkhir K, Tilak M, et al (2007) OrthoMaM: A database of orthologous genomic markers for placental mammal phylogenetics. BMC Evol Biol 7:241.

Rose MR (1984) Laboratory evolution of postponed senescence in Drosophila melanogaster. Evolution 38:1004-1010.

Semeiks J, Grishin NV (2012) A method to find longevity-selected positions in the mammalian proteome. PLoS ONE 7(6): e 38595. doi:10.1371/journal.pone. 0038595.

Semeiks J, Borek D, Otwinowski Z, Grishin NV (2013) Comparative genome sequencing of the toxigenic black mold Stachybotrys. Manuscript submitted for publication.

Sempowski GD, Hale LP, Sundy JS, Massey JM, Koup RA, et al (2000) Leukemia inhibitory factor, Oncostatin M, IL-6, and stem cell factor mRNA expression in human thymus increases with age and is associated with thymic atrophy. J Immunol 164:2180-2187.

Shi C, Smith ML, Miller JD (2011) Characterization of human antigenic proteins SchS21 and SchS34 from Stachybotrys chartarum. Int Arch Allergy Immunol 155:74-85.

Simpson JT, Wong K, Jackman SD, Schein JE, Jones SJM, Birol I (2009) ABySS: a parallel assembler for short read sequence data. Genome Res 19:1117-1123.

Speakman JR (2005) Correlations between physiology and lifespan - two widely ignored problems with comparative studies. Aging Cell 4:167-175.

Spiering MJ, Moon CD, Wilkinson HH, Schardl CL: Gene clusters for insecticidal loline alkaloids in the grass-endophytic fungus Neotyphodium uncinatum. Genetics 2005, 169:1403-1414.

Spröte P, Hynes MJ, Hortschansky P, Shelest E, Scharf DH, et al (2008) Identification of the novel penicillin biosynthesis gene aatB of Aspergillus nidulans and its putative evolutionary relationship to this fungal secondary metabolism gene cluster. Mol Microbiol 70:445-461.

Stetson PD, Ball EV, Mort M, Phillips AD, Shiel JA, et al (2003) Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 21:577-581.

Suhre K, Claverie J-M (2003) Genomic correlates of hyperthermostability, an update. J Biol Chem 278:17198-17202.

Voorhuis M, Broekmans FJ, Fauser BCJM, Onland-Moret NC, van der Schouw YT (2011) Genes involved in initial follicle recruitment may be associated with age at menopause. J Clin Endo Metab 96:E473-E479.

Walker M, Herndon J (2008) Menopause in nonhuman primates? Biol Reproduction 79:398-406.

Ward E, Parsons K, Holmes E, Balcomb III K, Ford J (2009) The role of menopause and reproductive senescence in a long-lived social mammal. Front Zool 6:4.

Williams GC (1957) Pleiotropy, natural selection, and the evolution of senescence. Evolution 11:398-411.

Williams LJ, Tabbaa DG, Li N, Berlin AM, Shea TP, et al (2012) Paired-end sequencing of Fosmid libraries by Illumina. Genome Res 22:2241-2249.

Wong P, Walter M, Lee W, Mannhaupt G, Münsterkötter M, et al (2011) FGDB: revisiting the genome annotation of the plant pathogen Fusarium graminearum. Nucl Acids Res 39:D637-D639.

Wu Z, Tsumura Y, Blomquist G, Wang X-R (2003) 18S rRNA gene variation among common airborne fungi, and development of specific oligonucleotide probes for the detection of fungal isolates. Appl Environ Microbiol 69:5389-5397.

Yancik R, Ries LA (1994) Cancer in older persons. Magnitude of the problem-how do we apply what we know? Cancer 74:1995-2003.

Yang Z (2007) PAML 4: Phylogenetic Analysis by Maximum Likelihood. Mol Biol Evol 24:1586-1591.

Yang Z, Bielawski JP (2000) Statistical methods for detecting molecular adaptation. Trends Ecol Evol 15:496-503.


[^0]:    Nick Grishin, Ph.D. (Mentor)

[^1]:    1 Definition from Finch (1990), although he prefers the term senescence.

[^2]:    
    Homo ERRRPYIPSTWRCFATDPDGLRELLEDCWDADPEARLTAECVQQRLAALAHPQESHPF Loxodonta ERRRPYIP-TWHCFAMEPGGLQELLEDCWDADPEARLTAECVQQRLAA-AHP-EAHPC

    Pan ERRRPYIPSTWRCFATDPDGLRELLEDCWDADPEARLTAECVQQRLAALAHPQESHPF
    Pongo ERRRPYIPSTWRCFATDPDGLRELLEDCWDADPEARLTAECVQQRLASLAHPQESHSF
    Equus ERRRPYIPSTWHCFATDPGGLRELLEDCWDADPEARLTAECVQQRLAALAQPQEAHSF Gorilla ----------------DPDGLRELLEDCWDADPEARLTAECVQQRLAALAHPQESHPF
    Tursiops ERRRPHIPSTWCCFATDPGGLRELLEDCWDADPEARLTAECVQQRLASLARPQEAHPF Macaca ERRRPYIPSTWRCFATDPDGLRELLEDCWDADPEARLTAECVQQRLAALAHPQES-PF
    Myotis ERRRPYIPPTWCCFATDPGVLREILEDCWDADPEARLTAECVQQRLAALAHPQEAHLF
    FeI is ERRRPYIPSTWHCETTDPGGLRELLEDCWDADPEARLTAECVQQRLAALARPQEARPF
    Sus ERRRPHVPSTWSCFATDPGGLRELLEDCWDADPEARLTAACVQQRLAALTHPQEARPF
    Canis ERRRPCIPSTWHSFTTDPGSLRELLEDCWDADPEARLTAECVQQRLAALAHPQEAQPF Dasypus ERRRPYIPSTWCSFSTEPGGLRELLEDCWDADPEARLTAECVQQRLATLAHPQEVHPL Pteropus ERRRPYIPPTWHCFATDPAGLRELLEDCWDADPEARLTAECVQQRLATLAHPQEAHSF

    Bos ERRRPHVPSTWCCLTTDPGGLRELLEDCWDADPEARLTAECVQQRLAALASPEEAHLF Echinops ERRRPFVPPTWRFFTAEPGELRELLEDCWDADPEARLTAECVQQRLAXXXXXXXXXXX Microcebus ERRRPYIPSTWCCFVTDPGGLRELLEDCWDADPEARLTAECVQQRLAALAHPQEAHSF
    Callithrix ERRRPYIPSTWRCFATDPDGLRELLEDCWDADPEARLTAECVQQRLAALAHPQESHPF
    Tarsius ERRRPYIPSTWYCEAT-----------CWDPDPEARLTAECVQQRLAALAHPQEAHPF Macropus ERRRPXXXXXXXXXXXXXXXXXELLEDCWDSDPEARLTAECIQHRLXXXXXXXXXXXX Procavia ERRRPYIPSTWHCFTTEPGRLRELLEDCWDADPEARLTAECVQQRLAALAHPQETQPC

    Cavia QRRRPYIPSTWGCSIRDPGGLRELLEDCWDADPEARLTAECVQQRLATLTYPGEADCL Erinaceus ERRRPHVPTTWHCESTDPGGLRDLLEDCWDADPEARLTAECVQQRLAALASSPETCPA Dipodomys ERRRPYIPPTWNYFATDLSGLRELLEDCWDADPEARLTAECVQQRLAALDHPQELHSF
    Oryctolagus ERRRPDIPSSWCCFATDPGGLRELLEDCWDADPEARLTAECVQQRLVALVHPQEAQPC
    
    Ochotona ERRRPCIPDSWHCFVTEPGALRELLEDCWDPDPEARLTAECVQQRLAAMLHPPEARPF
    Rattus ERKRPNIPSSWSCSATDPRGLRELLEDCWDADPEARLTAECVQQRLAALAYPQVASSF
    Mus ERKRPNIPSTWSCSATDPRGLRELLEDCWDADPEARLTAECVQQRLAALAYPHGASSF
    Sorex ERRRPCIPPAWHGCPTVPAGLREVLEDCWDADPEARLTAACVQLRLAALGPQQASGPG

